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Spontaneous and volume induced phasic activity in the isolated guinea pig
bladder is generated and modulated by a complex interaction of opposing excitatory
and inhibitory stimuli. Although the exact nature and location of these mechanisms are
not known, they represent local mechanisms inherent to the wall of the bladder. It has
been suggested that phasic activity represents a component of afferent activity involved
in the generation of sensation. Evaluation of the effects of the M3 specific muscarinic
antagonist 4-DAMP have identified cholinergic mechanisms involved in the generation
of pacemaker activity that are sensitive to the effects of M3 antagonism. It is therefore
suggested that antimuscarinics exert their clinical effects upon sensation through this
mechanism.
The intrinsic characteristics of spontaneous, phasic activity in response to
volume have also revealed a period of inhibition following volume reduction termed
the inhibitory phase. This is dependant upon the magnitude and duration of volume
increase prior to decrease and is regulated by a distinct mechanism comprising of a
combination of excitatory and inhibitory stimuli co-ordinated by ganglia. It can
manipulated by anticholinergic medication, nicotinic antagonists and purinergic
agonists suggesting its underlying generation and regulation to be complex.
The actions of hexamethonium and pancuronium upon phasic activity have
suggested the presence of non-ganglionic nicotinic receptors involved in the
modulation of spontaneous and volume induced activity; in addition to the role of
ganglia in co-ordinating the return of activity during the inhibitory phase.
Purinoceptors were found to display a varied and complex response, both on
pacemaker activity and upon the inhibitory phase. Both excitatory and inhibitory
receptors were present; however, individual subtypes seemed to display a differing
degree of functional relevance between low and high volume. Though P2X and P2Y
may have excitatory and inhibitory effects respectively, the overall effect of purinergic
receptor stimulation upon phasic activity is inhibitory.
The data obtained during the course of these experiments illustrate the
mechanisms involved in the generation and co-ordination of spontaneous activity to be
complex. It highlights novel mechanisms through which acetylcholine and adenosine
triphosphate may be exerting an effect, and may account for the therapeutic actions of
anticholinergic medications. It also highlights potential mechanisms which may act as
further therapeutic targets in the development of newer drugs for the treatment ofOAB.
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The overactive bladder syndrome (OAB) is a symptom complex characterised by
urgency, with or without urge incontinence, usually accompanied by frequency and
nocturia (Abrams et al, 2002). It is a common condition, affecting nearly 100 million
people in the western world (Milsom et al, 2001; Stewart et al, 2001) and although not
life threatening it seriously affects quality of life and ability to work. These lower
urinary tract symptoms (LUTS) become more prevalent in the aging population, where
40% over the age of 70 years are affected. Therefore, LUTS represents a major problem
to individuals, health professions and society alike. More importantly however, as the
population within the Western world is generally ageing, those affected by LUTS is set
to increase significantly.
The total economic cost of this collection of OAB symptoms is high. In 2002 the costs
in the USA were approximately $12.7 billion (Hu et al, 2004). These have been
estimated to rise to $17 billion and €22 billion/ year by the year 2005. Approximately
25% of expenditure is spent on treatment (drug therapy, clinical consultation and
surgery). Of those who suffer only 28% seek help, with only half of these currently
receiving treatments. Less than 3% regain long lasting normal control. Therefore, the
above costs may represent an under-estimation of a much larger problem.
The primary clinical problem behind OAB is that of an increased urge to pass urine,
termed 'urgency'. Remarkably, despite the prevalence and costs involved, the
mechanisms underlying increased urge are not fully understood. In order to simply
describe the condition the term OAB has been introduced (Abrams et al, 2002); a
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diagnosis based upon clinical symptoms. In many cases where patients with OAB are
studied using conventional urodynamics sensations of urgency are correlated with rises
in intra-vesical pressure, a condition classified as detrusor over activity (DO). In the
remainder of patients, sensations of urgency are not accompanied by pressure changes.
This situation is currently described as OAB in the absence of DO but previously has
been known as 'sensory urgency'. The differences seen in the relationship between
sensation and overactive detrusor activity may be indicative of different clinical states.
Alternatively, it may represent the fact that the nature of the clinical condition is not
fully appreciated.
Since the DO component ofOAB is associated with contractions of the bladder smooth
muscle (detrusor muscle), it was argued that drugs affecting contractility would
alleviate symptoms. Activity in the detrusor muscle is initiated at muscarinic receptors
(M3) and drugs designed to target these M3 receptors have been proven to be effective
in decreasing urgency and incontinence, (Chappie et al, 2005). However, it has been
suggested that, at therapeutic doses, these drugs do not significantly affect bladder
contraction (Andersson and Amer, 2004; Andersson and Yoshida, 2003; Finney et al,
2006). Therefore, if this is so our understanding of the mechanisms through which
antimuscarinics act, and in turn our understanding of the generation of the sensation of
urge and urgency, is incomplete.
Thus, OAB is a major problem affecting a large number of people. The underlying
causes are not fully understood and the economic costs are high. Pharmacological
treatment, in the fonn of antimuscarinic medication, is available but the precise mode
of action of these drugs is uncertain. It is therefore proposed that from these basic
2
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clinical observations alone, alternative physiological processes need to be considered
through which antimuscarinics may act, either wholly or in part. Furthermore, it also
needs to be considered that additional mechanisms involved in the generation of
sensation exist making afferent signalling more complex than traditionally thought.
1.2 Basic overview of bladder anatomy: the classical perspective
The bladder is a hollow, muscular organ situated in the pelvis in most mammalian
species. It is distensible and acts as a reservoir to collect urine draining from both
kidneys via the ureters, storing the urine till a time convenient for it's expulsion.
During urine expulsion, termed micturition, urine is expelled via the urethra. A diagram
illustrating the relationship of the bladder within the human is illustrated, Figure la.
The internal surface of the bladder is lined by transitional epithelium and is referred to
as the urothelium. The urothelium is usually in the region of six cells thick and rests on
a basement membrane. Immediately below the urothelium lies the lamina propria
which is comprised of a thick layer of fibroelastic connective tissue that allows the
considerable distension seen during bladder filling. Deeper still lies the smooth muscle
of the bladder wall, termed the detrusor muscle layer. Three layers of detrusor muscle
tend to exist; an inner longitudinal, middle circular and outer longitudinal layers. In the
upper most parts of the bladder these three layers are not separable with fibres from
each layer interlacing with those of different layers forming a meshwork of detrusor
muscle. This meshwork of detrusor fibres is ideally suited for emptying a spherical
bladder. A macroscopic example of these layers is illustrated, Figure lb. A microscopic
example of these layers is also shown, figure 1.
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Figure 1: illustration highlighting the anatomy relating to the urinary bladder in the
human. Figure la, illustrates the position of the bladder within the lower abdomen,
connected to the kidneys on either side via the ureters. Urine drains from the kidneys
down the ureters to the bladder where it is stored. Upon bladder contraction the urine is
expelled, tenned micturition, via the urethra. Figure lb, illustrates the macroscopic
relationship between the three layers of the bladder; urothelium (mucosa), lamina
propria (submucosa) and the detrusor. The relationship of the ureters, prostate and
urethra is also shown. (Illustrations have been reproduced subject to the regulations of














Figure 2: highlighting the classical structure and concept of bladder function during
the filling phase. A, is a typical full thickness section of bladder tissue, (reproduction of
a lithograph plate taken from Gray's Anatomy 20th edition, 1918). It can be seen that
discrete layers exist comprising of urothelium, lamina propria and detrusor muscle.
However, the limitations of reproductions obtained from light microscopy preclude the
identification of the ultra structural architecture of the bladder. B, represents a
schematic diagram of the classically described afferent and efferent input to the CNS.
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Innervation of the bladder arises from autonomic fibres arising from the anterior
portion of the pelvic plexus (alternatively known as the vesical plexus). These pass
along the lateral and posterior ligaments to innervate the bladder. The bladder has a
dense parasympathetic innervation with an abundance of postganglionic cell bodies,
and is related to the mediation of detrusor contraction. Sympathetic innervation has also
been identified though to a much lesser degree. However, the role of the sympathetic
supply in the mediation of detrusor relaxation is uncertain.
1.2.1 'Classical' views on bladder function.
For many years views on the structure and function of the bladder were relatively
simple. These entailed the bladder relaxing passively during filling, storing urine until a
conscious decision is made for it to be expelled via the act of micturition. As urine
accumulates, stretch receptors in the bladder wall send information on intravesical
volume to the CNS. At an appropriate time, the CNS coordinates urethral sphincter
relaxation and detrusor contraction resulting in voiding: termed the micturition reflex.
Contractions arise from activation of postganglionic parasympathetic nerves mediated
via the sacral parasympathetic nucleus resulting in the release of acetylcholine and
excitation of smooth muscle via M3 muscarinic receptors. This simple afferent/ efferent
innervation is illustrated, figure 2b. In keeping with this view of function the 'classical'
view of the structure of the bladder wall is also simple. As previously discussed, it
comprises of the urothelium, lamina propria and muscle, with the urothelium acting
solely as a protective barrier between the urine and the bladder wall.
However, as research into the bladder has evolved this description of physiological
events and structure is no longer adequate. It is becoming apparent that inconsistencies
6
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arise when attempting to explain the origins of urge, increased frequency or
incontinence. Furthermore, no physiological roles are assigned to specific micro-
anatomical structures in the bladder wall; such as the complex neural circuitry of the
intra-mural ganglia, the diversity of neurotransmitter substances in the intramural
nerves (sensory and motor), interstitial cells and the heterogeneous structure of the
urothelium, lamina propria and muscle layers. Additionally, no roles are evident for the
actions of urothelial signalling or non-micturition activity.
1.3 'Newer' views on bladder function
1.3.1 Components of afferent 'noise'
Over the past 60 years, data has been presented suggesting the presence of several
sensory modalities originating from the bladder. In 1955, Iggo demonstrated firing in
small myelinated AS fibres in response to stretching of the bladder wall. In addition,
small unmyelinated afferent fibres, C fibres, have also been identified that respond to
excessive stretch, cold and noxious stimuli; probably contributing to painful sensations
(Iggo, 1955; Morrison, 1998). More recently a complex system has been described with
the potential to allow interaction between the urothelium and afferent C fibres.
Adenosine triphosphate (ATP) and nitric oxide (NO) have been found to be released in
response to mechanical distortion of the urothelium (Ferguson, 1999; Birder et al 1998,
2001, 2002). In addition, ATP has been shown to directly modulate firing of afferent
bladder nerves (Rong et al, 2000). It has therefore been suggested that this urothelial
system is involved in stretch induced modulation of bladder sensations (de Groat,
2004). However, the role of this system in the integrated physiology of the bladder is
not known. But together, these observations suggest that afferent discharge arising from
the bladder has different components: stretch mediated signals (mechanical), signals
7
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emanating from noxious stimuli (pain) and signals modulated by chemicals released
from the urothelium (chemical). Thus, it would appear that the sensory output from the
bladder, 'afferent noise', consists of mechanical, pain and chemical components. A
more complex schematic taking account of these newer modalities is illustrated, Figure
3.
These observations on specific structures/ response, however, have difficulty
explaining cholinergic influence upon afferent activity. There is no doubt that the
commercially available antimuscarinic drugs used in current clinical practice are able to
reduce sensations of urgency by acting in the periphery and not in the CNS (Andersson
and Arner, 2004). However, in the description of the components of 'afferent noise'
described above, there are no elements that have been shown to involve acetylcholine
or muscarinic receptors. Suggesting either that there are still unknown elements of
these systems or that there are additional components of 'afferent noise'.
1.3.2 Potential cholinergic components to afferent noise
Data has been published however, suggesting additional responses involving
cholinergic mechanisms to be present within the bladder linked to sensation. One
possibility is that of muscarinic receptors on the urothelium (de Groat, 2004).
Exogenous carbachol has been shown to increase micturition frequency and it was
argued that muscarinic stimulation of the urothelium could lead to the release of ATP,
the activation of afferent nerves and so modulate sensation (de Groat, 2004). Strong
experimental evidence for this is not yet available and it is not clear what system would
activate these receptors in vivo. However, Yoshida et al (2004) have demonstrated that
8
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the urothelium is able to synthesise and release acetylcholine in response to stretch. It
has been suggested that acetylcholine released in this manner could act on muscarinic
receptors on sub-urothelial afferent nerves and so enhance firing. If this mechanism
were present, it would be another example of 'chemical noise' and a potential site
where antimuscarinic drugs could exert a therapeutic action. In relation to this idea it
has been reported that instillation of the muscarinic agonist carbachol into the bladder
increases micturition frequency (Kim et al, 2005). This could be brought about if
carbachol activated muscarinic receptors on urothelium (de Groat, 2004 as above).
Alternatively, carbachol could cross the urothelium and activate afferent nerves
directly. From the structural perspective muscarinic receptors have been reported on
nerve endings in the bladder (Somogyi et al, 1999). Where present, Mi receptors are
thought to be facilitatory while M2 and M4 inhibitory. A role for M3 receptors has not
been demonstrated. This conflicts with our current understanding, both clinically and
pharmacologically, as the therapeutic actions of antimuscarinic drugs are thought to be
M3 specific. Though this would strongly suggest other cholinergic mechanisms to be
present linked to sensation.
1.4 Cholinergic modulated non-micturition activity: a cholinergic
motor/sensory system
Classical thinking dictates that the bladder is a low pressure compliant reservoir that is
completely inactive during filling. However, the earliest cystometrogram on healthy
young female volunteers, dating from 1882 (Mosso and Pellacani, 1882), clearly
describe regular phasic rises in intravesical pressure during filling unrelated to the act
of micturition. These observations were confirmed in the 1930s (Denny-Brown and
Robertson, 1933) and 1960s (Plum, 1960) but their existence appears to have been
9
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subsequently overlooked. Similar findings which have subsequently been termed 'non-
micturition activity' have also been recorded in animal models. In the cat, the first
observations were made by Sherrington in 1892 and confirmed on many occasions
(Iggo, 1955; Gjone, 1965; Klevmark, 1977; Vaughan and Satchell, 1997).
1.4.1 Association between non-micturition activity and afferent discharge
The physiological role of this non-micturition activity is not known. However, it has
been shown that, in the cat, these phasic rises in intravesical pressure are associated
with bursts of afferent impulses thought to be emanating from rapidly adapting stretch
receptors (Andersson and Yoshida, 2003; Vaughan and Satchell, 1995). Thus, this form
of phasic motor activity may be part of a motor driven sensory system (Gillespie,
2004). If this is correct a further component to afferent noise can be introduced, that of
'motor' noise.
The amplitude and frequency of non-micturition activity alters during the filling phase
(Klevmark, 1980; Vaughan and Satchell, 1995). Thus, if phasic activity is related to
sensation then such changes suggest that the sensory outflow from the bladder could
vary during the filling phase. It has been found that non-micturition activity can be
modulated by both sympathetic and parasympathetic activity (Gjone, 1965; Vaughan
and Satchell, 1992 and 1995). This is an important observation. If non-micturition
activity can be modulated by efferent input to the bladder the implication is therefore
that there is efferent control of afferent output: a modulated motor/sensory system
(Gillespie, 2004). If modulation of such activity were to be altered the resulting effect
would be to change sensations from the bladder: an increase in non-micturition activity
10
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could thus represent one component to increased sensations of urgency (Gillespie,
2004).
1.4.2 Non-micturition activity in animal models of bladder dysfunction
A further indication to the potential importance of non-micturition activity may be
implied from models of bladder dysfunction. Close examination of the published
cystometry records of animals with experimentally induced increased micturition
frequency, show an increase in non-micturition activity in the filling phase of the
micturition cycle (Kim et al, 2005; Mitsui et al, 2001; Takeda et al, 2002). As
postulated above, an increase in non-micturition activity would increase sensation and
so trigger a micturition event earlier in the cycle; leading to increased frequency. It is
difficult to be certain about the reliability of such records, since all of the experiments
were undertaken using a single measurement of intra-vesical pressure (no independent
measurements were made of intra-abdominal pressure to obtain true detrusor pressure).
However, exaggerated and clear phasic rises in intravesical pressure can be seen in
almost all of these models. Although not concrete by any means, such circumstantial
evidence does however support the above arguments.
1.4.3 Mechanisms generating non-micturition activity
The mechanisms generating phasic activity in vivo are poorly understood. However, in
vitro experiments, on the whole isolated bladder, allow some insight into the
mechanisms in the bladder wall contributing to phasic activity. In 1892 Sherrington
reported that phasic activity similar to non-micturition activity could be recorded in the
isolated whole bladder. This observation has been confirmed in the isolated whole
11
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guinea pig and rat bladder (Drake et al, 2003a; Drake et al, 2003b). The activity is
intrinsic to the bladder wall and has been described as 'autonomous' activity. In the
guinea pig, autonomous activity is associated with propagating waves of contraction
spreading over the bladder surface accompanied by local areas of stretch. Autonomous
activity can be augmented by nerve stimulation or direct application of muscarinic
agonists: increasing concentrations of muscarinic agonist increase the amplitude and
frequency of these small pressure increases termed transient contractions (Gillespie et
al, 2004a). The initiation, coordination and control of this activity appear to be different
from that involved with the micturition contraction. This has led to the proposition that
there are two distinct systems capable of activating contractions in the detrusor: one
associated with the global micturition contraction and the other the generation and






Motor/ Sensory system M3,?
Detrusor contraction
Figure 3: highlighting the potential components to afferent sensation arising from the
urinary bladder, a) C fibre activity has been identified that responds to excessive
stretch, cold and noxious stimuli, b) Stretch has been shown to lead to tiring of A5
fibres, c) ATP and NO have been found to be released in response to mechanical
distortion of the urothelium, with ATP release leading to direct firing of afferent
nerves, d) A motor/ sensory system has been shown to exist whereby regular transient
rises in intravesical pressure, unrelated to the act of micturition, are associated with
transient increases in afferent activity. This activity increases in frequency with volume
and can in turn be modulated via efferent parasympathetic/ sympathetic activity.
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1.5 Interstitial cells and intramural ganglia: potential structures involved in
the regulation of 'Autonomous activity'
It is unlikely that the local propagating waves of contraction are due to the direct spread
of excitation from smooth muscle cell to smooth muscle cell. The trabecular
organization of the muscle bundles would not allow a direct coupling between adjacent
areas of muscle. Therefore, it has been postulated that there are specific structures
involving specialized cells to distribute activity over the bladder surface. Two
possibilities have been proposed. Firstly, a network of specialized cells, interstitial
cells. Secondly, that intra-mural ganglia and nerves form a neural network to initiate
and coordinate phasic activity (Drake et al, 2003a).
1.5.1 Interstitial cells
There are now a number of studies demonstrating the presence of a network of
interstitial cells on the surface and within the outer muscle bundles of the detmsor
(M'Closkey and Gumey, 2002; Hashitani et al, 2004; Davidson and McCloskey, 2005;
Gillespie et al, 2004), figure 4. These cells have been identified as cells which respond
to nitric oxide with a rise in cGMP and by the expression of c-Kit, a specific marker of
interstitial cells in the gut. However, at present there is no direct experimental evidence
to demonstrate the exact role of interstitial cells within the bladder. Although, in the gut
where the majority of work has been carried out into the roles of interstitial cells, they
are thought to be responsible for the generation, co-ordination and propagation of
peristalsis. Dennervated intestinal loops have been found to exhibit spontaneous,
rhythmical contractions (Huizinga JD et al, 1995), with increasing evidence to support
that the Interstitial Cells of Cajal (ICC) are the underlying cells responsible for this
14
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activity (Huizinga JD et al, 1995; Kobayashi S et al, 1995; Kobayashi S et al, 1996;
Huizinga JD et al 1997; Sanders KM et al, 1999). Therefore, it is conceivable, given the
similarities in spontaneous activity within the two organ systems that an analogous
situation exists within the bladder.
Furthermore, the ureter also displays evidence of spontaneous, co-ordinated, rhythmical
activity. These peristaltic waves are also analogous to peristalsis seen in the gut and
originate within the renal pelvis, travelling distally towards the bladder, (Hannappel
and Lutzeyer, 1978). Pacemaker cells, again similar to those characterised in the gut,
seem to be implicated in this activity, (Klemm et al, 1999). Pharmacologically, this
activity can be inhibited by the calcium channel blockers Nifedipine, Verapamil, and
Diltiazem (Hertle and Nawrath, 1984). Indomethacin, a non-steroidal anti¬
inflammatory drug, has also been shown to reduce the frequency and amplitude of
activity with PGE2, a prostaglandin, markedly increasing it, (Thulesius and Angelo-
Khattar, 1985).
The works of Lennon et al, have used animal models to illustrate the potential patho¬
physiological effects of bacterial infection, ureteric obstruction and ureteric stent
insertion upon spontaneous ureteric activity. The bacteria Escherichia coli, Proteus
mirabilis, Pseudomonas aeruginosa and Staphylococcus aureus added to the lumen of
the ureter was found to inhibit activity, whereas when added to the solution bathing the
extra-luminal surface activity was increased, (Lennon et al, 1993a). Suggesting that




Further work has also shown that obstruction of the ureter inhibits activity, but this
returns once the obstruction has been relieved, (Lennon et al, 1993b). Similarly,
insertion of ureteric stents in vivo has been shown to reduce ureteric motility leading to
the theoretical risk of delayed transit time for ureteric calculi, (Lennon et al, 1994).
It is now emerging that the network of interstitial cells seen within the bladder may be
made up of a heterogeneous population. Based on location, interstitial cells are found in
the sub-urothelial space (sub-urothelial interstitial cells: SU-ICs) and associated with
the outer muscle layers of the bladder wall. In the guinea pig three types have been
described: cells in the outer muscle coat (muscle coat interstitial cells: MC-ICs), cells
on the surface of the muscle bundles (surface muscle interstitial cells: SM-ICs) and
cells within the muscle bundles (intra-muscle interstitial cells: IM-ICs), (Gillespie et al,
2004). A further sub-population of cells may be identified from their expression of
choline acetyltransferase (Gillespie et al, 2005). Examples of the three types of












Figure 4: fluorescent image of a full-thickness section of the lateral wall of the bladder.
cGMP staining illustrated as green fluorescence and nNOS (neuronal nitric oxide
synthase) as red. cGMP positive cells are seen predominantly in the muscle bundles in
the outer region of the bladder wall. Intense cGMP reactivity is seen in the umbrella
cells of the urothelium and in a layer of cells immediately beneath the urothelium. A
distinct layer of nNOS positive cells are visible in the basal layers of the urothelium.
The horizontal bar at the bottom right corner = 10pm. Prior to staining the tissue was
incubated in the non-specific phosphodiesterase inhibitor isobutyl-methyl-xanthene,
followed by a further incubation in the nitric oxide donor NOnate. The above picture
illustrates the presence of a suburothelial layer of interstitial cells, in addition to a dense
network of interstitial cells in the outer muscle layers. (This illustration has been
reproduced with permission from Professor James Gillespie and BJU International;
Gillespie et al, 2005).
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Figure 5: cGMP fluorescence is seen in the outer muscle coat. A and B illustrate dense
staining on the outer muscle coat (+). Processes originating in the outer coat can be seen
descending into to the underlying muscle bundles (*). Cells within the muscle bundles
can also be seen (#). C and D show enlarged images of the muscle coat. These two panels
show that the interstitial cells comprise of individual cells and connecting fibres (MC-
IC). Horizontal bars in the bottom right represent 40pm in A and B, 15pM in C, and 8pm
in D. Prior to staining the tissue was incubated in isobutyl-methyl-xanthene, followed by
NOnate (This illustration has been reproduced with permission from Professor James
Gillespie and BJU International; Gillespie et al, 2005).
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Figure 6: cGMP and nNOS staining in the outer muscle bundles of the base of the guinea
pig bladder. cGMP positive cell processes and cells run over the surface of the muscle
bundles ((*), SM-ICs). Cells reactive to cGMP can also be seen within the muscles
bundles ((#), IM-ICs). As in the previous figures the tissue was incubated in isobutyl-
methyl-xanthene, followed by NOnate prior to staining. (This illustration has been
reproduced with permission from Professor James Gillespie and BJU International;
Gillespie et al, 2004).
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Figure 7: cGMP and nNOS staining of cells within the muscle bundles (IM-ICs). A and
B are from the base of the guinea pig bladder, C and D from the lateral wall, and E and F
from the dome. The cells have large central cell bodies and processes can be seen running
from the cell bodies parallel to the smooth muscle fibres. These cells are found primarily
in the central regions of the muscle bundles with only the cell processes apparent at the
ends of bundles. Horizontal bar at the bottom right represents 10pm. (This illustration has
been reproduced with permission from Professor James Gillespie and BJU International;




Intra-mural ganglia are found in the bladder wall ofmany species, including man (Smet
et al, 1997; Zhou and Ling, 1998; Gabella, 1990). At present there are no data to
demonstrate a specific physiological role for this network. The intra-mural ganglia
receive inputs from nerve fibres containing calcetonin gene related peptide (CGRP) and
substance P (sub P), (Smet et al, 1997; Zhou and Ling, 1998). These fibres are likely to
be collaterals from sensory fibres emanating from the sub-urothelial layer. The
observation, that CGRP can inhibit muscarinic augmented phasic activity has led to the
suggestion that the intra-mural ganglia play a role in the generation or modulation of
phasic activity (Gabella, 1990), with the interstitial cells being involved in the
distribution of this activity to larger areas of the bladder wall. Examples of ganglia





Figure 8: Fluorescent images of ganglia detected within the guinea pig bladder. A
represents a ganglion from the outer muscle layer, B - D represent ganglia from the
suburothelial layer. In A, cell bodies positive for nNOS (red) and cGMP (green) are
seen. B shows a ganglion stained for neurofilament protein (NF), green, and for
Choline acetyltransferase (ChAT), red. C shows a suburothelial ganglion staining for
calcitonin gene related peptide, green, and ChAT, red. D shows a ganglion staining for
aib adrenergic receptors, red, and NF, green. (These illustrations have been reproduced
with kind permission from Professor James Gillespie).
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1.6 Autonomous activity: integrated physiology of the isolated guinea pig
bladder
As previously mentioned, regular phasic rises in intravesical pressure, similar to non-
micturition activity seen 'in vivo', can be seen in the isolated bladder (Sherrington,
1892). More recently these observations were re-examined in the isolated guinea pig
bladder (Drake et al, 2003a; Drake et al, 2003b). Spontaneous complex activity was
observed on the outer surface of unstimulated bladders. This activity, termed
'autonomous' activity, consisted of localised micro-contractions, waves of activity and
microstretches confined to discrete regions of the bladder surface, which were
associated with transient rises in intravesical pressure. Incremental increases in
intravesical volume recruited additional areas of activity with subsequent increases in
phasic intravesical pressure. The addition of atropine or tetrodotoxin did not block this
activity suggesting the underlying mechanisms to be unrelated to the neuromuscular
junction or intrinsic nerves. The addition of arecaidine, a muscarinic agonist, or the
nicotinic ligand Lobeline augments the underlying 'autonomous activity'. Initially an
increase in the number of regions displaying micro-contractions is seen followed by the
development of large, co-ordinated waves of contraction over the surface of the
bladder. These lead to the generation of larger rises in pressure associated with
transient contractions with an associated increase in frequency: termed 'augmented'
activity, (Drake et al, 2003a). These simple effects have previously been highlighted as
important observations as they suggest this activity to be independent of central
mediation and generated by mechanisms distinct from post-ganglionic cholinergic
activation (Drake et al, 2003c). Additionally, as previously mentioned, in the cat these
phasic contractions are associated with bursts of afferent impulses thought to emanate
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from rapidly adapting stretch receptors (Andersson and Yoshida, 2003; Vaughan and
Satchell, 1995).
1.6.1 Effects of increasing intravesical volume
From these experiments upon the isolated bladder certain characteristics and responses
of the local mechanisms within the bladder wall have been well documented. It can be
seen that the amplitude and frequency of transient contractions increase with increasing
intravesical volume. This has been shown to be the case in both the unaugmented
('autonomous' activity) and augmented state ('augmented' activity). Figure 9
demonstrates the effects of increasing intravesical volume on autonomous activity. In
addition, with a fixed intravesical volume increasing doses of muscarinic agonists
similarly increases the amplitude and frequency of transients in a fashion similar to
increasing the intravesical volume. However, a much more marked effect is seen with
the muscarinic agonists, Figure 10, (Drake et al, 2003c).
1.6.2 Effects of nitric oxide
The addition of the nitric oxide (NO) donor sodium nitroprusside (SNP) results in an
excitatory response, increasing the frequency of phasic contractions, (Gillespie JI et al,
2004b). This would suggest that the nitrergic innervation of the bladder wall is
associated with an overall excitatory input to the mechanisms involved in the
generation of phasic activity. It has been shown that the detrusor smooth muscle does
not respond to NO stimulation with a rise in cGMP. However, the cells that do respond
in this manner are the suburothelial and intramuscular interstitial cells previously
24
Introduction
mentioned (Smet et al, 1996). Therefore, it is likely that interstitial cells are integral to
the generation and modulation of phasic activity (Gillespie et al, 2004b).
A small population of nerves within the guinea pig bladder also show elevated levels of
cGMP in response to SNP (Smet et al, 1996). A further possibility is that in addition to
an action directly upon interstitial cells, the excitatory effects of SNP application on
phasic activity could be mediated via these neural mechanisms. The increase in the
frequency of phasic activity induced by SNP could arise indirectly by either the
stimulation of excitatory neurones or the inhibition of inhibitory intramural neurones
(Gillespie et al, 2004b).
1.6.3 Effects of noradrenaline
In contrast to the excitatory effect of muscarinic agonists sympathomimetic stimulation,
via the addition of noradrenaline, results primarily in an inhibition of phasic activity. A
reduction in the amplitude of each transient is seen, coupled with a reduction in the
frequency of phasic activity. Two receptor subtypes have been identified, ai and (33, that
are involved in this inhibition with both displaying dose dependent responses. The
presence of these two functionally relevant receptor subtypes suggests that
noradrenaline has a number of sites of action within the bladder with the mechanisms




1.6.4 Effects of Adenosine Triphosphate
Following mechanical distortion, the urothelium is known to release adenosine
triphosphate (ATP), (Fergusson, 1999; Birder et al 1998, 2001, 2002). A non-
hydrolysable form of ATP, a/p methylene ATP, was found to have a marked excitatory
effect on phasic activity leading to an increase in both frequency and amplitude; in
addition to its direct effect on smooth detrusor muscle. Interestingly, following
'washing out' of alP methylene ATP from the preparation a profound inhibition is seen.
It is known that the excitatory effects of ATP are exerted via the P2X receptors
(McMurray et al, 1998) and in relation to autonomous activity these seem to be rapid in
onset. However, those leading to the resultant inhibition are less rapid with an uncertain
site of action (Gillespie, 2004a).
1.6.5 Effects of substance P and calcitonin gene related peptide
Phasic activity has also been found to be modulated by the sensory neuropeptides,
substance P and calcitonin gene related peptide (CGRP). Substance P was found to be
excitatory and CGRP inhibitory. The addition of capsaicin, known to release both sub P
and CGRP from sensory nerves, resulted in an excitation followed by an inhibition.
These observations suggest that the mechanisms generating complex phasic activity in
the bladder wall have an innervation from collateral axons of sensory nerves;
suggesting a local axonal reflex present within the bladder wall, (Gillespie, 2005a).
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1.6.6 Intrinsic changes in spontaneous activity during changes in intravesical
volume: the volume response
In addition to the effects of specific neurotransmitters known to be present within the
bladder wall, the integrated responses of the isolated bladder to changes in volume,
similar to those seen during micturition, have been characterised. It can be seen that the
frequency and amplitude increases with increased volume. However, following a
sudden increase in intravesical volume a rapid increase in frequency and underlying
basal pressure is seen. This initial increase in frequency settles and falls to a steady
state which is associated with a reduction in underlying basal pressure. Although the
frequency and basal pressure are still higher than those seen prior to the volume
increase. Once the intravesical volume is reduced back to baseline values a quiescent
period is seen. The frequency and amplitude of transient phasic contractions slowly
return over a period of time (Lagou, 2005). An example of a typical 'volume response'
is shown in Figure 11.
The addition of tetrodotoxin to the isolated bladder or pre-treatment with capsaicin has
no effect upon these volume induced responses. This would suggest that since most
neural sensory influences would be eliminated by this combination, local sensory
collateral reflexes are not directly involved with volume induced responses. However,
the effects of ODQ (oxadiazole quinoxalin-1-one) in reducing the volume induced
responses would support the involvement of interstitial cells, (Lagou, 2005).
From these experiments on the isolated guinea pig bladder a complex series of
responses inherent to mechanisms within the bladder wall can be seen, each with the
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potential of modulating phasic activity. This 'motor/sensory' system has the potential
to send bursts of afferent activity to the CNS proportional to intravesical volume. The
effects of which can be modulated by the neurotransmitters noradrenaline, substance P,
calcitonin gene related peptide and nitric oxide; suggesting a role for intramural nerves.
The effects of adenosine triphosphate in turn suggest a role for the urothelium.
Although the underlying mechanisms are not entirely clear, what is emerging is that
these local responses combine to form a modulated sensory system capable of altering
afferent discharge in response to both local and central inputs. Due to the relative
sensitivity of this system to the effects of acetylcholine it is feasible that it may be a
target for antimuscarinics. Additionally, due to the number of inputs to this system it
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Figure 9: a typical example of the effects of increasing volume upon autonomous
activity as described by Drake et al, (2003c). The trace represents intravesical pressure
measured in an isolated guinea pig bladder, (taken from the author's own personal
records). At time point 0 seconds the intravesical volume is at baseline volume, 800pl.
Each arrow (!) represents an incremental increase in intravesical volume of 400pl,
typically taking 3 seconds to be instilled. (!*) represents a reduction in volume of
2000pl. It can be seen that with increasing volume both the frequency and amplitude


















Figure 10: a typical example demonstrating the effects of increasing doses of
muscarinic agonist, arecaidine, upon 'autonomous activity' as previously described by
Drake et al, (2003c); the trace is taken from the author's/ candidates own records.
Arecaidine was added at the concentration shown during the time indicated by the
horizontal bar. Between drug applications the bladder was washed in Tyrode's solution.
During the 'washes' and prior to the addition of agonist small regular phasic rises in
intravesical pressure can be seen; termed 'autonomous activity'. Following addition of
agonist an increase in the frequency and amplitude of transient contractions is seen.
This activity, in the presence of muscarinic agonist, is termed 'augmented activity'.
Ordinate axis represents pressure (cmH20), and abscissa time (seconds).
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Figure 11: demonstrating a typical 'volume response' performed on an isolated guinea
pig bladder, with phasic activity augmented by lOOnM arecaidine, as described by
Lagou et al, (2005); trace taken from the author's own records. Q) represents a 2000pl
volume increase and Q*) a 2000pl decrease. Following the volume increase an
increase in frequency can be seen that settles down to a 'steady state'. Following a
volume decrease a quiescent period can be seen with the frequency and amplitude of




1.6.7 Overview of the human clinical relevance of observations of autonomous
activity in animal models.
As previously discussed, autonomous activity has been documented in a number of
animal models; cat, mouse, guinea pig, rat, monkey and dog. Although its exact
function isn't fully known, in the cat each transient contraction has been documented to
be associated with a burst of afferent activity, (Vaughan and Satchell, 1992). Since the
frequency of autonomous activity is associated with bladder volume it is therefore
assumed that autonomous activity is related to the perception of intravesical volume.
Support for this idea is seen in other animal models, where autonomous activity has
been found to be related to micturition frequency (Streng et al, 2006). In these cases,
increased autonomous activity is associated with an increase in the frequency of
micturition and a subsequent reduction in bladder capacity.
If such a system where to exist in the human then autonomous activity may act as a
means of mechanical-neurochemical transduction whereby intravesical volume can be
detennined. As such it may play a role in the perception of bladder sensation.
Abnormalities of this system may also be involved in the origin of increased micturition
frequency and reduced bladder capacity, and/ or, the development of the symptom of
urgency. Although no experiments have been performed as of yet to solely look at
autonomous activity in the bladder, indirect evidence for the presence of bladder
contractions unrelated to micturition have been seen on standard and ambulatory
urodynamic assessments (Robertson et al, 1994; Heslington et al, 1996). Work
described later in the thesis describes how autonomous activity is sensitive to the effects
of muscarinic agonists/ antagonists, and it is postulated that autonomous activity may
act as means through which anti-muscarinic medications exert their beneficial effects.
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The experiments upon animal models described above are largely limited since only
objective measurements indirectly associated with sensation (micturition frequency and
bladder capacity) can be made of animal voiding patterns. They do not allow an
appreciation of what the animal is actually thinking or their perception of bladder
sensation. In the human, however, the reverse is true. Animal experiments leading to
the above ideas are generally irreproducible in humans as it is difficult to obtain normal
healthy human bladders for isolated experiments. In addition it would also be difficult
to perfonn sensory afferent recordings. However, the advantage of the human over the
animal models is that the human is able to allow both the measurement of objective
recording of voiding patterns in addition to vocalising the rather more subjective
assessment of bladder sensation. Therefore, to fully translate the relevance of
autonomous activity to the human a combination of animal and human work needs to
be performed.
From each individual animal model it is possible to obtain data relating to distinct
physiological phenomenon and attempt to translate this to specific structures within the
bladder wall. Although difficult to achieve solely from a single animal model if studies
are repeated in a number of animal models, differences in physiology may be attributed
to structural variations, allowing some degree of assumption to be made regarding the
role of certain structures. Attempts can then be made to relate structure to function.
Certainly this has been seen already when traces from guinea pig bladders are compared
to those of the mouse. A distinct difference is seen in the character of these traces, with
mouse tracings being more sinusoidal in nature actively contracting above and relaxing
from a common basal pressure, (Lagou et al, 2004). Whereas guinea pig traces tend to
peak from an underlying basal pressure, (Figure 10), suggesting active contraction with
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little in the way of active/ passive relaxation below basal pressure. Since the mouse
bladder has no suburothelial interstitial cells, a putative suggestion is that the
suburothelial interstitial cell layer contributes to maintaining this underlying basal tone.
Although by no means complete, this comparison illustrates the nature of relating
structure to function and if performed on a number of animal models more accurate
assumptions may be able to be formulated for certain structures. This thesis
concentrates solely upon phenomenon characterised in the guinea pig bladder, as such a
degree of caution needs to be exercised in the translation of this work into the human
model.
Though it is extremely difficult to reproduce experiments on isolated human bladders,
access to human bladder tissue is a lot less problematic. It is therefore possible to
harvest normal bladder tissue at the time of operations, ethics permitting, to examine its
ultra-structure. Once more is known about the structure of the bladder then attempts
can be made to relate this to its function. This can also be repeated for pathologically
diseased bladders. In addition to this approach, iso-volumetric urodynamics may also be
performed on the human (in a fashion similar to standard urodynamics) where
autonomous activity is correlated both to intravesical volume and to sensation, and also
to structure. Once more is known about the relevance of autonomous activity to
sensation, both in the normal and pathological states, pharmacological manipulations
and subsequent treatments may then be developed.
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1.7 The Overactive Bladder syndrome (OAB): a clinical perspective and role
of antimuscarinic medications
1.7.1 Basic Problem
The overactive bladder syndrome (OAB) is a symptom complex characterised by
urgency, with or without urge incontinence, usually accompanied by frequency and
nocturia (Abrams et al, 2002). It is a common condition affecting 17% of the
populations of Europe and the USA (Milsom et al, 2001; Stewart et al, 2001). But
despite its prevalence the aetiology of OAB is not fully understood. Possible
explanations as to the aetiology of OAB have been proposed which, to a certain extent,
go some way in explaining a number of the observations seen. Examples of which
include the neurogenic hypothesis, abnonnal expression of the micturition reflex (de
Groat, 1997), and the myogenic hypothesis, changes in the properties of the detrusor
smooth muscle (Brading et al, 1994). However, no single hypothesis is, as yet, able to
fully incorporate all the observations seen in both the normal and abnonnal states.
Although not fully understood, the symptoms of OAB have been generally considered
to be due to abnonnal bladder contractions occurring inappropriately during the fdling
phase. On this assumption the mainstay of treatment for OAB has been anti-cholinergic
medications, in the belief that they will reduce the contractility of the detrusor muscle.
The logical argument was that by preventing these abnormal contractions this would
relieve symptoms. There is no doubt that the antimuscarinic drugs currently used in
clinical practice (oxybutynin, tolterodine, trospium, solifenacin and darifenacin) are
effective in reducing the symptoms of OAB. Also, there is no doubt, that at high
concentrations, antimuscarinics can reduce the amplitude of detrusor contraction.
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Indeed, patients given an excess of antimuscarinic drugs retain urine due to an inability
of the bladder to contract (Stahl et al, 1995).
Despite a large number of studies demonstrating the effectiveness of antimuscarinics on
symptoms of OAB there are few studies examining their actions on the bladder at the
doses which are effective on OAB symptoms. Certainly, little data is available on
whether antimuscarinics actually reduce the strength of abnormal contractions, thus
answering the question; 'Are the beneficial effects of antimuscarinics due to a
reduction of the DO component of OAB?' Despite this lack of data there is a slow but
growing anecdotal realisation that, at clinically effective doses, the drugs have little
effect on bladder contractility. If this is so, the generally accepted view of their mode of
action is incorrect.
1.7.2 Further complications
Only 54% of patients presenting with the OAB symptom complex show involuntary
bladder contractions during a cystometric investigation (Digesu et al, 2003). These
patients subsequently respond well to antimuscarinic drugs and the symptoms of OAB
decrease. Thus, at first sight, it would appear that this group of patients behave
according to 'classical theory'. In the remaining 46% of patients however, bladder
contractions are not seen during filling (Digesu et al, 2003). These patients have what
has previously been referred to as 'sensory urgency' as opposed to detrusor over
activity. Interestingly, these patients with OAB but no DO appear to respond equally
well to the antimuscarinic drugs with reduced symptoms of urge and incontinence
(Hashimoto et al, 1999). Based on the 'classical theory' there is no reason why these
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patients should benefit from an antimuscarinic drug since they have no pathological
contractions of the detrusor to inhibit.
A further complicating factor comes from studies of healthy asymptomatic volunteers
undergoing conventional urodynamics and ambulatory urodynamics. In one study 17%
had activity during conventional urodynamics similar to that seen in patients with OAB.
During ambulatory urodynamics 38% of these normal subjects had contractions during
the filling phase of the micturition cycle (Robertson et al, 1994). In a different study
60% of asymptomatic normal volunteers had bladder contractions during the filing
phase (Heslington et al, 1996). These observations bring into question the significance
of the apparent correlation of bladder contractions with OAB. If a high proportion of
'normal' subjects have bladder activity during filling, is it pathological or
physiological?
These observations therefore present three fundamental problems:
Why are the antimuscarinic drugs effective in patients with OAB but no DO? Why
do only halfof the patients with OAB symptoms have DO?




1.7.3 Effects of antimuscarinics upon muscle strips
The role of antimuscarinic drugs upon cholinergic mediated contraction of the detrusor
muscle is well established. For example, oxybutynin reduces carbachol induced
contractions in isolated animal bladder strips (Waldeck et al, 1997; Tonini et al, 1987;
Yono et al, 1999). It also reduces electrically stimulated contractions in guinea pig and
human detrusor strips (Waldeck et al, 1997; Tonini et al, 1987; Yono et al, 1999).
Similarly, tolterodine has been shown to reduce carbachol induced contraction of
human detrusor strips (Yono et al, 1999). Therefore, there can be no doubt that
inhibition of muscarinic receptors on the smooth muscle can decrease the force of
agonist or nerve mediated cholinergic contraction.
1.7.4 Role of muscarinic receptors
The receptors involved are muscarinic receptors. Five distinct subtypes of muscarinic
receptor have been described, Mi-M5 (Caulfield et al, 1998). All five receptor subtypes
are found in the bladder but the most abundant are the M2 and M3 subtypes. In the
human bladder the M2 receptors predominate (2/3) and are more abundant than M3 (1/3),
(Andersson and Wein, 2004). Data from knock out mice show clearly that the M3
receptors are responsible for activating the contraction of the detrusor (Hegde et al,
1999; Chess-Williams et al, 2001; Fetscher et al, 2002; Yamanishi et al, 2001). For this
reason M3 specific drugs were developed to treat bladder over activity. The function
and role of the M2 receptors is not known. However, there is the suggestion that M2
receptors may oppose P-adrenoreceptor mediated sympathetic relaxation of the detrusor
via the inhibition of adenyl cyclase (Hegde et al, 1997; Yamanishi et al, 2002).
Muscarinic receptors are also found on bladder urothelial cells and on structures in the
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suburothelium (interstitial cells, nerves), (Mansfield et al, 2005). Therefore
antimuscarinics have the capacity to block muscarinic receptors elsewhere and not just
on the detrusor muscle where they decrease the ability of the bladder to contract.
However, clinically, antimuscarinics act mainly during the storage phase, decreasing
urge and increasing bladder capacity.
1.7.5 In vivo animal models of bladder dysfunction
It has proven possible to make animal models of OAB where micturition frequency is
increased and the animals may also leak urine. When the antimuscarinic drugs are
studied on these models it is clear that they decrease the frequency of voiding and
increase bladder capacity. However, at these therapeutic doses little effect was noted on
the ability of the bladder to contract. For example, in conscious rats, with an increased
frequency of micturition due to urethral obstruction, oxybutynin (lmg/kg iv) decreased
frequency but did not significantly reduce micturition pressure (Guarneri et al, 1991).
Similarly, doses of solifenacin and tolterodine, sufficient to significantly raise the
bladder capacity of conscious rats with OAB induced by cerebral infraction, did not
significantly reduce micturition pressure (Suzuki et al, 2005).
Further supporting an effect of antimuscarinics on afferent nerves, low doses of
intravenous tolterodine were also found to significantly increase bladder capacity in
vehicle treated rats with detrusor overactivity caused by cerebral infarction, but had no
effects on bladder capacity in rats treated with resiniferatoxin, (Yokoyama et al, 2005).
Also, intravesical administration of tolterodine significantly increased bladder capacity
in control rats with cerebral infarction, but had no effect on bladder capacity in
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resiniferatoxin treated animals. Yokoyama et al therefore suggested that at low doses
tolterodine exerts an inhibitory effect on C-fibre bladder afferent nerves, thereby
improving bladder capacity during the storage phase.
These animal studies clearly illustrate the basic problem. At high doses the
antimuscarinic drugs have a direct effect on muscarinic receptors situated on the
detrusor muscle, preventing agonist or nerve mediated contractile responses. However,
at lower doses, where they clearly affect micturition frequency or bladder capacity, they
have little to no effect on contraction. The conclusion must be that inhibition of bladder
function by M3 specific antimuscarinic drugs must occur at receptors other than those
on the detrusor smooth muscle which are responsible for contraction.
1.7.6 In vivo evidence from human studies
An important question is therefore 'does this discrepancy occur in humans'? There
have been very few studies which have examined or reported parameters associated
with bladder contractility in patients with detrusor overactivity before and after
treatment with antimuscarinic drugs. This is somewhat surprising given the prevalence
of the syndrome and the necessity of understanding how the drugs work.
Therefore in order to investigate the cystometric effects of antimuscarinics at clinically
effective doses the available literature was reviewed, (Finney et al, 2006). Using a
standard 'pubmed' electronic search only 14 original articles (including 2 abstracts)
containing cystometric data for both filling and voiding phases in patients with DO
before and after treatment were identified. In these articles a great deal of variation in
40
Introduction
the cystometric parameters reported, patient numbers and methods of analysis was seen.
These factors made a formal cumulative statistical analysis difficult. In addition, the
changing definition of an overactive contraction during cystometry, from those
restricted to over 15cmH20 to all clinically relevant involuntary rises in detrusor
pressure, made a cumulative comparison inappropriate as a further subdivision in data
would occur. Therefore, due to the limitations in this approach, data from each
individual article was deemed to be significant, based upon p<0.05, and descriptive
analysis used to compare results between articles.
For the purpose of this analysis the published articles were divided into three groups
dependent upon the patient group described; "neuropaths", "idiopaths" and mixed (or
not specifically stated), labelled Groups I-III respectively. In Group I (neuropaths; table
one), data was reviewed from three articles (Madersbacher et al, 1995; Goessl et al,
2000; Stohrer et al, 1991) one of which contained two treatment groups (Madersbacher
et al, 1995), making a total of four reported treatment arms. During filling all treatment
arms commented upon an increase in maximum cystometric capacity (Ccmax), with
two arms both showing a significant decrease in maximum detrusor pressure
(pdetmaxfilling). The effects on compliance were equivocal; two arms showing no
significant change and two a significant increase. In reported voiding parameters,
maximum pressure (pdetmax) was significantly decreased in two arms, both from the
same article. No significant change was seen in maximum flow (Qmax) and the effects
on residual volume were equivocal.
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In group II (idiopaths; table two), data was reviewed from three articles and one
abstract (Giannitsas et al, 2004; Madersbacher et al, 1999; Athanasopoulos et al, 2003;
Rosario et al, 1996). One article, the only article to do so, subdivided patients with
OAB into four categories dependent on the volume and magnitude of the first
overactive contraction (Giannitsas et al, 2004). Patients were labelled as high
volume/low pressure, high volume/ high pressure, low volume/ low pressure or low
volume/ high pressure dependent on the volume and pressure of the first overactive
contraction with respect to the values 250mls and 25cmH20 respectively. This
subdivision was performed in the assessment of two antimuscarinics resulting in 8
treatment arms. However, as two of these arms had insufficient numbers only six from
this article were available for analysis, with one each from the remaining three.
In group II the effects of antimuscarinics on parameters associated with the storage
phase were not clear cut. First desire to void (FDV) was significantly increased in five
treatment arms with two reporting no significant change. This is mirrored by the
volume at first overactive contraction (VFOC), with six showing a significant increase
and two no change. Interestingly, in group II, maximum cystometric capacity (Ccmax)
was only significantly increased in three of the arms, and not significantly changed in
five, conflicting with data from Group I. The maximum pressure of the largest
overactive contraction (pdetmax-oc) again was equivocal with one arm showing a
significant decrease and one no significant change. However, in all groups reporting the
pressure of the first overactive contraction (PFOC), there was no significant change.
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The effects on parameters associated with the voiding phase were unequivocal,
although relatively few anns were available for comment. No significant changes were
seen in either maximum pressure during micturition (pdetmax), maximum flow (Qmax)
or residual volume.
In group III (mixed or aetiology not specified; table three), data was reviewed from six
articles (Jonas et al, 1997; Cardozo et al, 2000; Thuroff et al, 1991; Wagg et al, 2003;
Goode et al, 2002; Griffiths et al, 1994) and one abstract (Abrams et al, 2002). Group
III contained a combination of mixed patient groups and groups where aetiology was
not commented upon. Each article contained one treatment arm examining the effect of
an antimuscarinic in current routine use. (One treatment ann containing data for an
older medication, propantheline, was not analysed). In one article (Goode et al, 2002),
anti-cholinergic and behavioural modification therapy was compared solely with
behavioural modification. Although the results for the effects of antimuscarinics were
not directly presented, they could be deduced from the results.
In this mixed group, antimuscarinics significantly increased both the volume at which
the first overactive contraction occurs (VFOC) and the maximum cystometric capacity
(Ccmax), suggested by four and six articles respectively. In addition, the pressure of
first overactive contraction (PFOC) and the maximum pressure of the largest overactive
contraction (pdetmax-oc) where not significantly changed; although only one article
apiece described these findings.
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No conflict was seen in voiding parameters. Three articles reported no significant
change in maximum flow (Qmax) or detrusor pressure at maximum flow (pdetQmax).
Six articles suggested an increase in residual volume, and in one there was no
significant change in detrusor pressure at either urethral opening or closure.
In general a uniform trend can be seen between groups II and III. However, the main
exception to an overall trend is the effect on reported detrusor pressures seen in group I
(neuropaths); with two arms from the same article demonstrating a significant decrease
in detrusor pressure during both filling and emptying. This may be representative of the
small numbers involved, or, signify difference in the aetiologies of "idiopathic" and
"neuropathic" OAB.
In examining the data as a whole a more convincing picture emerges as to the effects of
anti-cholinergics on urodynamic findings. Parameters associated with storage, such as
first desire to void (FDV) and maximum cystometric capacity (Ccmax) are significantly
increased in the vast majority of articles. With parameters associated with voiding, such
as the pressure at maximum flow (pdetQmax) and maximum flow (Qmax) not being
significantly altered. However, the effect on pdetmax seems equivocal, with two
articles suggesting a decrease in pressure and one suggesting no significant change.
Descriptive analysis of the data allows some conclusions to be formulated for the
majority of urodynamic parameters as either the results are consistent between articles,
or in the case of some disparity, the vast majority of articles suggest one variable over
another. In cases of equivocal results, articles were torn between either similar changes
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or no change. There were no cases of opposing results between articles, i.e. a decrease
and an increase.
This analysis illustrates an absence of data to support antimuscarinics having a
significant inhibitory effect upon detrusor contraction. Most notably, no effect was seen
in the idiopathic (or 'mixed') group of patients and although some reduction was seen
in the neuropathic group, this was limited to one article. This anomaly with the
neuropathic group may represent the small number of articles involved overall. Or
alternatively, be representative of potential differences behind the aetiologies of
'idiopathic' and 'neuropathic' detrusor overactivity. Especially since the majority of
neuropaths generally display higher detrusor pressures, which may be more sensitive to
effects of anti-cholinergics.
It must be emphasised that these findings do not dispute the effects of anti-cholinergics
at higher doses but do suggest that at clinically relevant doses alternative effects need to
be considered. The benefits of decreased urgency, frequency and leakage arise through
improvements in bladder capacity and sensations to void; not, in the case of idiopaths,
through reducing the ability of the detrusor to contract. Consequently, it must therefore
be assumed that antimuscarinics act at sites other than at the detrusor, effecting
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Drug Trosp. Oxy. Tolt. Trosp.
Dose
20mg bd 5mg tds 0.1mg/ kg 20mg bd
Number
(n)
52 43 12 29
Ccmax
(ml)
inc. inc. inc. inc.
Compliance
(ml/cmH20)




- - dec dec
pdet max
(cmH20)
dec dec - -
Qmax
(ml/s)
- - - no change
Residual
vol.(ml)
inc. inc. - no change
Table 1: Table showing the effects of antimuscarinics upon cystometric parameters in
patients with 'neuropathic' related detrusor overactivity. Each column represents a
treatment ami whose effects have been compared to placebo. Cystometric parameters
are shown on the left. Entries show either a significant increase (inc.), decrease (dec.),
or no significant change (no change) compared to placebo (p<0.05) for each of the





























Drug Oxy Oxy Oxy Tolt Tolt Tolt Oxy Tolt Darif
Dose





G2 G3 G4 G2 G3 G4
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Table 2: Table showing the effects of antimuscarinics upon cystometric parameters in
patients with 'idiopathic' related detrusor overactivity. Each column represents a
treatment ana whose effects have been compared to placebo. Cystometric parameters
are shown on the left. Entries show either a significant increase (inc.), decrease (dec.),
or no significant change (no change) compared to placebo (p<0.05) for each of the
cystometric variables shown. (-) appears against parameters not recorded in that article.
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Drug Tolt Trosp Oxy Tolt Oxy Oxy Tolt
Dose







99 132 63 61 105 59 149
FDV
(ml)
inc - - - no change - -
SDV
(ml)
- - - - inc. - -
VFOC
(ml)
inc. inc. inc. - - - inc.
PFOC
(cmH20)
- no change - - - - -
pdetmax-oc
(cmH20)
no change - - - - - -
Ccmax
(ml)
inc. inc. inc. inc. inc. - inc.
Compliance
(mi/cmH20)
inc. no change - - - - -
pdetQmax
(cmH20)
- - - no change - no change no change
Qmax
(ml/sec)
no change - - - - no change no change
Residual
vol(ml)
inc. inc. inc. inc. - inc. inc.
pdet-uo
(cmH20)
- - - no change - -
pdet-uc
(cmH20)
- - - no change - -
Table 3: Table showing the effects of antimuscarinics upon cystometric parameters in
patients whose aetiology was not stated. Each column represents a treatment ann whose
effects have been compared to placebo. Cystometric parameters are shown on the left.
Entries show either a significant increase (inc.), decrease (dec.), or no significant
change (no change) compared to placebo (p<0.05) for each of the cystometric variables




The data presented thus far highlights the current inconsistencies in the traditional
views of bladder function and patho-physiology. It is emerging that the primary event
in the generation of overactive bladder syndrome (OAB) is urgency and this is distinct
from detrusor overactivity (DO). Furthermore, the role of DO is becoming uncertain as
contractions unrelated to either the act of micturition or the perception of sensation are
present in 'normal' healthy individuals as the bladder fills. These contractions are
analogous to the 'non-micturition' activity seen in animals and are becoming more
apparent with the advent of ambulatory urodynamics. Contrary to traditional thinking
antimuscarinic drugs are effective in individuals with OAB but no DO and have been
found to exert their beneficial effects through improvements in sensory parameters as
opposed to affecting motor activity; suggesting the presence of cholinergic mechanisms
involved in the generation/ modulation of afferent activity.
Additional mechanisms involved in the generation of afferent activity have also been
demonstrated in addition to the identification of structures with the potential to support
these mechanisms. In the cat, regular phasic contractions termed 'non-micturition'
activity are associated with synchronous 'bursts' of afferent activity. This activity can
be modulated by direct input from the CNS suggesting the presence of an integrated
motor/ sensory system. In the isolated bladder this 'non-micturition' activity has been
explored further where it has been termed 'autonomous activity'. It has been shown to
be sensitive to the effects of both muscarinic agonists and antagonists. It is relatively
sensitive to the effects of muscarinic agonists, more so than that of detrusor contraction,
and as such may act as a target for current antimuscarinic drugs. This effect would
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explain the current clinical anomaly of antimuscarinics effecting sensation as opposed
to contraction.
The responses of 'autonomous activity' within the isolated guinea pig bladder have
been well characterised, however, the majority of these were studied at fixed
intravesical volumes. Where the effects of changing intravesical volume were studied a
complex series of events were noted, consisting of a rapid excitation of activity
following volume increase, followed by the formation of a steady state with a period of
quiescence seen following volume reduction. It is likely that each of these distinct
phases are regulated by specific mechanisms within the bladder wall interrelated to




The medical literature suggests that the anti-muscarinic medications currently used in
routine medical practise exert their beneficial effects upon sensory parameters, not
those associated with motor function. This is at odds with our traditional understanding
of both bladder physiology and our treatment of OAB. However, it does suggest that
sensory mechanisms exist within the human bladder that are more sensitive to the
effects of antimuscarinic medication than motor mechanisms. The targets whereby
antimuscarinics may be acting are not clear, however, recent data both relating to
bladder structure and physiology has emerged suggesting potential new targets. One of
these is the concept of autonomous activity, as discussed previously, in which local
reflexes inherent to the bladder wall regulate rhythmical, transient contractions in
response to changes in intravesical volume; suggesting a direct motor/ sensory
interaction.
The aim of this thesis is to test the hypothesis that autonomous activity is a
mechanism through which anti-muscarinic medication may act and to characterise in
more detail the phenomenon ofautonomous activity. Secondary, experimental aims will
be tested to elicit whether other mechanisms are present that alter autonomous activity
suggesting the presence ofother, potentially therapeutic targets.
To test the hypothesis that autonomous activity represents a sensitive cholinergic
mechanism through which anti-muscarinics may act, the effects of increasing doses of
muscarinic agonists upon autonomous activity will be assessed (Chapter 3.3) in
addition to the effects of increasing doses muscarinic antagonists (Chapter 3.4). This
will give some insight into the doses required of both agonists/ antagonists in order to
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significantly alter autonomous activity. An idea will therefore be gained as to the
sensitivity of cholinergic mechanisms responsible for autonomous activity. In addition,
the use of two different agonists and antagonists each with a relative specificity for
either M2 or M3 muscarinic receptors will allow some insight into the roles of the two
muscarinic receptors in the generation of autonomous activity and whether any of the
subtypes can be implicated as the therapeutic target of antimuscarinics.
Since the process of micturition is a dynamic process, consisting of a filling and a
voiding phase, the response of autonomous activity to increases and decreases in
intravesical volume (termed the 'volume response') will be assessed. The work of
Lagou et al, 2004 will be expanded to determine the roles of changes in intravesical
volume (3.5.3), the duration of volume increase (3.5.4) and the effects of agonist
concentration (3.5.5) in the generation of volume induced activity. This will allow
further insight into the mechanisms involved in the regulation of autonomous activity in
response to volume changes.
It is known that autonomous activity can be modulated by other compounds suggesting
further non-cholinergic mechanisms to be also involved in its regulation. Since
autonomous activity was found to be sensitive to the effects of muscarinic agonists and
antagonists (3.3 and 3.4), especially for those specific to the M3 muscarinic receptor
subtype, it is possible that other mechanisms exist that may subsequently be targeted
therapeutically. To explore this idea further, the effects of an anti-muscarinic agent used
in current clinical practise (Tolterodine) upon volume induced autonomous activity was
tested (3.6) in order to demonstrate what may be happening in vivo, bearing in mind the
limitations discussed previously, 1.6.7. Subsequently, similar experiments were
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performed using nicotinic and purinergic compounds to explore the role of other
mechanisms.
The human bladder is known to contain both ganglia and nicotinic receptors, and the
aim of these experiments was to examine the role of these in the modulation of volume
induced activity. To explore the potential effects of ganglia the effects of increasing
doses of the nicotinic receptor antagonist Hexamethonium was assessed, 3.7.1.
Hexamethonium was used as this is typically specific to nicotinic receptors associated
with ganglia found within the autonomic system. Pancuronium was used to explore the
potential for other nicotinic receptor subtypes within this system, 3.7.2. Pancuronium
was chosen as this should have no effect upon receptors found upon ganglia.
The role of the purinergic system within the regulation of volume induced autonomous
activity was also explored. The aims of these experiments were to assess the effects of
purinergic stimulation, non-specific purinergic inhibition and purinergic inhibition
specific to P2Xi and P2Yi receptors. To assess the effects of purinergic stimulation the
response of volume induced autonomous activity to increasing doses of the purinergic
agonist a/(3 methyl-ATP were recorded, 3.8. The effects of non-specific purinergic
inhibition were assessed by the responses to increasing doses of the non-specific
purinergic antagonist, PPADS, 3.9. The role of P2Xi and P2Yi purinergic receptors in
the modulation of volume induced autonomous activity were assessed by using
increasing doses ofNF 279 and MRS 2179 respectively.
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Materials and Methods Chapter Two
2.1 Overview
Female guinea pigs (weight range 250 - 400g) were killed by cervical dislocation in
accordance with Schedule 1 of the UK Home Office regulations. The urinary bladder
was removed en bloc, typically leaving a length of urethra 8 - 10mm long and ureters 6
- 8mm long., and then placed in Tyrodes solution. The solution was bubbled with a 5%
C02 and 95% 02 mixture (pH 7.4). The urethra was cannulated with a polyethylene
cannula (external diameter 2mm) and secured distal to the bladder neck using a fine
thread ligature. Residual urine was gently removed and replaced with Tyrodes solution.
The bladder was then transferred to a heated organ bath (volume 30ml, temperature
maintained at 33 - 36°C) containing constantly gassed Tyrodes solution. The cannula
was connected via a fluid filled tube and 3 way connector to a pressure transducer
(Becton Dickinson DTX Plus) and a 2.5ml syringe to enable variation of the
intravesical volume. The transducer output was amplified, digitalised (sampling rate 20
Hz) and recorded using a Biopac MP 100 data acquisition system, which gives the
facility to capture a wide range of pressures from 0.02 to 80cmH2O. The transducer was
calibrated before each experiment. At the outset each bladder was filled with Tyrodes
solution to give a baseline volume of 800 - 1200pl. These volumes were typically the
amount of urine recovered from animals immediately after cervical dislocation. The
time taken from killing the animal to beginning recording was typically 30 minutes.
Pressure recording was begun immediately but the bladder was left to equilibrate for at
least 20 min before any manipulations. Concentrated drug solutions were added directly
to the bath to achieve the required final dilution. All drugs were added to the solution




2.2.1 Organ bath and associated equipment:
Organ Bath: A jacketed, glass organ bath with an internal volume of 30ml. A schematic
diagram is shown below. One port serves to act as an overflow, regulating the volume
of Tyrodes solution to 30ml. Two ports are involved with the continual heating of the
organ bath contents by the constant flow within the surrounding jacket of water heated
to 33 - 36°C. One port allows the continual aeration of the solution within the organ
bath with 5% C02 and 95% 02. The final port allows drainage via gravity of the








Water heater: electric thermostatically controlled water heater regulating temperature
between 33 - 36°C. An inbuilt pump allows for continuous irrigation of heated water
through the jacket surrounding the organ bath.
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Cannula: A polyethylene cannula 2cm long with an external diameter of 2.0mm and
internal luminal diameter of 1,5mm is introduced into the bladder via the urethra. A
bevelled tip secures the cannula within the bladder once the urethra has been ligated.
Tubing: The length of tubing between the cannula and transducer was 50cm. To prevent
dampening of transmitted pressure impulses stiff, inelastic polyethylene tubing was
used. Internal diameter 1.5mm.
Calibration chamber: an open ended cylinder with a tapered tip allowing connection to
a three way tap via a 50cm length of tubing. Measuring 1cm in diameter and 4cm tall.
Held in position via a stand and clamp to allow calibration.
Three way tap: standard three way tap used in routine clinical practice. Allows an
uninterrupted fluid connection to be made between either two or all of its connections.
The tubing is fixed to the tap via a Tuer' lock.
2.2.2 Pressure recording and data acquisition system
Transducer (Becton Dickinson): Becton Dickinson DTX Plus transducer
Amplifier (Biopac, USA): General purpose single channel, differential amplifier module
DA100C (Biopac, USA).
Specifications: Gain: 50,200, 1000, 5000




Low pass filter: 10Hz, 300Hz, 5000Hz.
High pass filter: DC, 0.05Hz.
Input voltage (max): + 200mV
Noise voltage: 0.11 pV rms - (0.05 - 10Hz)
Temperature drift: 0.3pV/ °C
Data acquisition unit (Biopac, USA): Data acquisition system MP100-CE (Biopac,
USA) performing the same functions as a chart recorder allowing data to be digitalised
before being recorded direct to and subsequently analysed upon a standard laptop
computer.
Specifications: Analogue inputs
Number of channels: 16
Input voltage range: ± 10V
A/D resolution: 16 bits
Accuracy (% of FSR): +0.003
Input impedance: 1.0MO
Analogue outputs
Number of channels: 2
Output voltage range: + 10V
D/A resolution: 12 bits
Accuracy (% of FSR): ±0.02
















USB port type 1
Windows 98 (or above)
Laptop computer (Evesham, UK): a standard household laptop computer was used for
data display, collection and analysis. 1.8GHz processor speed, utilising Windows XP®
(Microsoft, USA) with a USB connection from the Biopac MP100-CE.
'AcqKnowledge' version 3.7.3 data interpretation programme (Biopac, USA): software
package used to collect and interpret data on a standard laptop computer.
2.2.3 Consumables
Tyrodes solution: composition (mM): NaCl 120; KC1 4.5; CaCl2 2.5; MgCl2 1; NaHC03
25; NafTPCb 1; sodium pyruvate 1, glucose 5. (pH 7.4 when constantly gassed with 5%




Arecaidine but - 2 - ynyl ester tosylate (Tocris, UK): Potent muscarinic agonist, 4.6-
fold selective for M2 receptors in the atrium versus those in the ileum. Muscarinic
activity M2>M3. (Barlow and Weston-Smith, 1985; Moser et al, 1989).
Carbamoylcholine chloride (Carbachol), (Sigma, UK): Non specific muscarinic
agonist.
2.2.5 Muscarinic antagonists
[3H] - 4 - DAMP (Tocris, UK): Antagonist at the M3 cholinergic receptor. [3H]-4-
DAMP selectively labels M3 and Mi receptors. (Barlow and Shepherd, 1986; Michel et
al, 1989).
AF-DX116 (Tocris, UK): Selective M2 muscarinic receptor antagonist. Kj values are 64,
417, 786, 211 and 5130nM for human recombinant M2, Mi, M3, M4 and M5 muscarinic
receptors, respectively. (Hammer et al, 1986; Billard et al, 1995; Eglen et al, 1996;
Mansfield et al, 2005).
2.2.6 Nicotinic antagonists
Hexamethonium Bromide (Sigma, UK): Nicotinic antagonist specific to receptors found
on autonomic ganglia.
Pancuronium dibromide (Tocris, UK): Neuromuscular nicotinic receptor antagonist.




2-Methylthioadenosine triphosphate tetrasodium salt (Tocris, UK): P2 purinoceptor
agonist, a non-hydrolysable form of ATP. (Cusack et al, 1982; Burnstock et al, 1983;
McMurray et al, 1998; Khakh et al, 2001).
2.2.8 Purinoceptor antagonists
PPADS tetrasodium salt (Tocris, UK): Non-selective P2 purinergic antagonist. Blocks
recombinant P2X,, P2X2, P2X3, P2X5 (IC5o = 1 - 2.6pM), native P2Y2-like (IC5o ~
0.9pM), and recombinant P2Y4 (ICso ~ 15pM) receptors. (Lambrecht et al, 1992;
McLaren et al, 1994; Ziganshin et al, 1994).
MRS 2179 Tetrasodium salt (Tocris, UK): Competitive antagonist at P2Yi receptors (KB
= lOOnM). Selective over P2X, (IC50 = 1.15pM), P2X3 (IC50 = 12.9pM), P2X2, P2X,,
P2Y2, P2Y4 and P2Y6 receptors. (Boyer et al, 1998; Moro et al, 1998; Nandanan et al,
2000).
NF 279 (Tocris, UK): Selective P2Xi antagonist (ICso = 19nM). Selective over P2X2
(ICso = 0.76pM), P2X3 (ICso = 1.62pM), P2X, (IC50 > 300pM), and P2Y receptors.




2.3.1 Preparation of the isolated guinea pig bladder
Experiments were performed using bladders isolated from female guinea pigs, weight
range 250 - 400g. From delivery animals were stored in conditions complying with UK
Home Office regulations, typically allowing a period of at least 48 hours
acclimatisation before use.
2.3.2 Animal sacrifice
Animals were removed from their surroundings and killed immediately in accordance
with Schedule 1 of the UK Home Office regulations. On all occasions cervical
dislocation was used.
2.3.3 Dissection of the animal bladder
The time from cervical dislocation to the start of dissection was typically <4 minutes. A
midline incision was made over the abdomen from the rib cage inferiorly to the pubis.
Lateral extensions were made bilaterally at the inferior end of the incision to allow
exposure of the abdominal contents. The small and large bowels were displaced
superiorly exposing the genitourinary tract. Using heavy scissors a transverse cut was
made across the animal, 1 cm superior to the dome of the bladder, separating the upper
abdomen/ thorax from the lower abdomen/ pelvis. For ease of dissection the pelvis was
then pinned to a cork board and secured.
Once the pelvis was secured the bladder was dissected under magnification using light
microscopy. (During this time the bladder was washed frequently with heated (33 -
36°C), gassed (5% C02 and 95% 02) Tyrodes solution to prevent drying). Initially, the
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pubic arch was transected both sides of the urethra and dissected free. Once the urethra
was fully exposed it was mobilised off the underlying vagina. Keeping this plane, the
bladder was subsequently dissected off the uterus. The ureters were identified
bilaterally and dissected free from their enclosing fascia. The ureters, bladder and
urethra were fully mobilised and were removed en bloc into a petrie dish containing
heated, gassed Tyrodes solution. The urethra was cut to leave a length 8 - 10mm and
the ureters to a length 6 - 8mm long. The ureters were not ligated as a length of 6 -
8mm was found to be sufficient to prevent leakage of the bladder contents. Overlying
fat and fascia were excised from the bladder.
2.3.4 Cannulation of the animal bladder
The urethra was cannulated with a polyethylene cannula (external diameter 2mm) and
secured 2-3mm distal to the bladder neck using a fine thread ligature. The cannula was
placed such that the tip was positioned within the centre of the bladder. Residual urine
was gently removed via the cannula and replaced with heated, gassed Tyrodes solution.
Care was taken to remove air from the bladder.
2.3.5 Weighing of the animal bladders
The weight of the cannula, ligature, Tyrodes solution and the petrie dish were all known
prior to the addition of the bladder. Residual urine removed from the bladder was kept
separate and the Tyrodes solution used to replace this taken directly from the petrie
dish. The cannulated bladder within the petrie dish was then weighed with the bladder




2.3.6 Transferring of the bladder to the organ bath
The bladder was placed within a heated organ bath (33 - 36°C) containing gassed (5%
C02 and 95% 02) Tyrodes solution. The cannula was attached to a fluid filled (Tyrodes
solution) tube connecting to the transducer and data acquisition unit, and suspended
upside down in the organ bath. (The urethra being superior and the bladder dome
inferior). Again, care was taken to prevent air entering either the bladder or fluid filled
tube during attachment. Typically, < 30minutes was taken from the time of cervical
dislocation to transferring to the organ bath and starting pressure recording.
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2.4 Preparation of pressure recording equipment
2.4.1 Setup of recording equipment
The equipment was setup prior to dissection of the animal bladder. A schematic
diagram of the equipment is shown in Figure 12. The cannulated bladder was attached
to a tube filled with Tyrodes solution connecting the bladder to a transducer and data
acquisition system. Two '3 - way' taps were placed in the system, one to allow
calibration of the transducer and the other to allow alteration in intravesical volume.
Prior to attachment of the bladder the system was flushed with Tyrodes solution to
remove air bubbles. The organ bath was also pre-filled with Tyrodes solution, gassed
with 5% C02 and 95% 02 (to give a pH of 7.4) and heated to 33 - 36°C.
2.4.2 Equilibration
Following attachment the bladder was gently emptied via the 2.5ml syringe attached to
the system by way of a 3 way tap and then instilled with 1200pl of Tyrodes solution.
The preparation was allowed to equilibrate for 20 minutes before any manipulations
were made. Although, recordings were made as soon as calibration of the transducer
had been performed these were not used for analysis.
2.4.3 Calibration of the transducer and data acquisition system
For calibration the fluid filled 'calibration' chamber was connected directly to the
transducer via a '3 - way tap', with the connection to the bladder being closed. The
output from the transducer and pressure recording by the data acquisition system (in
cmH20) were calibrated against known heights of a standing column of fluid; in this
case the height of the fluid level within the calibration chamber above the transducer. It
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was assumed that the pressure from a standing column ofwater would be comparable to
that of a standing column of Tyrodes solution.
2.4.4 Recording of intravesical pressure
Following calibration the transducer, by way of the '3 way tap', was reconnected to the
bladder and the connection to the calibration chamber closed. Intravesical pressure
measurements were continuously recorded in cmH20 with a digital capture rate of
20Hz.
2.4.5 Assessment of minimal quality of experimental preparation
Following calibration of the equipment and equilibration of the organ system, the
'quality' of the isolated bladder was assessed. From the previous works of Gillespie and
the authors own anecdotal experience it can be seen that the guinea pig bladder
demonstrates typical responses following the addition of increasing doses of arecaidine,
an example of a typical response to arecaidine is illustrated in Figure 17. Prior to the
commencement of any experiments the response of the preparation to 30nM, lOOnM
and 300nM arecaidine was assessed. Those bladders that failed to respond in a typical
fashion were discarded and not used for data collection. Approximately 15 bladders
were discarded for this reason. 46 bladders were used for data collection throughout the
course of these experiments.
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2.5 Manipulation of the guinea pig bladder
2.5.1 Augmentation of Autonomous Activity:
In all experiments, except those assessing the effects of increasing doses of carbachol,
arecaidine was used to augment autonomous activity. At steady state arecaidine was
found to result in rises in intravesical pressure that were regular in both frequency and
amplitude with little in the way of low amplitude irregular contractions when compared
with carbachol. As such, arecaidine allowed for ease of interpretation of the effects of
various compounds upon augmented activity as there was less inherent variability in the
effects of the 'driving' muscarinic agonist. It is for this reason that the use of arecaidine
has become widespread in these types of experiments, (Drake et al, 2003; Gillespie et
al, 2003 through to 2006).
2.5.2 Addition of drugs
Concentrated drug solutions were added directly to the solute bathing the abluminal
surface of the bladder to achieve the final desired concentration within the organ bath.
2.5.3 Removal of drugs ('washout')
The solution bathing the isolated bladder was drained via the 'waste port'. Fresh
Tyrodes solution, pre-heated and gassed, was then immediately added to the organ bath.
The organ bath was allowed to equilibrate for 180seconds prior to any further
manipulations. At higher doses of drug concentrations further washouts were performed
until the effects of the drug had been fully removed.
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2.5.4 Alteration of intravesical volume
Intravesical volume was increased and decreased by a 2500pl syringe connected to the
system via a 3 way tap. Prior to assessing the effects of muscarinic agonists/ antagonists
on augmented activity intravesical volume was typically 1200pl. This volume remained
fixed between these experiments. However, prior to experiments upon the 'volume
response' intravesical volume was reduced to the minimum volume that would allow
for a recordable variation in intravesical pressure, referred to as the 'baseline volume'.
This was typically in the region of 200 - 400pl. Given the nature of measuring
intravesical pressure via a fluid column, a minimum volume is required within the
bladder to prevent collapsing of the bladder around the cannula tip and to allow
transmission of pressure elevations.
2.5.5 Marking of time points
Each time the bladder was manipulated the time and nature of the manipulation was
















Figure 12: Schematic diagram demonstrating the setup used for recording intravesical
pressure within the isolated guinea pig bladder. The bladder is suspended within the
organ bath containing heated (33 - 36°C), gassed (5% CO2 and 95% O2) Tyrodes
solution. The cannula within the bladder is connected to a transducer by fluid filled
tubing 50cm in length. Two 3 - way taps are present. One connecting to a fluid filled
chamber to allow calibration of the transducer, and the other to a 2.5ml syringe to allow
manipulation of intravesical volume. The transducer is in turn connected to a data




2.6.1 Number of data samples (n)
For all experimental analyses, only one set of data from each bladder was used.
Typically this was taken from the first experiment of the day, immediately after
equilibration, calibration and assessment of bladder quality, 'n' refers to the number of
bladders used during the course of each experiment with only one set of data being
taken from each bladder. (No more than one set of data was taken from a bladder).
2.6.2 Mean average, standard deviation (SD) and standard error of the mean
(SEM)
The mean average and standard deviation were calculated using the basic statistics
function of Excel (Microsoft ®). As calculation of the standard error of the mean
(SEM) is not part of this software's application this was calculated manually within an
Excel spreadsheet using the equation,
2.6.3 Paired Student's t-test
This test was performed to compare differences between groups of data obtained from
the same isolated bladders where all data points were present. Excel (Microsoft ®) was
used to calculate these. All results were 'two-tailed'.
2.6.4 t-test assuming unequal variances
This test was used to compare differences between data were either comparison of
different bladders was made or data points were missing. Excel (Microsoft ®) was used
to calculate these. All results were 'two-tailed'.
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2.6.5 One way Analysis of variance (ANOVA)
In instances were multiple comparisons were performed across a range of different
doses a one way analysis of variance was performed. To assess the significance of
individual comparisons between doses Tukey's post hoc test was used to calculate
significance and obtain a p-value. ANOVA and post hoc Tukey's tests were performed
using the 'SPSS®' software package, SPSS inc.
2.6.6 Two way Analysis of Variance (ANOVA)
In instances were multiple comparisons were performed across a range of different
doses and across two compounds a multi-factorial analysis, two way ANOVA, was
performed. Again Tukey's post hoc test was used to calculate significance and obtain p-






During the course of these experiments two physiological responses inherent to the
isolated guinea pig bladder were studied; 'Phasic Activity' (Drake et al, 2003a; Drake
et al, 2003b) and the 'Volume Response' (Lagou et al, 2004). For each, data was
acquired in the form of traces plotting intravesical pressure against time; a typical
example of one of these traces is shown in Figure 13. Comparison between traces was
possible qualitatively, allowing for gross differences and overall trends to be identified.
However, in order for a quantitative assessment suitable for identification of subtle
differences, in turn allowing fonnal statistical analysis, parameters specific to certain
characteristics of the responses needed to be calculated, described below. Parameters
common to both physiological responses are defined initially with parameters relating
to a specific response being discussed at the beginning of the relevant results
subsection. Mean values are expressed ± 1 standard error of the mean, significance is
attributed to p values <0.05.
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3.2 Interpretation of results
3.2.1 Definition and calculation of parameters common to spontaneous activity
under iso-volumetric conditions and volume induced responses
(i) frequency (transients/sec)-, frequency of phasic activity was determined by
measuring the time interval between adjacent pressure
rises, (b) - (a). The reciprocal of this interval represents
the instantaneous transient frequency, at point (b), as the
instantaneous frequency for a specific time point refers to
the intertransient interval immediately preceding it.
Therefore,
freq at point (b) = 1 (Figure 13)
(time (b) - time (a))
A plot showing the instantaneous frequency for the transients displayed in Figure 13 is
illustrated, Figure 14.
(ii) amplitude (cmH20): calculated as the pressure between the trough
immediately preceding the transient contraction and the
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Figure 13: Typical trace plotting pressure (cmH20) against time (seconds); in this case
showing the response following addition of 300nM Arecaidine to the solution bathing
the isolated bladder, (b) - (a) highlights the time interval between adjacent pressure
rises, (c) demonstrating the points used to calculate the amplitude of a transient
contraction, (d) underlying pressure, (e) initial phase, (1) steady state.
Figure 14: shows analysis of the record shown in Figure 13 illustrating the change in
the frequency of transients during exposure to 300nM arecaidine. The data show the
instantaneous frequency of the transients (defined and the reciprocal of the inter-spike
interval) for each event in relation to the subsequent transient. Ordinate, frequency
(transients/ second) and abscissa, time (seconds). Maximal initial frequency (IFmax) and
frequency at steady state (Fss) are shown.
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3.2.2 Definition and calculation of parameters specific to spontaneous activity
under iso-volumetric conditions
The addition of a muscarinic agonist to the isolated guinea pig bladder results in a series
of complex changes in intravesical pressure, such as the effects of 300nM arecaidine
demonstrated in Figure 13. Typically, an initial rise in basal pressure is seen with a
superimposed increase in transient frequency. During prolonged exposure, the rise in
basal pressure declines, the frequency of transients falls and the amplitude of transients
increases. These two sets of events are consistent between the two agonists, arecaidine
and carbachol, and as such parameters have been defined to help differentiate between
these 'initial' and prolonged, 'steady state' phase,
(i) initial phase: this is a qualitative tenn to represent the initial response of the
preparation to the application of agonist. The transition between
the initial phase and steady state varies between compounds and
doses, making an exact demarcation between the two, and
therefore a definition, difficult. Flowever, ((e), Figure 13)
highlights the area of increased frequency and rise in basal
pressure typically referred to as the initial phase.
(ii) steady state: refers to the time from which the frequency of transients and the
basal pressure remains relatively constant, ((f), Figure 13).
(iii) maximum initial frequency (IFmax)\ refers to the maximum instantaneous
intertransient frequency seen following addition of agonist and is
calculated from a frequency/ time plot for each experimental
trace, (Figure 14). To calculate IFmax a line of best fit was added
74
Results
manually to the freq/ time plot, taking into account overall trend
and to exclude aberrant points.
(iv) frequency at steady state (Fss): calculated in a manner similar to IFmax, Fss refers
to the relatively constant frequency seen following a prolonged
exposure to an agonist. Again, due to some small variability in
frequency a line of best fit was added manually by the researcher
to calculate Fss. An example of Fss is shown in Figure 14.
(v) maximal underlying pressure (Pmax): inspection of the responses, particularly at
higher doses, reveals that the transient pressure rises do not fall
back to basal pressure, i.e. the pressure prior to addition of
agonist. Instead the transients appear to be superimposed upon
an underlying rise in pressure. During the initial phase this
includes a slow increase followed by a gradual decrease. Plots of
pressure from baseline to the trough preceding each transient
were constructed for each experiment, ((d), Figure 13). A line of
best fit was drawn manually, by interpretation of the researcher,
to include all the points of smallest amplitude, so to reduce the
effects of aliasing, whereby pressure of the transients is not
allowed to fall back to basal pressures due to the onset of another
contraction. Maximal underlying pressure (Pmax) refers to the
maximal amplitude seen on the line of best fit. An example of an
underlying pressure/ time plot for the trace seen in Figure 13 is
shown below, (Figure 15).
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(vi) underlying pressure at steady state (Pss): as for Pmax, Pss is calculated from a line
of best fit drawn on an underlying pressure/ time plot.
(vii) Amplitude during the initial phase (Am): refers to the amplitude of transients
((c), Figure 13) during the initial phase. For calculation of the
mean of amplitudes during the initial phase the amplitude of 2
transients either side of, and including, the transient at maximal
frequency were used.




Figure 15: underlying pressure/ time plot for the trace seen in Figure 13. Ordinate,
underlying pressure change from basal value (cmH20) and abscissa, time (seconds).




3.3 Effects of arecaidine and carbachol upon spontaneous activity
Addition of the muscarinic agonists arecaidine and carbachol resulted in the generation
of augmented autonomous activity, consisting of regular transient contractions.
Qualitatively, comparison of each drug individually revealed effects upon,
• frequency of transient contractions
• amplitude of transient contractions
• underlying pressure
For both agonists, amplitude and frequency of contractions increased at lower doses
with underlying pressure increasing at doses > 300nM. Examples of typical traces
illustrating the effects of increasing doses of carbachol and arecaidine are shown,
figures 10 and 11 respectively. Clear distinctions between the 'initial' and 'steady state'
phases are seen at doses > 300nM carbachol and > 100 arecaidine. To illustrate this
phenomenon, an initial 'burst' of frequency settling down to a steady state upon
prolonged exposure, traces of doses 30 - 300nM arecaidine shown in Figure 17 have
been expanded, Figure 18 (a-c), with the instantaneous frequency for the transients
charted for the three doses, Figure 18 (d).
Comparison of the traces for the two agonists reveals an overall trend, with frequency,
amplitude and underlying pressure increasing with dose. However, differences exist
mainly during the initial phase, between the agonists in their relative effects on these
three variables. Figure 19 (a) and (b) illustrate typical instantaneous frequency plots
derived from responses to different doses of carbachol (dose range 100-3000 nM) and
arecaidine (dose range 30-3000 nM) respectively, taken from the same preparation. It
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can be seen that with progressively higher concentrations of carbachol IFmax increases.
IFmax also increases with arecaidine but to a lesser extent. Little difference in Fss is seen
between to two agonists. Figure 20 shows mean data accumulated from 6 different
bladders, (n=6 bladder preparations), with standard error bars shown to 1 standard error
of the mean. At 3000 nM carbachol, IFmax was 0.36 + 0.04 transients/sec, significantly
greater than the value of 0.13 ± 0.01 transients/sec in 3000nM arecaidine (p=0.02). For
lOOOnM the means of IFmax between carbachol and arecaidine were 0.21 + 0.05 and
0.12 + 0.007 respectively, (p=0.048). No significant difference was evident at doses <
300nM. In contrast, Fss was not significantly different comparing carbachol with
arecaidine at any concentration.
The effects of different concentrations of carbachol and arecaidine on the amplitude of
the transients in the initial phase (Ainit) and in the steady state (Ass) are shown in Figure
20 c) and d). At low doses, <lOOOnM, the amplitude of the transients generated by
arecaidine, in both the initial phase (Ainit) and steady state (Ass) are significantly greater
than those generated by carbachol. At 300nM mean Aj„it for arecaidine was 13.1 +_
2.2cmH20, and for carbachol 3.4 ± 0.4cmH2O, (p=0.002). At lOOnM mean Ainit for
arecaidine and carbachol were 8.63 ± 1.4 and 1.4 ± 0.46cmH2O respectively, (p=0.001).
A similar pattern was also seen with mean amplitudes at steady state (Ass). At 300nM
mean Ass for arecaidine was 20.8 + 2.7cmH20, and for carbachol 7.3 + l.lcmH20,
(p=0.001). At lOOnM Ass for arecaidine and carbachol were 12.3 ± 2.2 and 1.6 +_
0.42cmFI2O respectively, (p=0.002). No significant difference in amplitudes of transient
contractions during either the initial or steady state phases was seen between arecaidine
and carbachol at doses > lOOOnM.
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Figure 20 e) and f) illustrate the effects of carbachol and arecaidine in the apparent
underlying contraction in the initial phase (Pinit) and steady state (Pss). Apart from at a
dose of 300nM, for both compounds, there appears to be no significant difference in the
amplitude of the rise in underlying pressure generated by carbachol or arecaidine.
An interesting observation to note is that at higher doses, > lOOOnM, both agonists
show a dip in frequency at around 350 seconds to levels below those generated by
lower doses of agonist. This reduction slowly increases back to basal levels by 550
seconds; the significance of this 'undershooting' phenomenon is uncertain but its
presence is best highlighted by the addition of lOOOnM arecaidine illustrated in Figure
19 b).
The addition of muscarinic agonist to the isolated bladder gives a complex response
consisting of two distinct phases, suggesting the presence of two distinct but
interconnected cholinergically processes involved in the regulation of spontaneous
bladder activity. The frequency of the initial phase is significantly increased at doses of
lOOOnM carbachol and higher with no significant difference seen with any dose of
arecaidine. This would suggest that initial frequency is mediated by an M3 response.
The fact that carbachol has little effect upon the frequency at steady state could signify
either that there is little to no M3 mediation of the frequency at steady state or that there
is little cholinergic mediation of steady state frequency since arecaidine also has no
significant effect, ffowever, regulation of the amplitude of spontaneous contraction
seems to be more M2 mediated since there is a significant increase in amplitudes both
initially and at steady state, at doses of 300nM or less. The insignificant differences at
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Figure 16: Dose dependent actions of carbachol on an isolated guinea pig bladder, a)
shows the effects resulting from different concentrations of carbachol added to the
bathing solution. Carbachol was added at the concentration shown during the time
indicated by the horizontal bar. Between drug applications the bladder was washed in
Tyrode's solution, (b) shows the records illustrated in (a) for each concentration of
carbachol on an expanded time scale. Different components to the responses can be
seen. At the low doses, 100 nM and 300 nM, the most obvious action is the generation
of small transient rises in intra-vesicle pressure. At higher concentrations, 1000 nM and
3000 nM there is a clear initial burst of high frequency phasic activity which is
superimposed on a rise in basal pressure. After this initial burst of high frequency
activity the frequency of the transients declines to a constant level. (Note the complex
and varied amplitude of the phasic activity during exposure to the highest
concentrations of carbachol). In all panels the ordinates show pressure in cmH20 and
abscissae time in seconds.
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Figure 17: shows similar responses for different concentrations of arecaidine. (a)
shows the responses resulting from application of 4 different concentrations, (b) shows
the same responses but on an expanded time scale. In all panels the ordinates show
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Figure 18: A detailed analysis of the response of the whole bladder to arecaidine. a) -
c) show the records of the responses generated by 30, lOOnM and 300nM arecaidine
respectively, d) shows analysis of these records illustrating change in the instantaneous
frequency of the transients during exposure to arecaidine, (300nM (■), lOOnM (A), and
30nM (♦)). The data show the instantaneous frequency of the transients (defined and the
reciprocal of the inter-spike interval) for each event in relation to the previous transient.
Ordinates in a) - c) pressure (cmH20) and d) frequency (transients/ second) and















































Figure 19: The effects of different concentrations of carbachol and arecaidine on the
frequency of augmented spontaneous activity. A shows, from a single experiment, data
derived from exposure to 4 different concentrations of carbachol. The upper panel show
the data during the entire exposure to carbachol lasting 600 seconds. The initial 150
seconds of these responses are shown in the panel below. B shows data from the same
bladder exposed to different concentrations of arecaidine. The upper panel show the
data during an exposure to arecaidine lasting 600 seconds. Hie initial 150 seconds of
these responses are shown in the panel below. Ordinates, frequency (transients/ second)
and abscissae, time (seconds). For both agonists, 3000nM (■), lOOOnM (blue ♦),











































































100 nM 1000 10000
Figure 20: Data accumulated from 6 different bladders illustrating the effects of
carbachol and arecaidine on the frequency and amplitude of the transients and the
initial rise in basal pressure, a) and b) show the effects of carbachol (A) and arecaidine
(O) on the initial and steady state frequencies respectively, c) and d) show the effects of
the agonists on the amplitude of the transient rises in intra-vesical pressure in the initial
phase and steady state respectively, e) and f) show data derived for the underlying rises
in basal pressure in the initial phase and in the steady state respectively. Data are shown
as mean values ± 1 SEM (n=6). Ordinates, a) - b) frequency (transients/ second), c) — f)
pressure (cmH20) and abscissae, logio agonist concentration (nM). A significant
difference between the data for carbachol and arecaidine is indicated (* denotes a




3.4 Effects of 4-DAMP and AF-DX upon spontaneous activity
Using the response of the isolated guinea pig bladder to lOOOnM arecaidine, as
described previously, as a control the effects of each of the two muscarinic antagonists,
4-DAMP (M3 > M2) and AF-DX (M2 > M3), were compared. An example of typical
responses of lOOOnM arecaidine in the presence of increasing doses of 4-DAMP is
shown in Figure 21 A. This shows the original records taken from one bladder, Figure
21 A. A control response to a 5 minute exposure of lOOOnM arecaidine was performed
(control) with further responses performed in the same concentration of arecaidine but
in the presence gradually increasing doses of 4-DAMP. A washout of pre-heated/
carboxygenated Tyrode's solution was performed between each dose increase. Figure
21 B shows each of the responses shown in A on an expanded time scale. Figure 21 C
shows the instantaneous frequency plots for each dose over the first 250 seconds of the
response, illustrating the effects of increasing doses of 4-DAMP during the 'initial'
phase.
From cursory examination of the traces it is clear that 4-DAMP, at low concentration,
had a marked effect on the responses generated by lOOOnM arecaidine. Close
examination of these responses demonstrate that the frequency of the initial burst of
activity (IFmax) to be reduced by increasing concentrations of 4-DAMP as well as the
amplitude, both initially and at steady state. The underlying pressure also seems to fall
with increasing doses.
Figure 22 shows an analysis of the experiments illustrated in Figure 21, performed
upon six bladders, (n=6). The mean values along with error bars representing 1
standard error of the mean are shown. Figures 16 a) and b) show mean values for
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maximum initial frequency (IFmax) and frequency at steady state (Fss) respectively. At
low concentrations, 0.3nM, there is a significant reduction in IFmax. As the
concentration of 4-DAMP is increased the reduction in IFmax becomes more
pronounced, appearing to reach a minimum value around lOnM 4-DAMP of 0.07
transients per second. In contrast, the effect of 4-DAMP on Fss is less marked. It is
noted that the lowest value of IFmax in lOnM 4-DAMP (0.069 transients/ second)
approaches the values of Fss. Thus, it is therefore possible that a component responsible
for the initial fast component/ burst of activity has almost been removed leaving the
slow component seen during the steady state relatively unaffected by 4-DAMP. If this
is the case then concentrations of 4-DAMP as low as 0.03nM are sufficient to reduce
the initial frequency by 50%. (Suggesting the mechanisms generating the initial
transients are particularly sensitive to inhibition by M3 specific antagonists). Values for
the mean IFmax in the presence of increasing doses of 4-DAMP are shown in table 4. No






0 0.137 + 0.008 -
0.1 0.128 + 0.004 0.48
0.3 0.112 + 0.006* 0.042
1 0.096 + 0.004* 0.02
3 0.083 ±0.01* 0.01
10 0.069 ± 0.007* 0.007
Table 4: showing the mean effects of increasing doses of 4-DAMP (nM) upon the
maximum initial frequency (IFmax), (transients/ second), calculated from six bladders,
(n=6). A statistically significant reduction compared to control (p<0.05) is illustrated
by an asterix (*) with the respective p value shown in the third column (one way
ANOVA and post hoc Tukey's).
Mean values for maximal underlying pressure (Pmax) and underlying pressure at steady
state (Pss) are shown in figures 16 c) and d) respectively. A significant reduction in Pmax
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is seen at doses > 0.3nM 4-DAMP with the amplitude approaching 0 by lOnM. Mean
values (± 1 standard error of the mean) for Pmaxare shown in table 5. However, the only
significant reduction in Pss was seen at lOnM 4-DAMP, were again it approached 0.
Mean control Pss was 0.87 cmH20 ± 0.09, with a Pss at 3nM 4-DAMP 0.41 cmH20 ±
0.2, (p=0.12). However, mean Pssin the presence of lOnM 4-DAMP was 0.025 cmH20






0 4.45 + 0.52 -
0.1 4.3 ±0.7 0.36
0.3 2.8 ±0.28 0.11
1 2.24 ±0.51 0.08
3 1.81 +0.78* 0.042
10 0.19 ±0.043* 0.007
Table 5: showing the mean effects of increasing doses of 4-DAMP (nM) upon the
maximum underlying pressure (Pmax), (cmH20), calculated from six bladders, (n=6). A
statistically significant reduction compared to control (p<0.05) is illustrated by an
asterix (*) with the respective p value shown in the third column (one way ANOVA
and post hoc Tukey's).
Figures 16 e) and f) show values for the mean amplitude of transient contractions
during the initial phase, mean Ainit, and at steady state, mean Ass. A significant
reduction in mean Ainit was seen at lOnM only. Mean control Ainit was 5.6 cmH20 ±
0.67 and mean Ainit in the presence of lOnM 4-DAMP was 1.5 cmH20 ± 0.37,
(p=0.008). For mean Ass a significant reduction was seen at doses of 4-DAMP > 3nM.
Mean Asscontrol 14.8 cmH20 ± 1.5, 3nM 4-DAMP 9.1 ± 1.72 (p=0.044), and lOnM 4-
DAMP 2.8 ± 0.51 (p=0.0016).
The effects of 4-DAMP upon spontaneous activity stimulated by lOOOnM arecaidine
reveal that the frequency generated in the initial phase is strongly M3 mediated since 4-
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DAMP significantly reduces initial frequency even at small doses, 0.3nM. However, it
has little effect upon the frequency at steady state, again suggesting little M3 regulation
of the frequency of spontaneous activity once the initial phase has passed. The effects
of M3 mediation in the generation of underlying activity may be a direct result of M3
mediated contraction however, in the initial phase it is likely to be related to a degree of
aliasing whereby transients are unable to return to baseline values since the frequency
of subsequent contractions are to high. With a reduction in frequency a reduction in
basal pressure is therefore automatically seen. In addition, the reduction in underlying
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Figure 21: Dose dependent actions of the M3 specific antagonist 4-DAMP on an
isolated guinea pig bladder in the presence of lOOOnM arecaidine. A shows the effects
resulting from adding lOOOnM arecaidine to the bathing solution in the presence of
different concentrations of 4-DAMP. Between arecaidine applications the bladder was
washed in Tyrode's solution containing the next incrementally increased dose of 4-
DAMP. B shows the records illustrated in A for each concentration of 4-DAMP on an
expanded time scale. C shows the instantaneous frequency plot for the first 250 seconds
following addition of arecaidine in the presence of doses 0-1OnM 4-DAMP, (control
(■), 1 nM (♦), 3 nM (A) and 10 nM (•)). These illustrate the different components of
the responses. At low doses, InM, the most obvious action is the reduction in
frequency during the initial phase. At higher concentrations, 3nM and lOnM, there is a
reduction in amplitude and underlying pressure in both the initial phase and at steady
state. In panels A and B the ordinates show pressure in cm H20 and abscissae time in




























Figure 22: Data accumulated from 6 bladders illustrating the effects of different
concentrations of the M3 antagonist 4-DAMP on arecaidine induced responses, a) and
b) illustrate the effects of 4-DAMP on the maximum initial frequency (IFmax) and
frequency at steady state (Fss) respectively, c) and d) illustrate the effects of 4-DAMP
on the initial (Pinit) and steady state (Pss) rises in basal pressure respectively, e) and f)
show the effects on the mean amplitudes of the initial (Ainit) and steady state (Ass)
transients respectively. Data are shown as mean values + 1 SEM (n=6). Ordinates, a)
and b) frequency (transients/sec), c) - f) pressure (cmFFO) and abscissae, antagonist
concentration (nM). A significant difference between the data points compared to
control is indicated (*), (p<0.05, one way ANOVA and post hoc Tukey's).
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In examining the effects of the relatively M2 specific antagonist AF-DX a different
pattern of responses is seen. Figure 23 shows a typical response to lOOOnM arecaidine
in the presence of increasing doses of AF-DX; following the same experimental
protocol as described for 4-DAMP. It illustrates little effect of AF-DX upon the
instantaneous frequency of transients during the initial phase. Though the amplitude of
transient contractions and the underlying pressure seem to be reduced at higher doses.
Figure 23 A illustrates traces taken from a typical experiment. Figure 23 B shows each
of the responses on an expanded time scale. Figure 23 C shows the instantaneous
frequency plots for each dose for 600 seconds following addition of lOOOnM
arecaidine, highlighting relatively little effect of increasing doses of AF-DX on the
'initial' phase.
Figure 24 shows an analysis of the experiments illustrated in Figure 23. The effects of
AF-DX were studied upon six bladders, (n=6), and mean values are expressed along
with error bars representing 1 standard error of the mean. Figures 18 a) and b) show
mean values for maximum initial frequency (IFmax) and frequency at steady state (Fss)
respectively. Neither IFmax nor Fss were appreciably affected by AF-DX; IFmax was only
reduced significantly at lOOOnM and no significant reduction was seen upon Fss.
Figures 18 c) and d) show the effects of AF-DX upon maximal underlying pressure
(Pmax) and underlying pressure at steady state (Pss) respectively. Mean Pmax was
significantly reduced at doses > 30nM. No significant reduction was seen upon Pss.








L 0 8.18 ±0.43 -
30 5.39 ±0.14* 0.048
100 3.63 ±0.15* 0.032
300 1.91 ±0.08* 0.037
1000 0.98 ±0.20* 0.021
Table 6: showing the mean effects of increasing doses of AF-DX (nM) upon the
maximum underlying pressure (Pinit), (cmH20), calculated from six bladders, (n=6). A
statistically significant reduction compared to control (p<0.05) is illustrated by an
asterix (*) with the respective p value shown in the third column (one way ANOVA
and post hoc Tukey's).
Mean amplitudes of transient contractions during the initial phase, mean Ainit, and at
steady state, mean Ass are shown in figures 18 e) and f). For mean Ainit significant
reductions were seen at doses of AF-DX > lOOOnM, table 7. Significant reduction in






0 9 + 0.23 -
30 6 ± 1.10 0.47
100 7.4 ± 0.92 0.56
300 2.7 + 0.23 0.054
1000 2.35 ±0.03* 0.032
Table 7: showing the mean effects of increasing doses ofAF-DX (nM) upon the mean
amplitude of contraction during the initial phase (Ainit), (cmFfO), calculated from six
bladders, (n=6). A statistically significant reduction compared to control (p<0.05) is
illustrated by an asterix (*) with the respective p value shown in the third column (one
way ANOVA and post hoc Tukey's).
A direct comparison was made between the data obtained with 4-DAMP and AF-DX.
Figure 25 combines the data from figures 16 and 18. It is clear that 4-DAMP is dose for
dose, more effective than AF-DX in affecting all parameters investigated. However, it
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is noteworthy that the frequency of the transients in the steady state are only marginally
affected.
AF-DX was not seen to have any significant effect upon frequency during either the
initial phase or at steady state; except at lOOOnM during the initial phase. This would
suggest that the mechanisms involved in the generation of frequency have little in the
way of M2 mediation. The significant reduction seen in the amplitude of the
spontaneous contractions seen during the initial phase suggests a degree of M2
mediation of the mechanisms involved in the generation of contractions as opposed to





















Figure 23: Dose dependent actions of the M2 specific antagonist AF-DX on an isolated
guinea pig bladder in the presence of lOOOnM arecaidine. A shows the effects resulting
from adding lOOOnM arecaidine to the bathing solution in the presence of different
concentrations of AF-DX. Between arecaidine applications the bladder was washed in
Tyrode's solution containing the next incrementally increased dose ofAF-DX. B shows
the records illustrated in A for each concentration of AF-DX on an expanded time
scale. C shows the instantaneous frequency plot for the first 600 seconds following
addition of arecaidine in the presence of doses 0 - lOOOnM AF-DX, (control (A), 300
nM (■) and 1000 nM (♦). In panels A and B the ordinates show pressure in cm H20 and





















































Figure 24: Data accumulated from 6 bladders illustrating the effects of different
concentrations of the M2 antagonist AF-DX on arecaidine induced responses, a) and b)
illustrate the effects ofAF-DX on the maximum initial frequency (IFmax) and frequency
at steady state (Fss) respectively, c) and d) illustrate the effects of AF-DX on the initial
(Pinit) and steady state (Pss) rises in basal pressure respectively, e) and f) show the
effects on the mean amplitudes of the initial (Ainit) and steady state (Ass) transients
respectively. Data are shown as mean values + 1 SEM (n=6). Ordinates, a) and b)
frequency (transients/sec), c) - f) pressure (cmH20) and abscissae, antagonist
concentration (nM). A significant difference between the data points compared to
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Figure 25: a composite figure accumulating all of the data from 12 animals comparing
the effects of 4-DAMP (•) and AF-DX (A) upon the response induced by lOOOnM
arecaidine. Data is expressed as a mean percentage of maximal response + 1 standard
error of the mean, and represents data shown in figures 16 and 18. IFmax and Fss are
shown in figures a) and b) respectively. Underlying pressures initially (Pi„it) and at
steady state (Pss) are shown in c) and d) respectively. Figures e) and f) show the mean
amplitudes during the initial phase and at steady state respectively.
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3.5 Intrinsic characteristics of volume induced changes in augmented
spontaneous phasic activity: the volume response
3.5.1 Overview
Intrinsic characteristics of the volume response with relation to volume increase, time
of increase, and agonist concentration were assessed in addition to the effects on the
response itself by hexamethonium, pancuronium, tolterodine, a/p methylene ATP, and
purinergic receptor antagonists. Calculation of the instantaneous frequency and
amplitude of the transients were calculated in a manner similar to that previously
described. However, further characteristics of this specific response are described
below. A typical example of a standard volume response is illustrated, Figure 26.
Initially, regular transient contractions are seen and these are associated with a fixed
baseline intravesical volume, typically in the region of 200 - 400pl. 2.0ml are added to
the intravesical volume and this is associated with an increase in frequency and
underlying pressure. Initially after the volume increase the frequency and underlying
pressure is highest. Both reduce over time and settle at a steady state. After a set time,
typically 500seconds, the intravesical volume is reduced by 2.0ml back to baseline
volume. This results in a quiescent period where no transient contractions are seen
which is followed by a gradual return in transient frequency and amplitude back to
levels seen pre-volume increase.
Figure 27 shows a plot of the instantaneous frequency of the transients shown in Figure
26. It illustrates calculation of the 'baseline frequency', 'initial frequency', 'frequency
at steady state', and tau values related to the length of the 'inhibitory phase'. Figure 26




Figure 26: typical example of a 'volume response' performed in an isolated guinea pig
bladder, with phasic activity augmented by lOOnM arecaidine. ti represents the time
point at which intravesical volume was increased, in this case by 2.0ml, and ti the time
point where volume was reduced back to baseline volume, (ti - tz) is termed the
'duration of volume increase' and in this case is 500 seconds. The time interval taken to
increase, or decrease, volume is typically < 10 seconds, (a) refers to the period
immediately following the volume increase where there is an initial increase in
frequency and underlying pressure followed by a gradual decrease. Qualitatively this
area immediately succeeding the volume increase is known as the 'initial phase', (b)
refers to the area following a volume increase where the frequency, amplitude and
underlying pressure of transient contractions remain relatively constant, tenned 'steady
state', (c) refers to the time immediately following a volume decrease where a
quiescent period is seen followed by a gradual return in activity, tenned the 'inhibitory
phase'. A clear demarcation of the end of the inhibitory phase is difficult; therefore, the
point at which the frequency returns to 66.6% of the frequency prior to the volume
increase is typically used in calculations; labelled the 'tau value', (d) refers to the points
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Figure 27: shows the instantaneous frequency of transients during the volume response
illustrated in Figure 26. The red dashed line represents a line of best fit drawn during
the period of increased volume, (yi) represents a vertical axis drawn at the point of
volume increase. Intersection of the line of best fit and (yi) represents the frequency at
the point of volume increase (IFimt), extrapolation of this intersection to the ordinate
axis giving the value of IFm,t, shown as (xi). In this case IF,mt equals 0.78 transients/
second, (d) represents the frequency at steady state, (a) - (c) are used in the calculation
of the tau value for the inhibitory phase; the point when frequency returns to 66.6% of
its baseline, 'pre-volume increase' amount, (a) represents the baseline frequency prior
to volume increase, note the frequency following volume decrease is returning to this
level, (b) represents the lowest frequency following volume decrease, (c) represents an
arbitrary line drawn 66.6% of the distance between (a) and (b). (Ti) represents the time
at volume decrease, (T2) is extrapolated from the intersection between the instantaneous
frequency plot and (c); representing the point at which the frequency returns to 66.6%




3.5.2 Definition and calculation of parameters specific to the 'volume response'
(i) Pre-fill phase: refers to the period prior to volume increase.
(ii) Initialphase: a qualitative term referring to the time immediately succeeding
volume increase that is associated with an increase in the
instantaneous frequency of transients and rise in underlying
pressure. Illustrated in Figure 26, (a).
(iii) Steady state: refers to the period during a volume increase where transient
frequency, amplitude and underlying pressure remain relatively
constant, ((b), Figure 26).
(iv) Inhibitory phase: refers to the time following volume decrease where a period of
quiescence is followed by a gradual return in activity, ((c),
Figure 26). For the purpose of quantitative analysis the tau
value of the inhibitory phase is calculated, defined as the time
taken following a volume decrease for the frequency to return to
66.6% of its pre-fill value. Illustrated Figure 27.
(v) pre-fill frequency (Fpre)'■ refers to the mean instantaneous frequency of the 4
transients prior to a volume increase.
(vi) initial frequency (IFimf- refers to the instantaneous frequency of transients
immediately at the time of a volume increase. This value is
calculated from extrapolating a line of best fit of the transient
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frequencies back to the time of volume increase, illustrated in
Figure 27.
(vii) frequency at steady state (Fss): refers to the instantaneous frequency of transients
during steady state. Calculated from a line of best fit constructed
manually by the researcher, illustrated Figure 27 (d).
(viii) amplitude ofpre-fdl transients (Apre): refers to the amplitude of transients in the
pre-fill phase. Mean Apre is calculated for the 4 transient
contractions immediately preceding the volume increase.
(ix) amplitude during the initial phase (Am,): refers to the amplitude of transients
during the initial phase. Mean Am, is calculated from the first 4
transient contractions observed following a volume increase.
(x) amplitude at steady state (Ass): refers to the amplitude of transients during the
steady state phase. The last 4 transients of the steady state phase
are used to calculate the mean Ass.
(xi) underlying pressure change (Pshift): refers to the underlying pressure increase
from that during the pre-fill phase to that seen at steady state,
illustrated ((d), Figure 26). Similar to the underlying pressure at
steady state, described prior to the previous results section, Pshift
is calculated from a line of best fit added to a pressure/ time plot,
incorporating the points of least amplitude, (Figure 9).
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(xii) duration of volume increase (tinc): refers to the time from which the volume
increase has been completed to the time of completion of the
volume decrease, illustrated by (t2 - h) Figure 26.
3.5.3 Differing effects of volume increase and decrease
The effects of three different changes in intravesical volumes were assessed; a typical
example of these responses on the same organ preparation is shown in Figure 28. All
volume responses were performed in the presence of lOOnM arecaidine with the
duration of volume increase lasting 500 seconds. Figure 28 a) shows a response to a
volume increase and decrease of 2.0ml. In comparison Figure 28 b), shows the effects
of an increase and decrease of 1.5ml. Figure 28 c) shows the response to a 2.0ml
volume increase with a 1.5ml decrease. In all an increase in frequency both during the
initial phase (IFimt) and at steady state (Fss) can be seen. In addition, it is clear from
both traces that the frequency during the initial phase is higher than that at steady state.
It can also be noted that the length of the inhibitory phase reduces from trace a) through
to c).
Figure 29 shows mean data + 1 standard error of the mean for five different
preparations. Figure 29 a) shows the effects of the differing volumes on the inhibitory
phase. This was most prolonged following a volume increase and decrease of 2.0ml,
with a mean tau value of 212 + 19 seconds. A volume increase and decrease of 1.5ml
gave a shorter inhibitory phase, mean tau 157 + 9 seconds. However, the shortest
inhibitory phase was seen where the volume was increased by 2.0ml and only
decreased by 1.5ml, leaving 0.5ml above the pre-fill baseline volume; mean tau value
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118 + 9 seconds. A significant difference (p<0.05) was seen between the tau values for
all three sets of volume responses, except for between an increase and decrease of
1.5ml (1.5_1.5ml) and an increase of 2.0ml and decrease of 1.5ml (2.0_1.5ml), (one
way ANOVA, post hoc Tukey's).
Figures 23 b) -d) show the responses to volume increases of 1.5 and 2.0ml on
underlying pressure (Pshift), frequency following volume increase (IFmax) and frequency
at steady state (Fss) respectively. All show a significant increase in these parameters
after a 2.0ml increase compared to that of a 1,5ml increase. Table 8 shows the mean
data ± 1 standard error of the mean for the figures 23 b) - d).
1.5ml vol increase 2.0ml vol increase P value
Mean Pshift
(cmH20) ± 1 SEM
1.41 ±0.19 1.98 ±0.41* 0.048
Mean IFinit (trans/
sec) ± 1 SEM
0.081 ±0.004 0.106 ±0.004* 0.014
Mean Fss (trans/
sec) ± 1 SEM
0.048 ±0.007 0.062 ±0.009* 0.005
Table 8: showing the mean effects of the two volume increases 1.5ml and 2.0ml upon
the change in underlying pressure (PShm), (cmFFO), frequency following volume
increase (IFinit) and at steady state (Fss), (transients/ second). Data has been calculated
from five bladders, (n=5). A statistically significant increase between the two volume
responses (p<0.05) is illustrated by an asterix (*) with the respective p value shown in
the third column (two tailed, student t-test).
Figure 30 shows the effects of the two volume increase, 1.5 and 2.0ml, upon the mean
amplitude of transient contractions during the pre-fill, initial and steady state phases.
As expected no difference exists between the amplitudes pre-fill. However, the
amplitudes during both the initial phase and at steady state are significantly higher
following a 1.5ml volume increase than for a 2.0ml increase. Mean Ainit for a 1.5ml
increase is 13.4 ± 1.5 cmH20 and for 2.0ml is 9.7 ± 1.2 cmH20, (p=0.021). For the 1.5
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and 2.0ml volume increases mean Ass is 14.5 ± 1.1 and 12.6 ± 1.9 cmH20 respectively,
(p=0.015).
This data shows that the mechanisms involved in the generation of the inhibitory phase
are related to both volume decrease as well as volume increase, since the inhibitory
phase is longer after a volume increase and decrease of 2.0ml as opposed to an increase
of 2.0ml and decrease of 1.5ml. Although not a significant difference, an increase and
decrease of 1.5ml leads to a longer inhibitory phase than an increase of 2.0ml and
decrease of 1.5ml. This may infer that it is not the amount by which the volume is
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Figure 28: shows three volume responses, relating to differing volume changes, from
the same isolated guinea pig bladder preparation. The amount by which intravesical
volume was increased and then decreased is illustrated beneath each trace. Each
response was performed in the presence of 1 OOnM arecaidine and the volume increased
for 500 seconds, a) underwent a 2.0ml increase followed by a 2.0ml decrease, b) a
1.5ml increase and 1.5ml decrease and c) a 2.0ml volume increase with a decrease of
1.5ml. Ordinate axes pressure (cmH20) and abscissa time (seconds). The pre-fill phases
are similar for all three, however, in comparing a) and b) and increase in frequency can
be seen initially and at steady state. Also, note a reduction in the inhibitory phase from
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Figure 29: Data accumulated from 5 bladders illustrating the effects of different
volumes changes on the 'volume response', a) illustrates the effects of three
combinations of volume changes on the tau value of the 'inhibitory phase'. Ordinate,
tau value (seconds) and abscissa, volume increase/ decrease (ml), b) represents the
change in underlying pressure (PShift). Ordinate, pressure (cmFfO) and abscissa, volume
increase (ml), c) and d) illustrate the effects the two volume increases upon frequency
following volume increase (IFinit) and at steady state (Fss) respectively. Ordinates,
frequency (transients/ second) and abscissae, volume increase (ml). Data points
separated by a line in b) - d) represent results from the same bladder. Data in a) are
shown as mean values ± 1 SEM (n=5). A significant difference between the data sets
for each volume change b) - d) is indicated (*), (p<0.05, two tailed student t-test).
Significance between data points in (a) are illustrated, *1 significant difference between
1.5_1.5ml and 2.0_2.0ml, *2 significant difference between 2.0_2.0ml and 2.0_1.5ml





stage during volume response
Figure 30: shows mean amplitudes for the two volume increases, 1.5ml (blue) and
2.0ml (maroon), during the three phases of the volume response; pre-fill, initial phase
and steady state. Data was collected from five different isolated guinea pig bladder
preparations, (n=5). Mean amplitudes are expressed ± 1 standard error of the mean.
Ordinate, amplitude (cmH20) and abscissa, stages of the volume response. A
significant difference between the two volume increases during a specific stage of the
volume response is indicated (*), (p<0.05, student t-test).
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3.5.4 Effects of duration of volume increase
In the presence of lOOnM arecaidine and using a volume increase/ decrease of 2.0ml
the effects of increasing volume for a period of 10, 30, 100 and 500 seconds were
assessed. A typical example of these different durations of volume increase performed
on the same isolated bladder is shown in Figure 31. As the volumes both at baseline
and following volume increase remain constant between the 4 experiments no
differences in either the pre-fill or initial phase is seen between volume responses.
What is apparent though is that the inhibitory phase increases along with the duration
of volume increase.
Figure 32 shows the mean tau values of the inhibitory phase collected from 5 bladders.
This illustrates that the inhibitory phase is dependent upon the duration of which
intravesical volume is increased. A statistically significant difference is seen between
all data points apart from the durations 10 and 30 seconds, and 100 and 500seconds.
This data suggests that a duration of volume increase of >30seconds is required in order

















Figure 31: illustrates volume responses performed upon the same organ preparation; in
the presence of lOOnM arecaidine. Volumes were increased and decreased by 2.0ml for
a period of 10, 30, 100 and 500 seconds respectively, (a-d). The duration of each





Figure 32: Data acquired from 5 bladders illustrating the effects of different durations
of volume increase on the inhibitory phase. The abscissa represents the duration by
which volume was increased (seconds). The ordinate axis represents the tau value for
the inhibitory phase (seconds). Data points are shown as mean values ± 1 SEM (n=5).
Apart from between the data points 10 and 30 seconds and 100 and 500 seconds a




3.5.5 Effects of agonist concentration
The effects of the two arecaidine concentrations 100 and 300nM on the volume
response were compared, with typical examples from the same bladder being shown in
Figure 33. As shown previously increases in the frequency and amplitude of transient
contractions is seen with increasing doses of arecaidine; illustrated again in these
preparations by an increase in the frequency/ amplitude at baseline volume immediately
prior to volume increase. Additionally, at the same dose, the frequency during the
initial phase is higher than that at steady state. Comparing between the two doses, both
IFinjt and Fss are higher in the presence of 300nM than lOOnM arecaidine. However, the
inhibitory phase is shorter in the presence of 300nM arecaidine.
Figure 34 shows mean data collected from 5 different bladders on the effects on the
inhibitory phase (tau value), change in underlying pressure at steady state (Pshm),
frequency following a volume increase (IFinit) and frequency at steady state (Fss), a) - d)
respectively. Table 9 summarises the mean data ± 1 standard error of the mean shown
in Figure 34. All volume responses were performed with duration of fill of 500seconds
and a volume increase and decrease both of 2.0ml.
Figure 35 shows the effects of the two agonist concentrations, 100 and 300nM
arecaidine, upon the mean amplitude of transient contractions during the pre-fill, initial
and steady state phases. It shows that the amplitudes of transient contractions are larger
with a higher dose of arecaidine, 300nM, during the pre-fill stage, which has essentially
been highlighted previously in the 'effects of arecaidine/ carbachol'. However, the
amplitudes during the initial phase become smaller with 300nM. But, during the steady
state phase the amplitudes become larger again with 300nM. Mean Apre with lOOnM
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arecaidine was 6.5 ± 1.2 CIT1H2O and for 300nM arecaidine was 13.4 ± 0.7 cmH20,
(p=0.0005). Mean Ainit in the presence of 100 and 300nM were 9.5 ± 0.7 and 6.3 ± 0.9
cmH20 respectively, (p=0.014). For 100 and 300nM respectively, mean Ass was 14.3 ±
1.1 and 16.4 ±0.8 cmH20, (p=0.01).








2.8 ±0.6 3.7 ± 0.5* 0.017
Mean IFinit (trans/
sec) ± 1 SEM
0.091 ±0.014 0.143 ± 0.015* 0.018
Mean Fss (trans/
sec) ± 1 SEM
0.059 ± 0.008 0.075 ±0.01* 0.021
Table 9: summarises the mean data ± 1 SEM from Figure 34, comparing the effects of
two concentrations of arecaidine, 100 and 300nM, on the volume response. Data has
been calculated from five bladders, (n=5). A statistically significant difference between
the two agonist concentrations (p<0.05) is illustrated by an asterix (*) with the
respective p value shown in the third column (two tailed student t-test).
This data shows that the addition of an increased dose of arecaidine reduces the
inhibitory phase suggesting that the mechanisms involved in the return of spontaneous
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Figure 33: Typical traces of volume responses performed in the presence of lOOnM
and 300nM arecaidine, a) and b) respectively. The amounts by which the intravesical
volumes were changed are illustrated beneath each trace, in addition to the duration of
volume increase. In these cases volume changes were 2.0ml, lasting for 500seconds.
Ordinates represent pressure (cmH20) and the abscissa time (seconds). Note, the
increased frequency in all three phases, (pre-fill, initial, steady state), in the presence of
300nM arecaidine, b), compared to lOOnM, a). Also, note the reduction in the
inhibitory phase in the presence of 300nM arecaidine, b).
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Figure 34: Data collected from five different isolated bladder preparations on the
effects on the volume response in the presence of lOOnM and 300nM arecaidine. Data
points connected by a line represent results collected from the same bladder
preparation, a) illustrates the effects of the two arecaidine doses on the inhibitory
phase; ordinate axis, tau value for the inhibitory phase (seconds), b) represents the
effects upon change in underlying pressure (PSh,ft); ordinate axis, pressure (cmFFO). c)
and d) represent the effects upon frequency following volume increase (IF,nit) and
frequency at steady state (Fss) respectively; for both ordinate axis, instantaneous
frequency of transients (transients/ second). In all four panels the abscissae relate to the
two doses of arecaidine in which the volume response was performed (nM). A
significant difference between the effects of the two concentrations is indicated (*),




stage during volume response
Figure 35: Mean amplitudes for three phases of the volume response performed in the
presence of lOOnM (blue) and 300nM arecaidine (maroon). Data was collected from
five different isolated guinea pig bladder preparations, (n=5). Mean amplitudes are
expressed + 1 standard error of the mean. Ordinate, amplitude (cmH20) and abscissa,
stages of the volume response. A significant difference between the two arecaidine
concentrations during a specific stage of the volume response is indicated (*), (p<0.05,
two tailed student t-test).
117
Results
3.6 Effects of tolterodine upon the volume response
Tolterodine is an orally administered anti-muscarinic drug commonly used in the
treatment of OAB. It is a competitive muscarinic antagonist selective for M3 receptors
> M2. Its effects on the volume response in the isolated guinea pig bladder were
assessed with a typical example of the responses to increasing doses illustrated in
Figure 36. These 4 traces highlight a clear reduction in the amplitude of transient
contractions at higher doses, with a slight reduction in frequency both initially and at
steady state. However, the inhibitory phase seems to be obviously prolonged from
lOnM upwards. Figure 37 illustrates data collected from 4 different guinea pig bladders
showing the effects of tolterodine upon the inhibitory phase, change in underlying
pressure (Pshift), frequency following volume increase (IFmax) and at steady state (Fss);
panels a) to d) respectively. This data is also summarised in table 10.
Control lOnM 30nM lOOnM
Mean tau
187 ± 20
221 ±26 260 ± 22 400±14*
(seconds) (0.39) (0.059) (0.003)
Mean Pshift
1.56 ± 0.5
1.1+0.3 1.0 + 0.42 0.84 ±0.9
(cmH20) (0.15) (0.16) (0.22)
Mean IFmax
0.074 ±0.006
0.065 + 0.008 0.062 + 0.005 0.058 ±0.003*
(trans/ sec) (0.17) (0.072) (0.046)
Mean Fss 0.049 ± 0.005
0.049 ± 0.005 0.046 ± 0.006 0.043 + 0.004
(trans/ sec) (0.62) (0.068) (0.055)
Table 10: summarises the mean data ± 1 SEM illustrated in Figure 36; comparing the
effects of increasing doses of tolterodine upon the volume response. Data has been
calculated from four bladders, (n=4). A statistically significant difference between
doses and the control is illustrated by an asterix (*, p<0.05). Respective p values
referring to the statistical difference between a dose and its control are shown in
brackets, (one way ANOVA and post hoc Tukey's).
118
Results
Figure 38 illustrates the effects of tolterodine upon the amplitude of transient
contractions during the different stages of the volume response.
This data illustrates that at higher doses of tolterodine, lOOnM, the inhibitory phase is
significantly prolonged and the initial frequency is significantly reduced. Since
tolterodine has been shown to be clinically effective in the treatment of OAB it can be
speculated that some of these beneficial effects are due to effects upon mechanisms








































Figure 36: Typical traces, from the same isolated bladder preparation, showing the
effects of increasing doses of tolterodine upon the volume response, a) control, b)
lOnM, c) 30nM and d) lOOnM. In all traces responses were elicited in the presence of
lOOnM arecaidine with volume increased/ decreased by 2.0ml and the duration of fill
lasting 500seconds. Ordinates represent pressure (cmH20) and the abscissa time
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Figure 37: Data collected from 4 bladders illustrating the effects of increasing doses of
tolterodine upon the volume response, a) effects on the tau value of the inhibitory
phase. Ordinate, tau value (seconds), b) represents change in underlying pressure (PShift)-
Ordinate, pressure (crnFFO). c) and d) illustrate the effects of tolterodine upon
frequency following volume increase (IFimt) and at steady state (Fss) respectively.
Ordinates for c) and d), frequency (transients/ second). For all panels the abscissa
represents the dose of tolterodine added to the preparation (nM). Data points are shown
as mean values ± 1 SEM (n=4). A significant difference between the data points
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Figure 38: Data from 4 bladders showing the effects of increasing doses of tolterodine
upon the amplitude of transient contractions during the pre-fill, initial and steady state
phases. Blue column represents the control response for each stage where no
tolterodine was added. Maroon, in the presence of lOnM tolterodine; gold, 30nM; and
green, lOOnM. Mean amplitudes are expressed + 1 standard error of the mean, (n=4).
Ordinate, amplitude (cmTfO) and abscissa, stages of the volume response. A
significant difference between doses and the control during a specific stage of the
volume response is indicated (*), (p<0.05, one way ANOVA and post hoc Tukey's).
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3.7 Effects of the nicotinic receptor antagonists, Hexamethonium and
Pancuronium, on the volume response
The effects of hexamethonium, an antagonist specific to ganglionic nicotinic receptors,
and pancuronium, an antagonist selective for nicotinic receptors typically found on
skeletal muscle, were assessed on the volume response in the isolated guinea pig
bladder. Both were found to have an effect during the volume response following a
volume increase, however, only pancuronium exhibited any effect on underlying
augmented activity, i.e., activity during the pre-fill stage. In the first instance the effects
of the individual antagonists upon the volume response will be described followed by a
comparison of their effects during the pre-fill phase.
3.7.1 Effects of hexamethonium on the volume response
Hexamethonium was found to significantly prolong the inhibitory phase at a dose of
3pM. However, no significant effect was seen on either the frequency following
volume increase (IFinit), frequency at steady state (Fss) or change in underlying pressure
(Pshift) when compared to control values. A typical example of traces collected from the
same organ preparation is illustrated in Figure 39. These volume responses were
performed in the presence of lOOnM arecaidine, with a 2.5ml increase in intravesical
volume lasting for 500seconds.
Mean data collected from 5 different bladders are shown in Figure 40. Figure 40a)
illustrates the increase in tau values for the inhibitory phase associated with
hexamethonium. A dose dependent response was not seen as the inhibitory phase was
more prolonged in the presence of 3pM rather than lOpM. The mean tau value with no
hexamethonium added, (control), was 239 ± 23 seconds; mean + SEM. In the presence
of 3pM hexamethonium mean tau value was 346 + 35 seconds, with a statistically
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significant increase being seen compared with control, (p=0.025). For lOpM mean tau
was 320 ± 79 seconds; (p=0.054). The change in underlying pressure from pre-fill to
steady state, PShi«, is illustrated in Figure 40b). No significant reductions are seen at
either dose. Figure 40c) and d) illustrate that hexamethonium has no effect upon either
the instantaneous frequency of transient contractions following volume increase (IFinit)
or the frequency at steady state Fss respectively.
The effects of hexamethonium upon the amplitude of transient contractions are
illustrated in Figure 41. It can be seen that the amplitude of contractions increase
through the three stages of the volume response, pre-fill, initial and steady state.
However, no statistical difference can be seen between control and either dose of
hexamethonium during any single stage.
This data shows that hexamethonium at a dose of 3pM significantly prolongs the
inhibitory phase. This would suggest that nicotinic receptors, more specifically those
related to ganglia, are involved in the return of activity following volume induced
inhibition. Since there little response on the other parameters is seen it would seem that
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Figure 39: Typical traces showing the effects of 3 and 10pM hexamethonium upon the
volume response in the isolated guinea pig bladder; taken from the same organ
preparation. Volume responses were perfonned in the presence of lOOnM arecaidine,
with a volume increase of 2.5ml lasting for 500 seconds, a) control response, no
hexamethonium added, b) and c) illustrate responses in the presence of 3 and lOpM
hexamethonium respectively. Arrows indicate the point at which hexamethonium was
added to the Tyrode's solution bathing the abluminal surface of the bladder. Ordinates
represent pressure (cmH20) and the abscissa time (seconds). The volume and duration





































Figure 40: Data collected from 5 bladders illustrating the effects of two doses of
hexamethonium, 3 and lOpM. on the volume response, a) illustrates the effects upon
the tau value of the inhibitory phase. Ordinate, tau value (seconds), b) represents the
change in underlying pressure (PShift). Ordinate, pressure (cmFfiO). c) and d) illustrate
the effects upon frequency following volume increase (IFmit) and at steady state (Fss)
respectively. Ordinates, frequency (transients/ second). Die abscissa in all panels
represents the dose of hexamethonium in which the volume response was performed
(pM). Data are shown as mean values ± 1 SEM (n=5). A significant difference between






stage during volume response
Figure 41: Data from 5 bladders showing the effects of 3 and 10pM hexamethonium
upon the amplitude of transient contractions during the pre-fill, initial and steady state
phases. Blue column represents the control response for each stage where no
hexamethonium was added. Maroon, 3pM hexamethonium; gold, 10pM
hexamethonium. Mean amplitudes are expressed ± 1 standard error of the mean, (n=5).
Ordinate, amplitude (cmffO) and abscissa, stages of the volume response. No




3.7.2 Effects of pancuronium bromide on the volume response
In contrast to hexamethonium, pancuronium exerted effects on all the stages of the
volume response. A typical example of responses obtained from the same bladder
preparation following the addition of 3 and lOpM pancuronium are illustrated in Figure
42. As with hexamethonium, these volume responses were performed in the presence
of lOOnM arecaidine with intravesical volume increased by 2.5ml for a period of 500
seconds.
The mean data from the six bladders used to study the effects of pancuronium are
described in Figure 43. Figure 43a) illustrates the increase in tau values for the
inhibitory phase associated with pancuronium. The mean control tau value in the
absence of pancuronium was 232 ±35 seconds. In the presence of 3pM pancuronium
mean tau was 307 ± 32 seconds, which was not significantly increased compared to
control. However, at lOpM mean tau was significantly increased at 410 ± 67 seconds,
compared to control (p=0.016). Figure 43b) illustrates that no significant change is seen
in the change in underlying basal pressure (Pshm) at either dose. The frequencies during
the initial phase were noted to be significantly reduced by both doses of pancuronium.
However, during steady state a decrease in frequency was only seen at 10p.m. Figure
43c) illustrates the effects upon frequency following volume increase (IFinit). Mean IFinit
for control, 3 and 10pM are 0.130 + 0.02 transients/ second, 0.082 + 0.01 (p=0.03,
compared to control) and 0.078 ± 0.01 (p=0.04) respectively. The effects upon
frequency at steady state are demonstrated in Figure 43d). Mean Fss for control is 0.004
± 0.01 transients/ second. In the presence of 3pM pancuronium although a reduction
was seen this was not significant, mean 0.036 ± 0.006 transients/ second. Mean Fss with
lOpM pancuronium was 0.034 ± 0.006, (p=0.048).
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Figure 44 demonstrates the effects of pancuronium upon the amplitude of transient
contractions. It can be seen that the amplitude of contractions are significantly reduced
compared to control values during the pre-fill and steady state phases. However, no
significant difference was seen during the initial phase. Also, no significant difference
exists between the two doses in any of the three stages.
This data reveals that pancuronium significantly increases the inhibitory phase at a dose
of lOpM in addition to significantly reducing the frequency at steady state. At doses of
3 and lOpM frequency both pre volume increase and immediately following volume
increase are significantly reduced. This again would suggest a role for nicotinic
receptors, similar in nature to those found on skeletal muscle, in the modulation of the
inhibitory phase and the generation of the frequency of spontaneous contractions. (It is
acknowledged that pancuronium can have non specific anti-muscarinic (M2/ M3) effects
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Figure 42: Typical traces showing the effects of 3 and lOpM pancuronium upon the
volume response in the isolated guinea pig bladder; taken from the same organ
preparation. Volume responses were perfonned in the presence of lOOnM arecaidine,
with a volume increase of 2.5ml lasting for 500 seconds, a) control response, b) and c)
illustrate responses in the presence of 3 and lOpM pancuronium respectively. Arrows
indicate the point at which pancuronium was added to the organ preparation. Ordinates
represent pressure (cmH20) and the abscissa time (seconds).
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Figure 43: Data collected from 6 bladders illustrating the effects of 3 and lOpM
pancuronium on the volume response, a) illustrates the effects on the tau value of the
inhibitory phase. Ordinate, tau value (seconds), b) represents the change in underlying
pressure (PShift). Ordinate, pressure (cmFFO). c) and d) illustrate the effects upon
frequency following volume increase (IFjmt) and at steady state (Fss) respectively.
Ordinates, frequency (transients/ second). The abscissa in all panels represents the dose
of pancuronium added to the organ preparation (fiM ). Data are shown as mean values ±
1 SEM (n=6). A significant difference between doses compared to control is indicated





stage during volume response
Figure 44: Data from 6 bladders showing the effects of 3 and 10pM pancuronium upon
the amplitude of transient contractions during the pre-fill, initial and steady state
phases. Blue column represents the control response for each stage where no
pancuronium was added. Maroon, 3pM pancuronium; gold, lOpM pancuronium. Mean
amplitudes are expressed + 1 standard error of the mean, (n=6). Ordinate, amplitude
(cmH20) and abscissa, stages of the volume response. A significant difference between




3.7.3 Effects of hexamethonium and pancuronium on underlying augmented
autonomous activity
The effects of hexamethonium and pancuronium on underlying augmented activity, i.e.
during the pre-fdl phase of the volume response, are considered further. From the traces
shown in Figure 45, representing typical examples of the responses following addition
of hexamethonium (column A) and pancuronium (column B), no obvious effect is seen
with hexamethonium. Flowever, following addition of pancuronium to the bathing
solution, at 3 and lOpM, a reduction in frequency and amplitude of transient
contractions can be seen. In addition, at 1 OpM there seems to be a reduction in the
underlying pressure.
Figure 46 summarises the mean data collected following the addition of
hexamethonium and pancuronium to five and six bladders respectively. Again, no
effect is seen on underlying autonomous activity following the addition of both 3 and
1 OpM hexamethonium. However, significant reductions are seen with pancuronium in
the instantaneous frequency of the transients and in their amplitude at both doses,
figures 40 B a) and b) respectively. Figure 46 B c) illustrates a significant reduction in
underlying pressure following the addition of lOpM pancuronium.
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Figure 45: Typical examples of traces showing the effects of hexamethonium and
pancuronium on the spontaneous activity augmented by 1 OOnM arecaidine seen during
the pre-fill phase of the volume response. Columns A and B represent the responses to
hexamethonium and pancuronium respectively. Rows a) and b) represent the doses 3
and lOpM respectively. Arrows represent points at which drugs were added to the
bathing solution of the organ preparation. In all panels ordinates represent pressure









































Figure 46: Data collected depicting the effects of hexamethonium and pancuronium on
autonomous activity during the pre-fill phase of the volume response, columns A and B
respectively. Panels a) represent instantaneous frequency of transients, b) the effects
upon amplitude of transients and c) shift in underlying pressure compared to control.
Mean data is expressed ± 1 standard error of the mean. (n=5 for hexamethonium) and
(n=6 for pancuronium). A significant difference between doses compared to control is
indicated (*), (p<0.05, a-b) one way ANOVA, c) two tailed Students t-test). Ordinates
in a) represent instantaneous frequency of transients (transients/ second) and in b) - c)
pressure (cmPbO). Abscissae for all panels dose (pM).
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3.8 Effects of a/p methylene ATP on the volume response
The effects of a/p methylene ATP on the volume response in the isolated guinea pig
bladder were assessed at two doses, 100 and 300nM. Both doses had similar effects by
increasing frequency during the initial phase and at steady state, in addition to
markedly prolonging the inhibitory phase. Figure 47 illustrates a typical example of
volume responses performed on the same organ preparation in the presence of 100 and
300nM ATP. The volume change for each was 2.5ml with the increase lasting for a
period of 500 seconds. These volume responses were performed in the presence of
lOOnM arecaidine added to the bathing solution. Figure 48 represents the traces
illustrated in figures 41 a) and c) with the time scale expanded, highlighting the
increase in initial frequency and the frequency at steady state between control and
300nM a/p methylene ATP.
Figure 49 summarises the mean data ± 1 standard error of the mean from 5 isolated
bladders on the effects of 100 and 300nM a/p methylene ATP on the volume response.
Figure 49a) illustrates the increase in the inhibitory phase associated with a/p
methylene ATP. The mean control tau value in the absence of a/p methylene ATP was
161 ± 19 seconds. In the presence of lOOnM a/p methylene ATP the mean tau was 352
± 10 seconds, which was significantly increased compared to control, (p=0.001). For
300nM, mean tau was 421 ± 40 seconds, again increased compared to control
(p=0.006). Figure 49b) demonstrates that a/p methylene ATP does not significantly
alter the increase in underlying pressure from baseline pre-fill levels to that at steady
state, (Pshift). Mean Pshrn for control, 100 and 300nM a/p methylene ATP are 2.2 ± 0.5
cmFfO, 2.3 ± 0.8 cmFfO and 1.3 + 0.4 respectively. Frequencies during the initial
phase were significantly increased by the two doses of a/p methylene ATP. However,
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the increase in frequency seen at steady state was not significant. Figure 49c) illustrates
the effects upon frequency following volume increase (IFinit). Mean IFinit for control,
100 and 300nM are 0.104 + 0.02 transients/ second, 0.199 + 0.02 (p=0.013 compared to
control) and 0.24 + 0.01 (p=0.006) respectively. The effects upon frequency at steady
state are demonstrated in Figure 49d). Mean Fss for control is 0.052 ± 0.006 transients/
second. In the presence of lOOnM and 300nM a/(3 methylene ATP although an increase
is seen these are not significant, means 0.081 ± 0.008 transients/ second and 0.084 +
0.013 respectively.
Figure 50 shows the effects of the two doses of a/p methylene ATP upon the mean
amplitude of transient contractions during the pre-fill, initial and steady state phases. It
illustrates that, compared to control there is a significant reduction in the amplitude of
transients in the presence of both doses during the pre-fill and initial phase. However,
no significant change can be seen during the steady state phase.
The data demonstrated during these experiments reveal that the frequency of transient
contractions immediately following an increase in intravesical volume is increased
following the addition of a/p methylene ATP. This would suggest that purinergic
receptors are involved in the regulation of frequency during this period. The fact that
the frequency at steady state is not affected may suggest either a degree of
desensitisation of purinergic receptors or no involvement at all. The increase seen in the
inhibitory phase would suggest that purinergic receptors, to a degree, are involved in





































Figure 47: Typical traces showing the effects of 100 and 300nM a/p methylene ATP
upon the volume response in the isolated guinea pig bladder; all traces are taken from
the same organ preparation. Volume responses were performed in the presence of
lOOnM arecaidine, with a volume increase of 2.5ml lasting for 500 seconds, a) control
response, no a/p methylene ATP added, b) and c) illustrate responses in the presence of
100 and 300nM a/p methylene ATP respectively. Ordinates represent pressure





















Figure 48: Traces a) and b) represent expanded versions of the traces seen in Figure 47
a) and c) respectively, a) control response, b) in the presence of 300nm. Time scale has
been expanded from the point of volume increase for its 500 second duration.
Ordinates, pressure (cmH20) and the abscissa, time (seconds). Note the increase in
frequency clearly visible during the initial and steady state phases. The amount by




Figure 49: Data collected from 5 bladders illustrating the effects of 100 and 300nM a/(3
methylene ATP on the volume response, a) illustrates the effects on the tau value of the
inhibitory phase. Ordinate, tau value (seconds), b) represents the change in underlying
pressure (PShift). Ordinate, pressure (cmFTO). c) and d) illustrate the effects upon
frequency following volume increase (IF,mt) and at steady state (Fss) respectively.
Ordinates for c) and d), frequency (transients/ second). The abscissa in all panels
represents the dose of a/(3 methylene ATP added to the organ preparation (nM). Data
are shown as mean values ± 1 SEM (n=5). A significant difference between doses
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Figure 50: Data from 5 bladders showing the effects of 100 and 300nM a/(3 methylene
ATP upon the amplitude of transient contractions during the pre-fill, initial and steady
state phases. Blue column represents the control response for each stage. Maroon,
lOOnM a/p methylene ATP; gold, 300nM a/p methylene ATP. Mean amplitudes are
expressed ± 1 standard error of the mean, (n=5). Ordinate, amplitude (cmTfO) and
abscissa, stages of the volume response. A significant difference between doses
compared to control is indicated (*), (p<0.05, one way ANOVA). The marked
reduction in amplitude noted is probably related to the 'aliasing' phenomenon whereby




3.9 Effects of the purinergic receptor antagonists NF 279, MRS 2179 and
PPADS on the volume response
The effects of the purinergic receptor antagonists NF 279, MRS 2179 and PPADS upon
the volume response in the isolated guinea pig bladder were assessed at the dose
lOOpM. Varying effects on each of the stages of the volume response were seen for
each of the antagonists. NF 279, a selective antagonist of the P2Xi receptor, was found
to significantly shorten the inhibitory phase and reduce spontaneous frequency
immediately after application to the isolated bladder. It also served to increase
frequency immediately following a volume increase (IFmax). No effect was seen upon
frequency at the steady state (Fss). MRS, a selective P2Yi antagonist, had no significant
effect on either the inhibitory phase or frequency at steady state (Fss). Though it did
significantly reduce the frequency of spontaneous activity following its application and
increase the spontaneous frequency immediately following volume increase (IFmax).
Data for these two antagonists were collected from the same guinea pig preparations
and as such their control responses were the same. The mean data ± 1 standard error of
the mean for NF and MRS are shown in table 9.
The effects of PPADS, a non selective P2 receptor antagonist, were more pronounced.
A marked reduction in the inhibitory phase was seen with a significant increase seen in
spontaneous activity following application, frequency following volume increase
(IFmax) and the frequency at the steady state (Fss). Since this data was acquired from a
separate set of bladder preparations results are shown in table 10. Typical traces
showing the responses of these three antagonists on volume induced activity are shown
in Figure 51. Figure 52 illustrates the effects of the antagonists upon the four
parameters; inhibitory phase, frequency following addition of antagonist to the
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Table 9: Data illustrating the effects of the purinergic antagonists, NF 279 and MRS
2179, upon the inhibitory phase, frequency of spontaneous activity immediately after
application of the agonist to the bladder preparation, frequency immediately following
volume increase (lFmax) and the frequency at steady state (Fss). Mean values for 4
separate guinea pig bladder preparations are shown ± 1 standard error of the mean
(mean ± 1 SEM). Significant differences compared to control values are highlighted by
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Table 10: Data illustrating the effects of the purinergic antagonist, PPADS, upon the
inhibitory phase, frequency of spontaneous activity immediately after application of the
agonist to the bladder preparation, frequency immediately following volume increase
(IFmax) and the frequency at steady state (Fss). Mean values for 4 separate guinea pig
bladder preparations are shown ± 1 standard error of the mean (mean ± 1 SEM).
Significant differences compared to control values are highlighted by an asterix
(p<0.05), with the respective p - value quoted (two tailed students t-test).
The purinergic antagonists NF 279 and PPADS both reduce the inhibitory phase
suggesting a role for purinergic receptors in either the generation or prolongation of the
inhibitory phase. The action of NF 279 suggests a specific role for P2Xi receptors in
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this activity, however, since no effect was seen with MRS 2179 P2Yi receptors are
unlikely to be functionally relevant. With regards to underlying spontaneous activity
both NF 279 and MRS 2179 significantly reduce the frequency of contractions
suggesting that P2Xi and P2Yi receptors have a positive effect in the modulation of
frequency. The non-specific effect of PPADS suggests however, that the overall
purinergic effect upon the modulation of frequency is inhibitory, (although this
contradicts the results of a/p methylene ATP possible reasons are discussed later).
Furthermore, following an increase in volume the immediate frequency is increased by
the three purinergic antagonists suggesting that purinergic activity during this time
period serves to inhibit frequency. Although the effects ofNF 279 and MRS 2179 upon
frequency at steady state suggest little modulation by P2Yi and P2Xi receptors the
effects of PPADS again suggest an overall inhibitory role for purinergic receptors in the
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Figure 51: Typical traces illustrating the effects of the purinergic antagonists upon the
volume response in the isolated guinea pig bladder; traces a, b, c are taken from the
same organ preparation, d is taken from a separate preparation. Volume responses were
performed in the presence of lOOnM arecaidine, with a volume increase of 2.5ml
lasting for 500 seconds illustrated at the base of the figures. The points at which these
agents were added to the organ preparation are not shown, a) control response, b)
lOOpM MRS 2179. c) lOOpM NF 279. d) lOOpM PPADS. Ordinates represent pressure









































Figure 52: Data collected from 4 bladders illustrating the effects of lOOqM NF 279,
MRS 2179 and PPADS on the volume response, a) illustrates the effects on the
inhibitory phase. Ordinate, tau value (seconds), b) represents the change in spontaneous
frequency following addition of antagonist to the preparation. Ordinate, transients/
second c) and d) illustrate the effects upon frequency following volume increase (IFimt)
and at steady state (Fss) respectively. Ordinates, frequency (transients/ second). The
abscissa in all panels represents the antagonist added to the organ preparation. Blue
represent the control value and maroon represents the value with antagonist added.
Data are shown as mean values ± 1 SEM (n=4). A significant difference between





During the course of these experiments the isolated guinea pig bladder was found to
demonstrate a number of complex responses that would suggest the presence of a
number of interrelated mechanisms responsible for both the generation and co¬
ordination of spontaneous activity. Following the addition of the muscarinic agonists,
arecaidine and carbachol, two distinct phases could be seen; an 'initial phase' whereby
underlying pressure and frequency of transient contractions increase followed by a
'steady state' whereby frequency and basal pressure reduces down to steady, regular
levels. Carbachol was found to significantly increase the frequency of contractions
during the initial phase, whereas arecaidine did not. This in conjunction with the effects
of 4-DAMP (M3 antagonist) in reducing frequency and AF-DX (M2 antagonist) having
little effect, suggest that the mechanisms regulating frequency during the initial phase
are sensitive to cholinergic, and more specifically, M3 mediation. A similar response is
seen following an increase in intravesical volume, again consisting of an initial phase
and a steady state. However, following a reduction in intravesical volume (back to
baseline volumes) a period of quiescence is seen followed by a gradual return of
spontaneous activity back to the levels seen pre volume change. The inhibitory phase
was found to increase with increased amounts of volume increase/ decrease in addition
to longer durations of volume increase. Arecaidine, hexamethonium, pancuronium and
a/p methylene ATP also affected the inhibitory phase suggesting that the mechanisms
involved in the generation and modulation of this quiescence are regulated to a degree
by muscarinic, nicotinic and purinergic factors.
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With data emerging to question our basic understanding of the bladder it has become
apparent that our traditional views of its function, structure and pathology need to be
readdressed. New data has demonstrated complex structures within the bladder wall
that potentially could account for the novel mechanisms that have been recently
documented. Additionally, in retrospect review of older more established data also
suggests that these traditional views cannot be fully supported. In this regard, review of
clinical cystometric data over the years, albeit sparse, fails to support the idea that
antimuscarinic medications exert their beneficial actions through the inhibition of
detrusor contraction alone, overactive or otherwise. They do, however, demonstrate an
improvement in sensory parameters (Finney et al, 2006) and in doing so question the
role of acetylcholine (ACh) acting solely as a mediator of global detrusor contraction.
However, it must be acknowledged that at doses higher than those used in routine
clinical practice antimuscarinics are capable of reducing contractility; which previously
supported the traditional view. In context therefore, these observations go towards
suggesting the presence of two cholinergically mediated mechanisms within the
bladder. One relatively sensitive to cholinergic excitation involved in the generation or
mediation of sensation and another, less sensitive one, responsible for detrusor
contraction.
In attempting to account for these observations an alternative view of bladder
regulation needs to be considered taking into account recent data. The bladder has been
shown to be capable of spontaneous rhythmical contractions associated with bursts of
afferent activity (Andersson and Yoshida, 2003; Vaughan and Satchell, 1995);
suggesting the presence of cells within the bladder capable of spontaneous pacemaker
activity in addition to the presence of rapidly responding stretch receptors.
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Furthermore, within both the mouse and guinea pig, this spontaneous activity (termed
'Autonomous activity') has been found to be modulated in a manner suggesting the
presence of local reflexes within the bladder wall (Drake et al, 2003). A major
component of these local reflexes is the positive relation between intravesical volume
and the frequency/ amplitude of transient contractions. With strong evidence to support
that afferent discharge is related to these contractions (Andersson and Yoshida, 2003;
Vaughan and Satchell, 1995) it can be speculated that 'Autonomous activity' has a role
in the generation +/- mediation of sensation and therefore, the perception of bladder
volume. Since 'Autonomous activity' has a degree of cholinergic modulation, with
increases in activity associated with increasing doses of muscarinic agonist (Drake et
al, 2003), there is further support for a sensory mechanism with cholinergic
components. Therefore, 'Autonomous activity' may represent the relatively sensitive
mechanism described previously, upon which antimuscarinics act and through which
they exert their beneficial effects.
Evidence for the presence of 'Autonomous activity' has been seen both in vitro and in
vivo during animal studies (Streng et al, 2006). In the human, activity comparable to
'Autonomous activity' can be seen upon ambulatory urodynamic monitoring. However,
it is only recently, with the advent of modern technology, that mechanisms and
structures capable of co-ordinating these activities have been identified within the
bladder wall. Cells with 'pacemaker' function analogous to the Interstitial Cells of
Cajal, found in the gut, have been identified lying in close proximity to the urothelium
with a further set seen in and around the detrusor muscle. Ganglia have also been
identified, with some receiving projections from the urothelium. The role of these
ganglia is uncertain though they would seem to be of some significance since the
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urothelium has been found to release adenosine triphosphate (ATP), nitric oxide (NO)
and acetylcholine (ACh) in response to stretch. Therefore, these structures have the
capacity to account for the generation of spontaneous activity seen in 'Autonomous
activity', in addition to modulation and co-ordination of global contraction leading to
changes in its frequency and amplitude, potentially through a number of integrating
excitatory and inhibitory inputs.
Previous work has been performed upon the response of 'Autonomous activity' to
certain physiological stimuli in an attempt to relate structure to function. This work has
mostly been performed upon the isolated bladder under iso-volumetric conditions.
However, as the bladder undergoes both filling and emptying further complex
responses are seen (Lagou et al, 2004), suggestive of a dynamic process whereby the
mechanisms behind 'autonomous activity' are potentially seen throughout all stages of
the micturition cycle. In an attempt to categorise these mechanisms further the effects
of muscarinic stimulation/ inhibition, ATP and nicotinic antagonists upon the volume
response (Lagou et al, 2004) were assessed. Each group of experiments are discussed
individually within their own context, followed by a broader discussion including
further potential clinical ramifications.
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4.2 The effects of the muscarinic agonists, arecaidine and carbachol, and the
muscarinic antagonists, 4-DAMP and AF-DX, upon agonist induced phasic
activity under iso-volumetric conditions
It is widely accepted that antimuscarinic drugs are effective in reducing the symptoms
of OAB. Contraction of the smooth muscle cells in the bladder involves predominantly
activation of M3 muscarinic receptors (Andersson and Arner, 2004). However, it is
unlikely that it is this population of M3 receptors that are involved in the therapeutic
action of antimuscarinic drugs (Andersson and Yoshida, 2003; Finney et al, 2006;
Andersson, 2002; Kim et al, 2005; Yokoyama et al, 2005). In addition, it is emerging
that the antimuscarinic drugs diminish sensations of urge and so reduce the need for
frequent episodes of micturition. Thus, the therapeutic site of action of the muscarinic
drugs must be on M3 receptors operating within a system involved in the generation or
modulation of sensations during the filling phase of the micturition cycle. However, the
location of these receptors is not known nor is their role in the generation or
modulation of sensation.
A further complication concerns the location and function of M2 receptors in the
bladder wall. There are data available reporting that there are more M2 receptors in the
bladder than M3. Despite this, their exact location or the physiological roles they serve
is unknown (Barlow and Shepherd, 1986; Hegde et al, 1997; Yamanishi et al, 2001;
Yamanishi et al, 2002; Bravennan et al, 2002; Chess-Williams, 2004). Possible
mechanisms involving the M2 dependent regulation of detrusor contraction have been
suggested. M2 activation inhibits adenyl cyclase resulting in a decrease in intracellular
cAMP. Since a decrease in cAMP leads to an increase in contractility this was proposed
as a possible function of M2 receptors in the regulation of bladder contractility. In
151
Discussion
addition, M2 receptors have been demonstrated within the urothelial layer with some
studies to suggest a prevalence of M2 receptors within the urothelium (Hawthorn et al,
2000). Though more recent studies using real time quantitative polymerase chain
reaction (RT-QPCR) have suggested the presence of functional M2 receptors but
dispute the prevalence of the density in the urothelium over that of the detrusor (Tyagi
et al, 2006). However, in any case the presence of M2 receptors within the detrusor
suggests that the urothelium, to a degree, might be involved in the regulation of
detrusor contractility.
It has been recognised for more than 120 years that the bladder is not quiescent during
the filling phase. Small transient rises in pressure occur that become larger and more
frequent as the bladder fills (Mosso and Pellacani, 1882; Sherrington C, 1892; Vaughan
and Satchell, 1995; Streng et al, 2006). It was proposed that this non-micturition
activity generates afferent discharges that contribute to bladder sensation (Starling E,
1905; Gillespie J, 2005). Phasic activity similar to the non-micturition activity seen in
vivo can be detected in the isolated bladder (Gillespie J, 2005; Sherrington C, 1892).
Using this preparation it was shown that phasic activity, also known as 'autonomous
activity' can be augmented by muscarinic agonists and this 'augmented activity' is
increased by ATP and substance P (Gillespie J, 2005a). It can also be inhibited by
calcitonin gene related peptide and noradrenaline (Gillespie J, 2005a; Gillespie J,
2004c). This has lead to the idea that the non-micturition activity can be modulated to
alter the sensitivity and output of this motor/ sensory system (Gillespie J, 2005). As the
non-micturition activity is influenced by muscarinic stimulation it follows that
reduction of this muscarinic component by antimuscarinic drugs will reduce sensation.
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Thus, this mechanism could represent the therapeutic site of action of the
antimuscarinic drugs.
The observations described in these experiments illustrate the responses of the whole
isolated bladder to muscarinic stimulation. Exposure to agonist results in a complex
pattern of transient rises in intra-vesical pressure which change during the period of
application. Immediately following exposure to agonist the frequency of transients rises
rapidly to a maximum and then declines to a steady level. The value of the maximum
frequency during the initial phase (Finit) increases with increasing agonist concentration.
In contrast, the frequency of the transients in the steady state does not tend to change
with different agonist concentrations. The amplitude of the transients in the initial
phase is smaller and more irregular than those in the steady state. At present, the
mechanisms which generate and regulate both frequency and amplitude of the phasic
activity are not entirely understood. However, it is unlikely that they originate as a
result of activation of the M3 receptors situated on the detrusor muscle (Gillespie,
2005b).
It has been shown that the transient rises in pressure induced by muscarinic agonists are
accompanied by propagating waves of contraction that can be visualised over large
parts of the bladder wall which are accompanied by local stretches (Drake et al, 2003a;
Drake et al, 2003c). This has led to the idea that the transients are initiated by a
'pacemaker' like mechanism and that the activity is then distributed throughout the
bladder wall by a specialised distribution network. Structurally, this network may
consist of a combination of nerves, intramural ganglia and interstitial cells (Gillespie
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2004; Gillespie 2005b). The observations that the initial frequency of the transients is
dependent on muscarinic agonist stimulation, suggests an involvement of muscarinic
receptors on the cells directly responsible for the generation of pacemaker activity.
That the agonist dependent changes in the initial frequency are sensitive to the
relatively M3 selective muscarinic antagonist 4-DAMP (Barlow and Shepherd, 1986),
further suggests that the cells performing the pacemaker function express muscarinic
receptors and for these to be predominantly the M3 receptor subtype. The relative
insensitive effects of 4-DAMP upon amplitude however, suggests the mechanisms
regulating the amplitude of transient contractions are not exclusively M3 mediated;
involving both M3 and M2 receptor subtypes.
The amplitude of the transients was related, to a degree, to the concentration of the
muscarinic agonist and the degree of muscle activation resulting from the spread of
activity over the bladder surface. This suggests that the propagation of the activity is
regulated by a muscarinic mechanism that might be more dominated by M2 than M3
receptors. This is supported by the finding that the relatively M2 specific antagonist
AFDX-116 (Hammer et al, 1986) does not markedly influence the initial transient rise
in frequency. However, AFDX-116 does affect the amplitude of the transients.
The rapid activity generated in the pacemaker mechanism by muscarinic stimulation is
transient: the stimulus activates an initial burst of activity which declines to a steady
state. As already stated, the frequency of the initial burst of activity depends on the
applied agonist concentration and is inhibited by 4-DAMP. In contrast, the frequency
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of the transients in the steady state is less sensitive to agonist concentration and to 4-
DAMP. This could suggest that the initial and steady state transients may be dependent
upon different but interrelated mechanisms. In keeping with this idea the nicotinic
ligand Lobeline is capable of producing slow large transient rises in pressure similar to
those seen in the steady state but does generate a rise in basal pressure or burst of high
frequency activity (Drake et al, 2003c). Suggesting the presence of two mechanisms
generating and propagating phasic activity in the guinea pig bladder; a pacemaker, used
to determine the frequency of the phasic activity, and a distribution mechanism used to
propagate activity in waves of contraction throughout the bladder. An illustration
demonstrating these principles is shown in Figure 53. Since the initial burst of activity
is activated by muscarinic agonists and inhibited by 4-DAMP it is likely that this
pacemaker mechanism is regulated by predominantly M3 muscarinic receptors rather
than M2 (i.e. M3>M2). In contrast the large steady state transients are less sensitive to
the M3 antagonist and may be dependent on M2 operating via changes in intracellular
cAMP (M2>M3). Also, there must be a component of bladder activity resulting from
direct activation of the M3 muscarinic receptors on the smooth muscle. Activation of
the smooth muscle directly is likely to result in simultaneous activation of all of the
muscle resulting in a contracture.
The observation that the large transients generated during the steady state of an agonist
complex response are relatively insensitive to the M3 specific antagonist 4-DAMP
suggests that cholinergic stimulation of these cells may be via M2 receptors. Especially
since the specific M2 antagonist AFDX-116 reduces the amplitude of the transients.
The large transients in the steady state are larger and more regular when induced by
















Figure 53: A schematic diagram suggesting a possible arrangement of mechanisms to
account for the complex actions of carbachol and arecaidine on the isolated whole
bladder preparation. A illustrates a block diagrammatic representation of the three basic
phenomena. The different components shown are: the initial fast component of phasic
activity, the steady state component of the phasic activity and the initial rise in basal
pressure. B is a cartoon suggesting how these phenomena might be related to cellular
mechanisms and anatomical features within the bladder. The possibility is put forward
that there is (i) a pacemaker element, driven by a mechanism dominated by M3
receptors, (ii) A distribution network, involving M2 components. This network contacts
and communicates with the muscle resulting in phasic contractile activity, (iii)
Contractions of the detrusor, controlled by M3 receptors possibly activated directly by
efferent parasympathetic cholinergic nerves, (iv) A nicotinic receptor on the
distribution network, bypassing the mechanisms involved in the 'fast' phase (as
demonstrated by the effects of Lobeline; Drake et al, 2003c).
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a reported greater selectivity for M2 receptors over M3 (Barlow and Weston-Smith,
1985). Thus, the cells responsible for the co-ordination of transient contractions may be
activated and regulated by M2 receptors. Activation ofM2 muscarinic receptors in many
cells results in the inhibition of adenylate cyclase and a fall in intracellular cAMP
(Andersson and Arner, 2004). If this is correct then activity in these cells is regulated
by cAMP; a fall in cAMP results in an increase in excitability. In keeping with this idea
it has been shown that procedures which elevate cAMP (forskolin and
phosphodiesterase inhibitors) inhibit phasic activity in the isolated bladder preparation
(Gillespie, 2004d). This outline would offer a possible explanation and role for the
presence ofM2 receptors in the bladder.
There is recent evidence to support the presence of a structural framework within the
bladder capable, in part, of generating and co-ordinating the activity described above.
The presence of a heterogeneous network of cells, interstitial cells, has been
demonstrated associated with the detrusor which has the potential to function as a
coordinating network, controlling the waves of detrusor contraction (Smet et al, 1996;
McCloskey and Gumey, 2002; Hashitani et al, 2004; Gillespie et al, 2005; Davidson
and McCloskey, 2005; Gillespie et al, 2006; Gillespie et al, 2006a; Lagou et al, 2006).
In both the guinea pig and the mouse the responsiveness of interstitial cells to nitric
oxide with a resultant elevation in intracellular cGMP has been used to identify the
distribution of these cells (Gillespie et al, 2005; Gillespie et al, 2006; Lagou et al,
2006). In the guinea pig three types have been identified to be associated with the outer
muscle layer. These have been described by Gillespie et al, (2005), as cells running on
the outer margin of the bladder wall (muscle coat interstitial cells; MC-ICs), cells on
the surface of the muscle bundles (surface muscle interstitial cells; SM-ICs) and cells
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within the muscle bundles (intramuscular interstitial cells; IM-ICS). Furthermore, the
IM-IC's may consist of two populations of cells; those expressing choline acetyl
transferase (ChAT) and those that do not, (Gillespie et al, 2006). In the mouse there
appear only to be two types of interstitial cell associated with the outer muscle layers:
IM-ICs and SM-ICs. In both guinea pig and mouse the SM-ICs and IM-ICs come into
close contact with nerve fibres suggesting that activity in these cells might be under
neural control, possibly cholinergic (Smet et al, 1996; McCloskey and Gumey, 2002;
Hashitani et al, 2004; Gillespie et al, 2005; Davidson and McCloskey, 2005; Gillespie
et al, 2006; Gillespie et al, 2006a; Lagou et al, 2006). Corroborating these structural
findings, interstitial cells, isolated from the detrusor are activated by muscarinic
agonists (McCloskey and Gumey, 2002), in addition, activity in isolated bundles of
smooth muscle cells has been found to originate at specific points on the bundle
surface, presumably the interstitial cells (Hashitani et al, 2004). These findings support
the concept that cholinergic nerve mediated activity in the network of interstitial cells is
transferred to the underlying muscle bundles resulting in coordinated, episodic waves
of contraction. Further to this argument, nitric oxide has been shown to selectively
reduce phasic activity in the isolated mouse bladder (Lagou et al, 2006). As the major
cell type sensitive to nitric oxide in the mouse bladder are the interstitial cells, this
suggests that these cells play an integral part in the generation of phasic activity.
As the pacemaker mechanism is the key component to phasic activity, inputs from
various sources must integrate here to exert their effect. However, the location and
nature of this potential pacemaker mechanism is not known. In the guinea pig, a recent
study has demonstrated the presence of a sub-urothelial ganglionic network. The
neurones of which are contacted by different types of nerve fibre. Three types have
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been identified: fibres expressing calcitonin gene related peptide, fibres expressing
choline acetyl transferase (ChAT) and neurofilament protein (ChAT/NF+) and fibres
expressing ChAT but not neurofilament (ChAT/NP), (Gillespie et al, 2006a). The
calcitonin gene related peptide (CGRP) and ChAT/NP fibres may be collaterals of
sensory fibres which appear to originate in the sub-urothelial layer. The ChAT/NF+
fibres may represent axons from adjacent ganglia. Furthermore, two types of nerve
fibres have been seen to innervate the muscle layer ChAT/NF+ and ChAT/NF" fibres.
The ChAT/NF+ fibres may also contact interstitial cells in the outer muscle layer. Thus,
there is evidence for a sub-urothelial ganglionic network with the potential to receive
inputs from the urothelium and adjacent ganglia, which has an output to the muscle
layers. It has been speculated that such a network is involved in the local bladder wall
reflexes linking urothelial distortion to phasic contractile activity (Gillespie et al,
2006a). The sub-urothelial ganglion cells receive inputs from two types of nerve fibre
that are likely to be cholinergic suggesting that the ganglionic cells express cholinergic
receptors. Therefore, the mediation of ganglionic activity is likely to have a strong
cholinergic influence, with application of exogenous muscarinic agonists activating
these ganglia. Thus, there is circumstantial evidence to support a role for the
suburothelial ganglionic network, the pacemaker mechanism, and the different types of
interstitial cells; resulting in a heterogeneous network carrying pacemaker activity to
the muscle layer.
The present observations, derived from the isolated guinea pig bladder, show that the
rapid component of the phasic activity is generated and its frequency determined by
activation of muscarinic M3 receptors. This pacemaker activity is particularly sensitive
to the M3 specific antagonist 4-DAMP at sub-nM concentrations; concentrations
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unlikely to affect the micturition contraction. Therefore, it is suggested that a
mechanism is present that may act as a target for low doses ofM3 selective antagonists.
Non-micturition activity has been described both in normal human subjects and in
patients with OAB (Gillespie, 2005b; Mosso and Pellacani, 1882; Bristow and Neal,
1996; Heslington and Hilton, 1996; Van Os-Bossagh et al, 2001; Drake et al, 2005);
and, as previously discussed this activity may be involved in the modulation of bladder
sensation (Gillespie, 2005b). On this basis, the tentative suggestion is made that the
antimuscarinic drugs exert their therapeutic action, either wholly or in part, through the
inhibition of pacemaker activity within the bladder wall which in turn is involved in the
generation of non-micturition bladder sensation.
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4.3 Intrinsic characteristics of the volume response
As shown previously, changes in intravesical volume lead to changes both in frequency
and amplitude of spontaneous phasic activity (Drake et al, 2003a and 2003c), with each
transient contraction associated with a burst of afferent discharge (Andersson and
Yoshida, 2003; Vaughan and Satchell, 1995). Since phasic activity is considered to be
part of an integrated motor/ sensory system, the responses in activity to volume suggest
that the system receives inputs directly from, or related to, intravesical volume. In
addition, it has also been shown that phasic activity can receive further excitatory and
inhibitory inputs (Gillespie, 2004a; Gillespie and Drake, 2004b), and as such afferent
discharge related to volume could be influenced by these other stimuli. Therefore,
sensory perception of intravesical volume has the capacity to be modulated by
mechanisms acting in the periphery (Lagou et al, 2004).
It has been previously proposed (Lagou et al, 2004) that a number of complex
arrangements exist within the bladder that could account for the physiological
responses seen within phasic and volume related activity. The excitatory effect of
substance P and the inhibitory effect of calcitonin gene related peptide (CGRP),
(Gillespie, 2005a), upon phasic activity suggest the presence of a sensory-axon
collateral reflex within the bladder wall; supporting a role for the release of sensory
neurotransmitters within the wall of the bladder. Certainly, it has been documented
previously that afferent nerves can send collateral fibres to structures within the tissue
where they originate (Maggi, 1990; Maggi and Meli, 1986 and 1988). However, with
prolonged exposure to capsaicin, leading to the elimination of sub P/ CGRP sensory
nerves (Maggi and Meli, 1998), volume induced changes are not affected. This would
suggest that the local sensory-collateral reflex is not involved in the volume response.
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Additionally, since nearly all potential neural sensory influences would be removed via
the action of capsaicin, non-neural mechanisms must be considered to be involved in
the regulation of volume induced activity.
The urothelium is known to release adenosine triphosphate (ATP) in response to
mechanical distortion (Ferguson et al, 1997). It has been suggested that the role of
urothelial released ATP is to modulate firing of afferent nerve fibres, in turn
influencing bladder sensation (Ferguson et al, 1997; Birder et al, 1998; Lee et al, 2000).
However, it has been further suggested that ATP can indirectly act upon the bladder via
alterations in phasic activity (Gillespie, 2004), inducing sensory neurotransmitter
release via anti-dromic activation of collateral afferent nerve fibres (Lagou et al, 2004).
The effect upon volume induced inhibition, however, has not as yet been assessed.
Further potential sources of non-neuronal mechanisms include interstitial cells and a
non-specific substance termed 'inhibitory factor'. It has been postulated that interstitial
cells have a role in modulation of volume induced activity by inhibiting phasic activity
following a volume reduction; since ODQ, an inhibitor of guanyl cyclase, has been
found to suppress this inhibition (Lagou et al, 2004). Whilst 'inhibitory factor' is
speculated to be released from the urothelium resulting in an inhibition of detrusor




4.4 Effects of alterations in intravesical volume, duration of volume increase
and agonist concentration
The observations described in these groups of experiments illustrate the responses of
the isolated guinea pig bladder to changes in intravesical volume, duration of volume
increase and the effects of the two doses of arecaidine, 100 and 300nM, upon volume
induced 'augmented' activity ('volume response'). As previously shown a 'steady
state' is seen in phasic activity following prolonged exposure to arecaidine. The effects
of the volume response were assessed after a period of equilibration after addition of
agonist to allow for the experiments to be consistently perfonned during this 'steady
state'. Following an increase in intravesical volume a complex series of events are seen
similar to those described following the addition of arecaidine; again an 'initial phase'
consisting of a burst high frequency, low amplitude transients followed by a 'steady
state' consisting of regular transient contractions of a lower frequency but greater
amplitude. Following a reduction in intravesical volume a period of quiescence is seen
with transient contractions gradually returning to baseline frequency and amplitude.
The 'initial phase' seen following volume increase comprises a succession of rapid,
small amplitude transient contractions superimposed upon an initial sudden rise in
underlying basal pressure followed by a gradual decline. The overall magnitude of this
'initial' response is dependant on the increase in intravesical volume, illustrated by the
instantaneous frequency (IFjnit) and underlying pressure (PShift) being significantly raised
in comparison between a 2.0ml than 1.5ml increase. However, as PShm falls to 'steady
state' levels, frequency also gradually reduces with the amplitude of transients
increasing. As discussed, the magnitude of the 'initial phase' seems to be directly
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related to the magnitude of the increase in intravesical volume, as shown by the
differences between 2.0 and 1.5ml increases. Additionally, when raw data is analysed
from previously published records illustrating the effects of smaller sequential
increases in volume the initial phase, the initial phase is found to be smaller (Lagou et
al, 2004). However, the final 'steady state' between our data and that of Lagou, at
comparable volumes, remains similar suggesting that the 'steady state' is unaffected by
rate of volume increase. Furthermore, under physiological conditions an 'initial phase'
is not seen, though a gradual increase in frequency, amplitude and underlying pressure
is apparent (Streng et al, 2006), similar to that seen in the steady states at increasing
volumes during our experiments. Therefore, the burst of activity seen immediately
following a rapid increase in volume is likely to represent a non-physiological response
in the normal bladder. However, it does illustrate that the mechanisms involved in the
regulation of pacemaker frequency have difficulty compensating immediately for the
effects of increased filling rates, essentially becoming 'overloaded'. The reasons for
this are unclear. However, one possible explanation is that a rapid efflux of
acetylcholine (ACh) from the urothelium in response to stretch occurs that
preferentially activates a sensitive M3 component of pacemaker activity. Giving an
agonist induced initial 'burst' of activity in a manner analogous to that described in the
previous section. Though this phenomenon is non-physiological, further investigation
may give insight into the mechanisms involved in the generation and regulation of
volume induced spontaneous activity.
Following volume reduction a period of quiescence is seen termed the 'inhibitory
phase'. This has been noted both in vitro (Lagou et al, 2004) and in vivo (Streng et al,
2006); suggesting this to be a true physiological response as opposed to a factor related
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to increased fill rates (Streng et al, 2006). The experiments described here further
illustrate the 'inhibitory phase' to be influenced by a number of factors consisting of
volume increase, duration of increase, concentration of muscarinic agonist and degree
of bladder emptying. The length of the inhibitory phase increases with volume,
however, this is not entirely dependant upon the absolute change in volume increase. It
has been shown that the length of the inhibitory phase is also dependant upon volume
decrease, with longer inhibitory phases being seen when volume returns to baseline.
This is highlighted when the mean results of a volume increase and decrease of 1.5ml
(157 seconds) are compared with those following a volume increase of 2.0ml and
decrease of 1.5ml (118 seconds). From this simple observation it may be argued that a
two stage process is evident in the regulation of the inhibitory phase. Volume increase
may act as a volume dependant stimulus for the synthesis of agents, or initiation of
mechanisms, involved in the inhibitory phase that are only fully released/ triggered
again in a volume dependant manner as the bladder empties. The relationship between
the magnitude of bladder emptying and the length of the inhibitory phase would also
suggest that the stimulus of volume decrease is of similar importance to that of volume
increase in the determination of the length of the inhibitory phase. It can be further
argued that an increase in the inhibitory phase following a return to baseline volume
would suggest that maximal mechanical distortion, as opposed to pure stretch, is
required for the full effects of the inhibitory response to be seen. Whether this is
predominantly related to specific structures is open to speculation, however, it may
indicate a role for the urothelium since this may be indicative of the urothelium
unfolding as the bladder fills and re-folding as it empties. ATP and NO released from
the urothelium upon unfolding/ re-folding could easily exert an effect upon
suburothelial purinergic receptors (Ferguson et al, 1997; Birder et al, 1998; Lee et al,
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2000) or interstitial cells (Lagou et al, 2004). Certainly, suburothelial interstitial cells
seem to be implicated in some way to the inhibitory phase since ODQ, an inhibitor of
guanyl cyclase and therefore cells signalling via cGMP, significantly reduces its length.
Since in the mouse/ guinea pig interstitial cells are the predominant cells acting via the
NO/ cGMP pathway this would implicate interstitial cells as being directly involved in
either its generation or co-ordination.
Duration of volume increase has also been shown to play a role in the length of the
inhibitory phase, with longer durations of fill being associated with longer inhibitory
phases. An insignificant difference in the length of the inhibitory phase is seen
following durations of fill less than 30 seconds, with a small but significant difference
seen between the durations of fill of 100 and 500 seconds. However, a substantial
difference is seen following a 30 and 100 second volume increase; suggesting that
between these two time points the rate of increase in the initiation of these mechanisms
involved in the regulation of the inhibitory phase rise substantially. The relationship
between the inhibitory phase and duration of fill further supports the idea of agents/
mechanisms involved in the inhibitory phase being synthesised/ initiated in response to
volume increase. It also supports the inhibitory phase to be a true physiological
response as opposed to flaccidity related to stretch induced damage of the underlying
detrusor muscle. Further supporting the idea that quiescence following volume
reduction is related to inhibition of either pacemaker function or co-ordination of
activity and not due to a direct relaxant effect on the detrusor is that during the
inhibitory phase the bladder is still able to contract in response to electrical field
stimulation, (Lagou et al, 2004).
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The response of phasic activity in the isolated bladder to alterations in intravesical
volume is complex. However, the effects illustrated following addition of 100 and
300nM arecaidine suggest a strong cholinergic input, involved in the modulation of all
the three stages (initial, steady state and inhibitory phase); with cholinergic inputs
exerting an excitatory effect by acting directly on the pacemaker mechanism. This
increased pacemaker stimulus results in an increase in the instantaneous frequency
following volume increase (IFjnit) and frequency at steady state (Fss). However, it also
leads to a reduction in the inhibitory phase. This suggests the mechanisms involved in
the generation of the inhibitory phase to involve a balance involving both inhibitory
and excitatory stimuli, with an excitatory cholinergic component. Since the factors
involved in the inhibitory phase are unlikely to directly involve the detrusor, the likely
targets are again likely to be those mechanisms involved either the generation or co¬
ordination of spontaneous activity; either the pacemaker (M3>M2) or co-ordination
(M2>M3).
From these observations it has been speculated that the regulation of volume induced
spontaneous activity and modulation of the inhibitory phase relies upon a complex
series of excitatory and inhibitory inputs. Rapid increase in intravesical volume leads to
a burst of increased frequency that gradually declines, suggesting the presence of a
relatively rapidly adapting mechanism involved in the modulation of volume related
activity that becomes more pronounced at non-physiological rates of bladder filling.
Rapid reduction in intravesical volume leads to a quiescent period, termed the
inhibitory phase. This is related to both the duration of intravesical volume increase and
its magnitude. However, similar volume changes are more effective when volume is
reduced back to baseline as opposed to the bladder being incompletely emptied.
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Furthermore frequency of transient contractions remains constant once steady state has
been reached with no evidence of inhibition pre-volume reduction. These functional
observations suggest that mechanisms involved in the generation of the inhibitory
phase initiate during bladder filling, requiring a period of time >30seconds to exert a
significant effect. However, they depend upon a reduction in volume to be triggered,
with the response dependant upon the volume reduced. The mechanisms involved in
the generation and modulation of the inhibitory phase seem to be regulated by a strong
cholinergic input, however, the exact nature of these mechanisms are unknown.
Certainly structures have been identified, in the form of interstitial cells and ganglia,
capable of generating and modulating such activity. Furthermore, their close proximity
to the urothelium which is capable of releasing ATP, NO and ACh in response to
stretch strongly suggests a potential role for the urothelium in the transduction of such
activity.
4.5 Effects of Tolterodine upon volume induced changes.
Tolterodine is an orally administered anti-muscarinic drug commonly used in the
treatment of OAB. It is a competitive muscarinic receptor antagonist with a relative
selectivity for M2 receptors over M3 (Nelson et al, 2004), though its efficacious effects
are regarded to be derived from its increased affinity for muscarinic receptors found in
the bladder over those in the parotid gland (Nelson et al, 2004). Clinical trials have
shown it to be effective in reducing symptoms of frequency, urgency and urge related
leakage (Chappie et al, 2005). Although, at clinical doses there is no significant
reduction in the strength of detrusor contraction (Finney et al, 2006), higher doses
result in a significant reduction associated with a marked increase in residual volume
(Stahl et al, 1995).
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The observations reported in this series of experiments illustrate the response of
increasing doses of Tolterodine upon volume induced spontaneous activity in the
isolated bladder, augmented by lOOnM arecaidine. Compared to controls no significant
effect was seen following addition of lOnM Tolterodine. Doses of 30nM or more were
required before any significant effect was seen. These included a dose dependant
reduction in frequency immediately following volume increase (IFmax) and the
frequency at steady state (Fss), in addition to an increase in the inhibitory phase. As
discussed previously the mechanisms responsible for generating pacemaker activity
during IFmax and regulating frequency during the steady state, Fss, are likely to have a
cholinergic input; as increasing doses of muscarinic agonist increase both these
parameters. The observations seen with Tolterodine further support this suggestion.
The inhibitory phase (IP) also seems to be regulated, in part, by a cholinergic input. As
suggested previously, the inhibitory phase is modulated by both competing excitatory
and inhibitory inputs acting upon pacemaker activity. This data would suggest that the
mechanisms responsible for the excitatory component are cholinergic.
This data further supports the importance of cholinergic mechanism in the regulation of
volume induced spontaneous activity. Although the locations of these mechanisms
remain unknown they seem to exert a direct excitatory effect upon pacemaker function,
giving rise to an increase in IFmax and the frequency at steady state; in addition to
promoting the return of activity during the inhibitory phase. With the relative lack of
selectivity of Tolterodine between the M2 and M3 muscarinic subtypes no weight can be
given to the relative roles of either of these receptors in the modulation of volume
induced activity. However, it does further illustrate potential mechanisms that may be
involved to account for the clinical effects of anti-cholinergics.
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4.6 Effects of the nicotinic antagonists hexamethonium and pancuronium on
volume induced activity
It has been suggested previously that the regulation of both autonomous activity and
volume induced activity consists of a number of competing excitatory and inhibitory
inputs. Though the location of these mechanisms and inputs are unknown, structures
have been identified with the potential of generating and co-ordinating these competing
signals. In particular, ganglia have been identified close to, and receiving nerve fibres
from, the urothelium that synapse with the interstitial cells found around the detrusor.
Some of these ganglia have been found to consist of nerve bodies containing choline
acetyl transferase (ChAT) and calcitonin gene related peptide (CGRP). As shown
during these experiments cholinergic input exerts an excitatory effect upon spontaneous
activity, whilst CGRP has been found to be inhibitory (Gillespie, 2005a). As the
functional roles of ganglia in relation to the regulation of spontaneous and volume
induced activity are previously unknown the effects of the nicotinic receptor
antagonists, hexamethonium and pancuronium bromide, were assessed.
These experiments illustrate the effects of hexamethonium, a nicotinic antagonist
selective for receptor subtypes found on autonomic ganglia, and pancuronium, a
neuromuscular nicotinic receptor antagonist (Fryer and Maclagan, 1987; Maestrone et
al, 1994; Lowenick et al, 2001), upon spontaneous and volume induced activity
augmented by lOOnM arecaidine. Hexamethonium had no effect upon either the
frequency of transient contractions prior to volume increase, immediately following
increase (IFmax) or at steady state (Fss). On the assumption that these ganglia express
ganglionic nicotinic receptors, the lack of an effect seen following addition of
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hexamethonium suggests that regulation of the frequency of transient contractions
during filling is unrelated to mechanisms directly involving ganglia. It could also be
argued that if nicotinic receptors were present upon the pacemaker mechanism, they
would not be of 'ganglionic' origin.
The effect of hexamethonium in prolonging the inhibitory phase suggests a role for
ganglia in co-ordinating the return of phasic activity. It has been previously argued that
the 'inhibitory phase' derives from a transient inhibition of either the pacemaker or the
mechanisms co-ordinating spontaneous activity, and that these can be modulated by
both excitatory and inhibitory elements. As an antagonist, hexamethonium acts as an
antagonist it must act through inhibition of an excitatory, nicotinic mediated receptor.
This is unlikely to exist directly upon the pacemaker mechanism itself otherwise a
decrease in frequency would be seen upon direct application of hexamethonium. The
excitatory reflex mechanism whereby volume regulates frequency is also unlikely to be
directly effected since no change was seen in either the IFmax or Fss. Therefore,
hexamethonium must be acting on a mechanism distinct from the 'volume/ frequency'
reflex, at a point not directly related to the pacemaker mechanism. This would support
the idea of a ganglionic network involved in co-ordinating the return of activity during
the 'inhibitory phase', especially since there is structural evidence to support the
presence of ganglia.
An alternative mechanism to be considered is the role of the urothelium in this activity.
mRNA for the nicotinic subunits a3, a5, a7, (33, [34 have been detected in rat
urothelium by RT-PCR, with a3 and a7 also being confirmed upon Western blotting
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(Beckel et al, 2006). In cultured cells, addition of nicotine results in an increase in
intracellular calcium concentration suggesting that these subunits form functionally
relevant receptor channels. This activity has also been shown to be blocked by
hexamethonium, suggesting the presence of a functional hexamethonium sensitive
nicotinic receptor expressed upon the urothelium. Thus, it is conceivable that the
increase in the inhibitory phase seen with hexamethonium may occur, to some extent,
through inhibition of the release of excitatory mediators from the urothelium during
bladder emptying.
In contrast to the effects of hexamethonium, pancuronium was found to exert an effect
on both frequency and the inhibitory phase. The effects on frequency following
application of pancuronium in addition to IFmax and Fss, may suggest a direct input of a
pancuronium sensitive nicotinic receptor to the pacemaker mechanism. Furthermore, a
similar nicotinic receptor may be present in the mechanisms co-ordinating the return of
activity during the inhibitory phase. However, a degree of caution must be exercised in
the interpretation of these results as it is acknowledged that pancuronium has an anti-
muscarinic effect at higher doses, effecting both M2 and M3 subtypes (Hou et al, 1998).
Though these effects may represent, in part, non-specific muscarinic responses it does
potentially highlight the presence of nicotinic mechanisms within the bladder.
Especially when the effects of Lobeline, a nicotinic ligand, are also considered
(discussed previously). Whether this represents different nicotinic receptor subtypes, or
one with a binding affinity for both hexamethonium and pancuronium further work is
required to pinpoint their location and subunit composition.
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These observations illustrate a functional role for nicotinic receptors in the regulation
of volume induced spontaneous activity. Those sensitive to hexamethonium are likely
to be excitatory, co-ordinating the return of activity during the inhibitory phase. They
do not seem to have a direct input to the pacemaker mechanism and seem to be distinct
from the mechanism whereby volume regulates frequency; supporting a role for both
ganglia and a nicotinic mediated urothelial response. The effects of pancuronium are
less certain and may represent non specific cholinergic effects. However, pancuronium
sensitive nicotinic receptors may be present both on the pacemaker mechanisms and the
excitatory mechanisms during the inhibitory phase. Whether these hexamethonium and
pancuronium sensitive receptors are distinct nicotinic subtypes, or the same receptor
sharing some binding affinity for both drugs is open to speculation. However, it does
highlight the need for further work in order to identify and evaluate the nicotinic
mechanisms within the bladder.
4.7 Effects of a/p methylene ATP on volume induced activity
The data obtained during the course of these experiments illustrate a number of
observations that highlight potential novel roles for adenosine triphosphate ATP. The
addition of a/p methylene ATP (a/p MATP), a non-hydrolysable from of ATP, to the
isolated bladder resulted in a complex series of excitatory and inhibitory effects upon
phasic activity; suggesting ATP to be a potent modulator of the mechanisms regulating
pacemaker function.
ATP has been found to exert an effect directly upon smooth muscle, leading to non-
cholinergic detrusor contraction. It is currently believed that ATP released from nerves,
by itself or in combination with acetylcholine (ACh), acts to depolarise the muscle via
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P2X purinergic receptors located on the detrusor smooth muscle (Inoue and Brading,
1990; Fry et al, 2002). In addition there is also evidence to suggest a sensory role for
ATP in the generation of afferent activity from the bladder (Cook and McCleskey,
2000), probably acting via P2X3 receptors located upon suburothelial sensory C-fibres
(Lee et al, 2000). The combination of one, or both, of these ATP-dependant
components have been implicated in the pathological conditions, bladder hypertrophy
(Calvert et al, 2001), idiopathic detrusor overactivity (Bayliss et al, 1999), and
interstitial cystitis (Palea et al, 1993).
The effect of a/(3 MATP upon spontaneous phasic activity in the isolated guinea pig
bladder has been recently described under iso-volumetric conditions (Gillepie, 2004d).
The effects upon both augmented and un-augmented bladders in increasing phasic
activity, in addition to underlying contraction, suggest ATP to exert its influence on the
regulatory mechanisms controlling phasic activity, and not just upon the detrusor.
Addition of a/p MATP to the bladder preparation results in a rapid burst of frequency
superimposed upon a rise in underlying pressure that gradually declines as underlying
pressure falls. This effect has been previously documented by Gillespie, but has been
confirmed during the course of these experiments. Following washout of a/p MATP
from the preparation a profound inhibition in activity is seen that gradually returns;
similar in nature to the 'inhibitory phase' seen following a volume response. Together,
these two observations suggest the presence of two functionally relevant purinergic
receptors with direct inputs to the mechanism regulating pacemaker activity. One
excitatory, with a rapid onset, and the other inhibitory, with a slower onset. However,
when both are stimulated the overall, net effect is excitatory, suggesting the excitatory
mechanism to be dominant.
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The observations made during the course of these experiments further illustrate the
effects of a/p methylene ATP upon the volume induced activity of the isolated guinea
pig bladder augmented by lOOnM arecaidine. Volume responses performed in the
presence of both 100 and 300nM a/p MATP show an exaggerated increase in
frequency both immediately after volume increase (IFmax) and at steady state (Fss),
compared to baseline frequency pre-volume increase. This discrepancy between IFmax/
Fss and baseline frequency seems to be far more pronounced in the presence of a/p
MATP compared to the other compounds studied. So much so, that it may be putatively
speculated that ATP plays a role in the mechanism whereby volume regulates
frequency. In addition to the excitatory effect upon IFmax and Fss, a/p MATP also exerts
an inhibitory effect upon volume induced activity by prolonging the inhibitory phase.
With a/p MATP exerting a direct excitatory effect upon pacemaker activity, the
quiescence seen during the inhibitory phase suggests a degree of purinergic mediation
in the mechanisms that suppress pacemaker activity during this time.
The exact locations of the mechanisms through which a/p MATP may be acting, or the
purinergic receptor subtypes involved, are unknown. It is generally accepted however,
that P2X receptors exert excitatory actions on bladder smooth muscle (McMurray et al,
1998), and it is speculated that these may also be involved in the excitation of
pacemaker activity. Conversely, inhibition of pacemaker activity may be mediated by
P2Y receptors. P2Y receptors have been shown to be coupled to adenyl cyclase,
stimulation of which leads to an increase in cAMP. Experiments with forskolin, an
activator of adenyl cyclase, have shown a slowing of phasic activity (Gillespie, 2004d),
indirectly supporting a potential inhibitory effect ofP2Y receptors.
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The results from these experiments, using a/p methylene ATP alone, have illustrated a
number of novel roles for ATP in the regulation and modulation of spontaneous and
volume induced activity. ATP seems to display a dual response by exerting an
excitatory effect upon pacemaker activity in addition to an inhibitory effect through the
potentiation of the inhibitory phase. This would suggest the presence of two or more
functionally relevant purinergic receptors acting at various locations in the control and
regulation of spontaneous activity. Though these locations are currently open to
speculation, suburothelial afferent nerves lying in close proximity to the suburothelial
interstitial cell network have been found to display P2X3 receptors (Lee et al, 2000),
stimulation of which are thought to be related to the generation of sensation.
4.8 Effects of the purinergic receptor antagonists NF 279, MRS 2179 and
PPADS upon volume induced activity
These experiments illustrate the effects of the purinergic receptor antagonists NF 279,
MRS 21709 and PPADS upon spontaneous volume induced activity augmented by
lOOnM arecaidine. The individual effects of these antagonists were complex and
variable, showing that the frequency immediately following application of agonist and
prior to volume increase, in addition to the frequency immediately after volume
increase (IFmax), frequency at steady state (Fss) and the inhibitory phase to be altered
in different ways by specific antagonists. These observations illustrate that a number of
functionally relevant purinergic receptor subtypes to be present upon the mechanisms
responsible for the generation and modulation of spontaneous and volume induced
activity; inducing direct effects upon the pacemaker and the inhibitory phase.
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PPADS is a non specific P2 purinergic receptor antagonist addition of which resulted in
a significant increase in the frequency of transient contractions throughout the volume
response in addition to markedly reducing the inhibitory phase. In itself these
observations suggest the net effect of P2 receptor stimulation to be inhibitory, leading
to a direct inhibition of the pacemaker mechanism and excitation of the mechanisms
involved in the inhibitory phase. However, in conjunction with the effects of the a/p
methylene ATP data there seems to be a discrepancy between the effects of purinergic
receptors upon pacemaker activity. It is difficult to account for the increase in the
frequency of transient contractions seen by both a purinergic agonist and antagonist,
and therefore this may represent a pharmacological 'anomaly' of one of the
compounds.
Given the location and properties of the suburothelial interstitial cells it is postulated
that they may represent part of the regulatory mechanisms involved in either the
generation or modulation of pacemaker activity. They are known to express
purinoceptors, predominantly P2Y6 (Sui et al, 2006), and generate spontaneous
intracellular Ca2+ transients in isolated suburothelial interstitial cells in response to ATP
(Wu et al, 2004). However, Wu et al also described that a/p methylene ATP had no
effect upon these cells suggesting that their expressed purinoceptors are not ionotropic
and may be part of the P2Y family, confirmed later by Sui et al. The lack of an effect of
a/p methylene ATP on non-ionotropic P2Y receptors would certainly account for the
observations seen by ourselves; with a/p MATP exerting a preferentially excitatory
effect upon P2X receptors without the inhibitory effect of P2Y, and PPADS exerting an
effect upon both receptor subclasses. These observations would therefore suggest that
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the suburothelial interstitial cells are capable of exerting an inhibitory influence in the
modulation of pacemaker activity. Their expression of P2Y receptors may also indicate
this mechanism to involve induction of cAMP by stimulation of adenyl cyclase.
The actions of both a/p methylene ATP and PPADS upon the inhibitory phase suggest
a direct purinergic input into the mechanisms responsible for its generation. However,
given the potential relative sites of action of these two compounds, highlighted above,
the inhibitory phase must comprise of a number of purinergic mediated responses that
involve a balance of both excitatory and inhibitory stimulation.
NF 279, a relatively specific antagonist for P2Xi receptors, and MRS 2179, a relatively
specific P2Yi antagonist, were both found to significantly reduce the frequency of
transient contractions immediately after application to the organ preparation in addition
to significantly increasing the frequency immediately after volume increase (IFmax).
This would suggest that these receptors exert a direct excitatory effect upon the
mechanisms involved in the modulation of frequency, or on the pacemaker mechanism,
in addition to inhibiting the rapidly adapting mechanism that increases frequency along
with volume (illustrated by IFmax). Alternatively, as illustrated earlier, the mechanisms
involving purinergic responses seem to be complex. It is therefore conceivable that
their actions are indirect, by altering the balance of excitatory/ inhibitory stimuli.
At steady state following a volume increase, NF and MRS were found not to display
any significant effect upon the frequency of transient contractions (Fss). However, they
were found to significantly affect pacemaker activity at 'baseline' volume. This would
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suggest that P2Xi and P2Yi receptors are actively involved in the modulation of
pacemaker activity at low volumes, but exert less, or any, influence at higher volumes.
The effects of PPADS upon frequency at steady state (Fss) would suggest the presence
of functionally relevant purinoceptors at higher volumes, arguing that purinoceptors are
involved in the regulation of frequency throughout bladder filling. Although the effects
of PPADS are non-specific it would suggest that purinoceptors other than P2Xi and
P2Yi become more functionally relevant as the bladder fills. Therefore, it is
conceivable that the functional relevance of purinergic receptor subtypes are related to
volume; although it cannot be speculated whether this would be related to receptor
desensitisation or their related corresponding mechanisms. Additionally, the effects
upon the inhibitory phase would suggest an involvement of P2Xi receptors, but not
P2Y,.
The effects of NF 279, MRS 2179 and PPADS suggest a complex interaction of
functionally relevant purinoceptors subtypes throughout bladder filling, affecting the
mechanisms involved in the generation and modulation of spontaneous and volume
induced activity. The location and nature of these receptor subtypes are unknown;
however, there is indirect evidence to speculate that suburothelial interstitial cells may
be involved in this modulation in exerting an inhibitory affect. It may also be
speculated that the functional relevance of a purinoceptor subtype is volume dependant;
though whether this is a reflection of receptor desensitisation or the underlying




As with all animal experiments caution needs to be exercised when extrapolating data
to the human. However, given the relative inaccessibility of isolated human bladders
there is a necessity to perform functional experiments upon the more accessible animal
models. There are always going to be differences between the animal species, some
subtle others large, but if attempts are made to relate the structure of each animal model
to function this would further our understanding of the physiological mechanisms
within the human bladder. Although the experiments performed as part of this thesis
were upon the isolated guinea pig bladder a degree of anatomical and physiological
similarity between the guinea pig and human bladder is evident. Both consist of distinct
layers consisting of urothelium, lamina propria and underlying detrusor. More
importantly many of the structures that have been postulated, as part of this thesis, as
playing a part in the generation and modulation of spontaneous activity in the guinea
pig are also present in human bladder. Smet et al, 1996 demonstrated the presence of
cells analogous to the Interstitial Cells of Cajal present within the sub-urothelial and
detrusor layers of both the guinea pig and human, with both sets of cells from each
species responding to stimulation with nitric oxide with a rise in cGMP. They have also
demonstrated the presence of ganglia within the sub-urothelial and detrusor layers.
Other work has demonstrated a similar ratio of M3/ M2 receptors within the two
different bladders with M3 receptors being involved in the mediation of contraction for
both, (Wang et al, 1995). Furthermore, the response of the detrusor to purinoceptor
activation leads to similar responses, (Inoue and Brading, 1991).
However, the data evident for the similarities between the human and guinea pig relates
to individual specific responses and phenomenon. Little to no data is available
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regarding the integrative physiology for both species. Although similarity exists
regarding the anatomy and structure of the two bladders, insofar that certain cell types
are present in both species, the data presented as part this thesis illustrates the
'sensitivity' of the mechanisms involved in the regulation of spontaneous activity. As
such, a small variation in a single response or a different interaction between responses
could affect the overall integrative function. However, given the basic anatomical
similarities between the two species the isolated responses are likely to have some, if
only a minor, degree of similarity. Unfortunately, the similarity between the guinea pig
and the human can only be fully justified once the structures of both have been more
fully assessed, in addition to cataloguing the structure and function of a number of
other species.
Spontaneous and volume induced phasic activity in the isolated guinea pig bladder is
generated and modulated by a complex interaction of opposing excitatory and
inhibitory stimuli. Although the exact nature and location of these mechanisms are not
known, they represent local mechanisms inherent to the wall of the bladder. Activity
similar to the phasic transient contractions seen in the guinea pig have been described
in human subjects both in the 'normal' bladder and in those suffering from overactive
bladder syndrome (OAB) (Gillespie, 2005b; Mosso and Pellacani, 1882; Bristow and
Neal, 1996; Heslington and Hilton, 1996; Van Os-Bossagh et al, 2001; Drake et al,
2005). Furthermore, it has been suggested that phasic activity represents a component
of afferent activity involved in the generation of sensation; potential dysfunction of
which could be a factor in the development of OAB (Gillespie, 2005b). This system
involving direct motor/ sensory interaction leading to potential cholinergic modulation
of sensory afferents has therefore given rise to a mechanism upon which antimuscarinic
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medication may act. The importance of this finding is especially relevant in light of
retrospective analysis of older data suggesting antimuscarinic medication currently
used in clinical practice has little, if any, significant effect upon contraction, instead
acting on the afferent side by reducing sensations of filling (Finney et al, 2006); an
affect that could not be accounted for by the classical description of bladder
physiology. Further evaluation of the effects of the M3 specific muscarinic antagonist
4-DAMP have identified the initial response of the bladder to muscarinic stimulation to
be particularly sensitive to the effects M3 antagonism. Especially at sub-nM
concentrations, insufficient to generate detrusor contraction. It is therefore suggested
that the effects of the antimuscarinic drugs exert their therapeutic action, either wholly
or in part, through the inhibition of mechanisms related to pacemaker activity within
the bladder wall which are involved in the generation of non-micturition bladder
activity.
The potential importance of spontaneous activity as a therapeutic target is not restricted
to antimuscarinic medication. The intrinsic characteristics of spontaneous, phasic
activity in response to volume have highlighted induced changes that comprise of an
inhibitory phase whereby pacemaker activity, and therefore the frequency of transient
contractions, becomes quiescent for a period of time before gradually returning to
normal. This 'inhibitory phase' is dependant upon the duration of bladder filling and
the volume by which it has been increased and decreased. A volume change above and
back to baseline is far more effective in prolonging the inhibitory phase than a similar
volume change not returning to baseline volume. Suggesting that the inhibitory phase is
dependant upon the time and magnitude of the volume increase for the initiation of the
mechanisms potentially to be involved, in addition to being reliant upon maximal
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volume decrease (or alternatively maximal mechanical distortion of the bladder) for
these mechanisms to be fully triggered. The physiological relevance of this is not
entirely known, however, it is postulated that a decrease in afferent activity during
micturition could reduce sensation that otherwise may be uncomfortable or even
painful. From the clinical perspective further understanding of the mechanisms behind
the 'inhibitory phase' may give rise to further therapeutic targets; manipulation of
which may be able to induce artificial periods of quiescence.
The duration of the inhibitory phase following volume decrease has been found to be
altered by antimuscarinic agents, nicotinic antagonists and purinergic agonist/
antagonists suggesting its underlying generation and regulation to be complex. Though,
this data does suggest direct cholinergic and purinergic inputs into the modulation of
the inhibitory phase with ganglia playing a role in the co-ordination of the return of
activity during this time. In relation to current practise the 'inhibitory phase', occurring
following bladder emptying and being related to the volume reduction, raises an
interesting point regarding standard, non-ambulatory urodynamic investigations.
Although its significance in vivo is not known it does suggest that a reduction in
sensation may occur following voiding. As voiding prior to artificial filling is standard
practise during urodynamic assessment, it is conceivable that filling during the
'inhibitory phase' may involve filling during a period of sensory quiescence giving rise
to aberrant results.
In addition to the role of artificial filling following micturition, the rates of filling
during conventional urodynamics also need to be questioned. These experiments show,
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albeit at the extremes of fill rate, that the mechanisms relating volume to spontaneous
activity are unable to adapt immediately to non-physiological rates essentially
becoming 'overloaded', though given a short period of time can eventually adapt. The
ability of the bladder to adapt to higher rates of fill has also been questioned in humans.
When the results of ambulatory (physiological fill rates) and conventional urodynamics
(non-physiological fill rates) have been compared a reduction in spontaneous activity
can be seen with conventional studies, in addition to a comparative rise in the volume
threshold for micturition and an impairment in detrusor contractility, Robertson et al,
1994. Furthermore, underlying rise in intravesical pressure is more marked with higher
fill rates (lower compliance) and negligible at physiological fill rates (almost
completely compliant), giving rise to the argument that bladder compliance is strongly
related to, if not a factor of, the rate of bladder filling, Klevmark 2002. Though, it has
been previously argued that the differences seen between conventional and ambulatory
urodynamics need to be explained at the cellular level, Klevmark 2002, the exact nature
these have not been described. However, these experiments give some insight into the
mechanisms that could account for these findings.
The effects of hexamethonium and pancuronium have together suggested the presence
of nicotinic receptors involved in the modulation of spontaneous and volume induced
activity. The effects of hexamethonium suggest the presence of functionally relevant
ganglia, whilst the effects of pancuronium suggests the presence of nicotinic receptors
more akin to those found upon skeletal muscle. This was not a predicted finding as
pancuronium was not thought to exert an effect upon smooth muscle. Therefore, there
is the potential for the presence of a nicotinic receptor with similar binding
characteristics to those found upon skeletal muscle, which may act as a useful target if
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unique, or predominantly located to, the bladder. Certainly, the presence and nature of
nicotinic receptors within the bladder needs to be addressed further, both in structure
and function.
Purinoceptors were found to display a varied and complex response, both on pacemaker
activity and upon the inhibitory phase. Both excitatory and inhibitory receptors were
present; however, individual subtypes (P2Xi and P2Y,) seemed to display a differing
degree of functional relevance at low and high volume. Though P2X and P2Y may
have excitatory and inhibitory effects respectively, the overall effect of purinergic
receptor stimulation is inhibitory, as suggested by the actions of PPADS. The locations
of the mechanism involved in the modulation of spontaneous activity and the
generation of the inhibitory phase are not known. However, there is the suggestion that
the overall purinergic effect on the pacemaker effect is inhibitory, involving a balance
of excitatory and inhibitory purinergic stimuli. Some have postulated that
myofibroblasts are implicated in an inhibitory P2Y6 response, Sui et al, 2004, however,
though these cells are spontaneously active their relationship to the suburothelial
interstitial cell layer is not clear. However, the marked effects of the purinergic




FURTHER STUDY Chapter Five
(i) The effects of 4-DAMP and AF-DX need to be repeated upon the volume
response, to elicit the relative responses of the M2 and M3 muscarinic receptor
subtypes at various stages of filling, and upon the 'inhibitory phase'. It could
then be seen whether the M3 mediated rapid, initial component of cholinergic
activity (under iso-volumetric conditions) also mediates the initial, rapid
component seen immediately following volume increase.
(ii) The nicotinic responses within the bladder need to be considered further.
Effects of nicotinic agonists need to be assessed upon spontaneous and volume
induced changes, in addition to more specific nicotinic antagonists. Also, the
location of nicotinic receptors needs to be evaluated in addition to the subtypes
involved. This may involve a combination of immunohistochemical staining
techniques, in addition to the mRNA analysis of specific structures.
(iii) As the purinergic responses seem to be complex, potentially involving a
number of different subtypes from both the P2X and P2Y family, the effects of
the specific purinergic receptor antagonists need to be assessed. Functional
effects in addition to the location of these purinoceptors need to be investigated
further.
(iv) As with most animal experiments there is difficulty in translating the work into
human models. With the work on the isolated guinea pig bladder an attempt has
been made to relate structure to function. This working principle needs to be
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repeated in other animal models, so that the effects of both unique and common
structures can be assessed. Following which the structures and workings of the
human bladder can be speculated.
(v) The work of Hawthorn et al, 2000 in suggesting the production of a readily
diffusible 'inhibitory factor' derived from the urothelium could be assessed
further in this organ preparation. It would be interesting to see whether volume
distension of one isolated bladder in close proximity to another induces an
'inhibitory phase', and whether this would occur in a bladder in iso-volumetric
conditions. If so, the location of the mechanisms involved may allow the
development of a focused therapeutic target that could reduce non-micturition
activity; and therefore it's associated afferent discharge.
(vi) Additionally, more focus needs to be brought upon high gain urodynamics
performed at physiological fill rates in order to catalogue the characteristics of
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Antimuscarinic drugs are generally thought to
exert their therapeutic action on detrusor
overactivity by reducing the ability of the
detrusor muscle to contract. We review
currently available published data to
establish whether there is any evidence to
support this contention. Using a PubMed
data search, only 14 original articles
(including two abstracts) were found that
contained cystometric data for both filling
and voiding phases and where the actions of
antimuscarinic drugs have been reported
in detail. These articles were separated into
three groups dealing with neuropathic
patients (three papers), patients with
idiopathic overactive bladder (four papers)
and a group whose aetiology was unclear
(seven papers). Variables relating to bladder
function during the filling phase (time of
first desire to void, time to first unstable
contraction, and bladder capacity) were
identified. Similarly, variables relating to
voiding were identified and compared (e.g.
maximum detrusor pressure and detrusor
pressure at maximum flow rate). The
antimuscarinic drugs have a clearly
significant effect on sensations of urge, time
to first sensation to void, maximum bladder
capacity, decrease in voiding frequency and
reduction in incontinence episodes. However,
only one article (studying neuropaths)
reported a significant reduction of the
variables associated with detrusor
contraction. The remaining four studies
(idiopaths/not stated), reported no change in
bladder contractility with antimuscarinic
drugs. Thus the available data do not support
the conclusion that antimuscarinic drugs at
doses used in current clinical practice exert
their therapeutic action by inhibiting detrusor
contractility, but they suggest effects on
variables associated with sensation.
KEYWORDS
anticholinergic drugs, bladder overactivity,
urinary urge
INTRODUCTION
According to current ICS terminology
detrusor overactivity (DO) is defined as 'a
urodynamic observation characterized by
involuntary detrusor contractions during the
filling phase which may be spontaneous or
provoked'. The overactive bladder syndrome
(OAB) is a symptom complex characterized
by urgency, with or without urgency
incontinence, usually accompanied by
frequency and nocturia [1]. It is a common
condition affecting 17°/oofthe populations of
Europe and the USA [2,3]. Most patients with
OAB have urodynamically confirmed DO, and
the vast majority of patients with DO have
symptoms of OAB [4],
The symptoms of DO/OAB have been generally
considered to be due to abnormal bladder
contractions occurring inappropriately
during the filling phase. On this assumption
the mainstay of treatment for OAB has
been antimuscarinic medication, with
the contention that they will reduce the
contractility of the detrusor muscle. The
logical argument was that by preventing
these abnormal contractions this would
relieve the symptoms. There is no doubt that
the antimuscarinic drugs currently used in
clinical practice (oxybutynin, tolterodine,
trospium, solifenacin and darifenacin) are
effective in reducing the symptoms of OAB.
Also, there is no doubt that at high doses
antimuscarinics can reduce the amplitude of
detrusor contraction. Indeed, patients given
an excess of antimuscarinic drugs retain urine
because the bladder cannot contract.
However, what is the evidence that the
therapeutic effect of these drugs is to reduce
bladder contractility?
Our aim in this review is to analyse previously
reported data related to therapeutic doses of
antimuscarinics in current routine use on
bladder contractility and sensory variables.
PRECLINICAL STUDIES
It is generally accepted that detrusor
contraction in humans is mainly mediated by
acetylcholine released from cholinergic
nerves, with acetylcholine stimulating
muscarinic receptors on the detrusor
myocytes. Although all muscarinic receptor
subtypes have been detected in the human
detrusor, the M, and M3 subtypes
predominate. Although M2 receptors might
predominate in number over receptors, it
is the M3 receptors that are mainly responsible
for the normal micturition contraction [5].
Muscarinic receptors are also found on
bladder urothelial cells and on structures in
the suburothelium (interstitial cells, nerves)
[6], Therefore antimuscarinics block, more or
less selectively, muscarinic receptors not just
on the detrusor muscle, where they decrease
the ability of the bladder to contract.
However, clinically, antimuscarinicsact mainly
during the storage phase, decreasing urgency
and increasing bladder capacity. During this
phase it is generally considered that there is
no activity in the parasympathetic nerves.
Furthermore, antimuscarinics are usually
competitive antagonists. This implies that
when there is a massive release of
acetylcholine, as during micturition, the
effects of the drugs should be decreased,
otherwise the reduced ability of the detrusor
to contract would eventually lead to urinary
retention. The question is whether there are
other effects of antimuscarinics that can
contribute to their beneficial effects in the
treatment of OAB.
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TABLE 1 Details of the papers reporting results in group I
Madersbacher Madersbacher
Variable etal. [10] etal. [10] Goessl etal. [11] Stohrer etal. [12]
Drug Trospium Oxybutynin Tolterodine Trospium
Dose (x/day) 20 mg x 2 5 mg x 3 0.1 mg/kg 20 mg x 2
Number of patients 52 43 12 29
CCn-an increased increased increased increased
Compliance no change no change increased increased
PdeW-filling - - decreased decreased
Pdet^a, decreased decreased - -
(W - - - no change
Residual volume increased increased no change
TABLE 2 Details of the papers reporting results in group II
Variable [13] [13] [13] [13] [13] [13] [14] [15] [16]
Drug Oxy Oxy Oxy Tol Tol Tol Oxy Tol Darifenacin
Dose, mg (x/day) 5x3 5x3 5x3 2x2 2x2 2x2 5x2 2x2 2.5/10 stat
Comment* G2 G3 G4 G2 G3 G4
No. of patients 25 36 40 25 36 40 145 25 18
FDV inc inc inc NC inc NC inc -
VFOC inc inc NC NC inc inc inc inc
PFOC NC NC NC NC NC NC NC
PdeWOC - - - - dec NC
ccrax NC NC inc NC NC NC inc inc
Pdetmax - - - - NC
Qmax - - - - NC
Residual volume - - - NC NC
*G refers to a subclassification ofpatients with OAB determined by their volume and pressure of first OC,
i.e. G2, high-volume (>250mL)/high-pressure (>25 cmH.Qj; G3, low-volume (<250mL)/low-pressure
(<25 cmH20); G4, low-volume (<250mL)/high-pressure (>25 cmH20). NC, no change;inc, increased; dec,
decreased; Oxy, oxybutynin; Tot, Tolterodine.
The urothelium/suburothelium has
attracted considerable interest as a target
for antimuscarinics. Yoshida etal. [7] found
that there is a basal acetylcholine release in
isolated human bladder tissue. This release
was suggested to be of non-neuronal
origin and, at least partly, generated by the
urothelium. Intravesical administration of
muscarinic receptor agonists can generate
DO, which can be inhibited by antimuscarinics
[8] and it was suggested that such an effect
was mediated via afferent nerves in the
suburothelium. Further supporting an effect
of antimuscarinics on afferent nerves,
Yokoyama etal. [9] found that low i.v. doses of
tolterodine significantly increased bladder
capacity in vehicle-treated rats with DO
caused by cerebral infarction, but had
no effects on bladder capacity in rats
treated with resiniferatoxin. Intravesical
administration of tolterodine significantly
increased bladder capacity in control rats with
cerebral infarction, but had no effect on
bladder capacity in resiniferatoxin-treated
rats. Yokoyama etal. therefore suggested that
at low doses tolterodine has an inhibitory
effect on C-fibre bladder afferent nerves,
thereby improving bladder capacity during
the storage phase.
EVIDENCE FROM STUDIES ON PATIENTS
Articles containing cystometric data for
patients treated with antimuscarinics,
currently used in routine clinical practice,
were identified through a standard Medline
search. Generic and brand names were cross-
referenced with terms used to describe
urodynamic assessments, in addition to
filling/voiding variables. Few studies were
identified, which is surprising given the
prevalence of OAB and the global usage of
antimuscarinics.
There are only 14 original articles (including
two abstracts) [10-23] which contain
cystometric data for both filling and voiding
phases in patients with OAB before and after
treatment. In these articles there is much
variation in the way cystometric variables are
reported, the numbers of patients involved
and methods of analysis. These factors make a
significant formal statistical analysis difficult.
In addition, the changing definition of an
'overactive contraction' during cystometry,
from those restricted to >15 cmH20 to all
clinically relevant involuntary rises in detrusor
pressure (Pdet), makes a cumulative
comparison inappropriate, as a further
subdivision in data would occur. In view of the
limitations in this approach, the data from
each article were deemed to be either
significant or not, based upon P< 0.05, and
descriptive analysis used to compare results
between articles.
ANALYSIS OF PUBLISHED DATA
For the purpose of this analysis the published
articles were divided into three groups
depending on the patient group described, i.e.
'neuropaths', 'idiopaths' and mixed (or not
specifically stated), labelled groups I to III,
respectively.
In group I (Table 1) data were reviewed from
three articles [10-12], one of which contained
two treatment groups [10], in all making four
reported treatment arms. During bladder
filling all treatment arms commented upon an
increase in maximum cystometric capacity
(CCnJ, with two arms both showing a
significant decrease in maximum Pdet
(Pdetmaxfilling). The effects on compliance
were equivocal, with two arms showing no
significant change and two a significant
increase. In reported voiding variables, Pdet,nax
was significantly decreased in two arms (both
from the same article). There was no
significant change in maximum urinary flow
(Qmax) and the effects on residual volume were
equivocal.
In group II (Table 2) data were reviewed from
three articles and one abstract [13-16]. One
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TABLE 3 Details of the papers reporting results in group III
Jonas Cardoza Thuroff Wagg Goode Griffiths Abrams
Variable etal. [17] etal. [18] etal. [19] etal. [20] etal. [21] etal. [22] etal. [23]
Drug Tolterodine Trospium Oxybutynin Tolterodine Oxybutynin Oxybutynin Tolterodine
Dose, mg (x/day) 2x2 20x2 5x3 2x2 IT 2.5-5 x 2 2x2
No. of patients 99 132 63 61 105 59 149
FDV inc - - - NC - -
SDV - - - inc - -
VFOC inc inc inc - - - inc
PFOC - NC - - - - -
Pdetmax-0C NC - - - - - -
ccnsx inc inc inc inc inc - inc
Compliance inc NC - - - - -
PdetQ^ - - - NC NC NC
Qrrax NC - - - - NC NC
Residual volume inc inc inc inc - inc inc
Pdet-UO - - - NC - -
Pdet-UC - - NC - -
IT, individually titrated; NC, no change; inc, increased.
article, the only article to do so, subdivided
patients with OAB into four categories
depending on the volume and magnitude of
the first overactive contraction (OC) [13].
Patients were labelled as high-volume/
low-pressure, high-volume/high-pressure,
low-volume/low-pressure or low-volume/
high-pressure, depending on the volume
and pressure of the first OC in relation
to the thresholds 250 mL and 25 cmH20,
respectively. This subdivision was used to
assess two antimuscarinics, resulting in eight
treatment arms. However, as two of these
arms had too few patients, only six from this
article were available for analysis, with one
each from the remaining three.
In group II the effects of antimuscarinics on
variables associated with the storage phase
were not clear. First desire to void (FDV) was
significantly increased in five treatment arms,
with two reporting no significant change. This
is mirrored by the volume at first OC (VFOC),
with six showing a significant increase and
two no change. Interestingly, in group II, CCmax
was only significantly increased in three of
the arms, and not significantly changed in
five, conflicting with data from group I. The
Pdetmax of the largest OC (Pdetmax-0C) again
was equivocal, with one arm showing a
significant decrease and one no significant
change. However, in all groups reporting the
pressure of the first OC (PFOC), there was no
significant change.
The effects on variables associated with the
voiding phase were unequivocal, although
relatively few arms were available for analysis.
There were no significant changes in either
Pdetmax, Omax or residual volume.
In group III (Table 3) data were reviewed from
six articles [17-22] and one abstract [23].
Group III contained a combination of mixed
patient groups and groups where the
aetiology was not commented upon. Each
article contained one treatment arm
examining the effect of an antimuscarinic in
current routine use. (One treatment arm
containing data for an older medication,
propantheline, was not analysed). In one
article [21], antimuscarinic and behavioural
modification therapy was compared solely
with behavioural modification. Although the
results for the effects of antimuscarinics were
not directly presented, they can be deduced
from the results.
In this mixed group, antimuscarinics
significantly increased both the VFOC and
CCm„, suggested by four and six articles,
respectively. In addition, the PFOC and the
Pdetmax-0C were not significantly changed,
although only one article each described
these findings.
There were no conflicting results in the
voiding variables. Three articles reported no
significant change in Qmax or PdetQmax; six
suggested an increase in residual volume, and
in one there was no significant change in Pdet
at either urethral opening (UO) or closure
(UC).
In general there was a uniform trend between
groups II and III, but the main exception to an
overall trend was the effect on reported Pdet
in group I (neuropaths), with two arms from
the same article showing a significant
decrease in Pdet during both filling and
emptying. This might be a result of the few
patients involved or signify differences in the
aetiologies of 'idiopathic' and 'neuropathic'
OAB.
In examining the data as a whole, a more
convincing view emerges as to the effects of
antimuscarinics on urodynamic findings.
Variables associated with storage, e.g. FDV
and CCmax, are significantly greater in the vast
majority of articles, with variables associated
with voiding, e.g. PdetQmax and Qmax not being
significantly changed. However, the effect on
Pdetmax seems equivocal, with two articles
suggesting a decrease and one suggesting no
significant change.
Descriptive analysis of the data allows
some conclusions to be formulated for most
urodynamic variables, as either the results are
consistent among articles, or in the case of
some disparity, the vast majority suggest one
variable over another. In cases of equivocal
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results, articles were divided between either
similar changes or no change. There were no
cases of opposing results between articles, i.e.
a decrease and an increase.
DISCUSSION
For years antimuscarinics have been an
integral part of the treatment of DO/OAB.
Being designed to reduce the strength of
OCs, they were confirmed to do so in higher
doses and in animal models. However, in
the clinical setting they were found to be
therapeutically effective at lower doses.
With this success in treatment and with a
simple model of how this might be achieved,
there was little reason to question the true
effects on the bladder. However, with recent
increasing anecdotal evidence to suggest
an additional effect on sensory symptoms
[24], their exact actions have now started
to come under scrutiny. Data obtained
through this analysis show the sensory
effects of antimuscarinics, but more
importantly there are no data to support a
significant reduction in detrusor contraction
in the idiopathic group of patients. There was
some reduction in the neuropathic group,
but this was limited to results in one article.
This anomaly might be a result of the few
articles involved overall, or the different
causes of OAB, especially as most neuropaths
generally have a higher Pdet, which might be
more sensitive to the effects of
antimuscarinics.
These findings do not dispute the effects of
antimuscarinics at higher doses, but suggest
that at clinically relevant doses alternative
effects need to be considered. The effects
upon sensation are strongly supported, but
given the lack of data available, more work
is required into the effects of therapeutic
doses of antimuscarinics upon contraction.
Also, a further question remains; 'how do
antimuscarinics, and therefore muscarinic
receptors within the bladder, alter
sensation?
CONCLUSION
The data currently available do not support
the view that antimuscarinics have a
significant effect upon bladder contractility in
patients with idiopathic DO, but suggest that
the benefits seen in these patients are due to
improvements in sensory variables.
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OBJECTIVES
To analyse pressure changes induced by
muscarinic agonists on the isolated bladder in
order to examine whether there are different
responses representing different components
of a motor/sensory system within the bladder
wall.
MATERIALS AND METHODS
Whole isolated bladders from 19 female
guinea-pigs (280-400 g) were used. A
cannula was inserted into the urethra to
monitor intravesical pressure and the
bladder was suspended in a heated chamber
containing carboxygenated physiological
solution at 33-36 °C. Initially, the responses
to the cholinergic agonists, arecaidine but-2-
ynyl ester tosylate and carbachol were
assessed. Then, in an attempt to identify the
muscarinic receptor subtypes involved, the
effects of selective muscarinic antagonists on
the arecaidine-induced bladder responses
were assessed. The antagonists used were the
relatively M3-selective 4-diphenylacetoxy-N-
methylpiperidine methobromide (4-DAMP)
and darifenicin, and relatively M2-selective
AFDX-116. All drugs were added to the
solution bathing the ablumenal surface of the
bladder.
RESULTS
The whole bladders exposed to cholinergic
agonists respond with complex changes in
intravesical pressure. Immediately after
application of the agonist there was a burst of
high frequency transient contractions. During
continued application of agonist the
frequency of the transients decreased and
their amplitude increased. Thus, there appear
to be two components to the response: an
initial fast phase and a later slow component.
The maximum frequency of the initial burst
increased with increasing concentrations of
agonist. By contrast, the frequency of the
transients in the steady state showed little
dependence on agonist concentration. There
were quantitative differences between the
responses to arecaidine and carbachol.
Arecaidine was less effective in generating the
initial burst of high-frequency activity and
the transients were significantly larger. At low
dose, arecaidine was more effective in
producing the large transients in the steady
state. Pre-exposure of the bladder to 4-DAMP
(0.1-10 nM) or darifenicin (0.1-10 nM)
significantly reduced the frequency of the
initial burst of activity; 0.3 nM 4-DAMP
reduced the frequency by half. In this
concentration range, 4-DAMP reduced the
amplitude of the initial transients but did not
affect the frequency of the transients in the
steady state. There were similar results with
darifenicin. However, darifenicin was less
effective in reducing the amplitude of the
initial transients. By contrast, ADFX-116 had
little effect on the frequency of the initial
transients but did reduce amplitude; 300 nM
AFDX-116 was needed to reduce the
frequency of the initial burst by half.
CONCLUSIONS
This analysis suggests that there are different
but interrelated mechanisms in the isolated
bladder contributing to complex contractile
activity. Three components can be identified: a
mechanism operating during voiding to
produce a global contraction of the whole
bladder and two mechanisms, pacemaker and
conductive, involved in generating and
propagating local contractions in the bladder
wall. The pacemaker component is more
sensitive to darifenicin and 4-DAMP than to
AFDX-116 suggesting that the underlying
processes rely predominantly on M3 receptors
and less so on M2 (M3 > M2). The phasic
activity in the later stages is less affected by
M3 antagonists and might therefore involve
predominantly M2 receptors (M2 > M3). The
potential importance of these results in terms
of the general physiology and pharmacology
of the bladder is discussed.
KEYWORDS
phasic activity, 4-DAMP, AFDX-116,
darifenacin
INTRODUCTION
Incontinence, increased urge and increased
frequency of micturition affect nearly
100 million people in the western world [1,2],
These LUTS are not life-threatening but they
seriously affect quality of life and ability to
work. The primary clinical problem is an
increased urge to pass urine [3]. Remarkably,
despite the prevalenceof LUTS the mechanisms
underlying increased urge are not known. To
simply describe the condition the term 'Over
Active Bladder (OAB)' symptom complex has
been introduced [1]. In many cases, studied
using conventional urodynamics,sensationsof
urge are correlated with rises in intravesical
pressure, a condition classified as detrusor
overactivity (DO). In the remainder of patients,
sensation is not accompanied by abnormal
contractions, a condition previously described
as sensory urgency [1-4]
As the DO component of OAB is associated
with contractions in the bladder, it was
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FIG. 1. An example of the effect ofadding 300 nM arecaidine to an isolated guinea-pig bladder. A, the original
record of intravesicle pressure, the horizontal bar represents arecaidine addition to the bathing solution. B,
shows an analysis of this record. The instantaneous frequency of the transients (reciprocal of the time
interval between each transient) is plotted against the time of the second of each pair. This shows how the
agonist affects the frequency with time of application. Two measurements used in subsequent analysis are




argued that drugs affecting contractility
would alleviate symptoms. Activity in the
bladder smooth muscle is initiated at
muscarinic receptors (M3). Drugs, designed to
target these M3 receptors on the muscle, have
proven effective in decreasing urge and
incontinence. However, it is emerging that,
at therapeutic doses, these drugs do not
significantly affect bladder contraction [5-7],
In addition, anticholinergic drugs are effective
in reducing symptoms of urge in those
patients who do not have DO as determined
by medium-filling rate cystometry [5-7]. If
the anticholinergics are only affecting the
uncontrolled contractions of the detrusor
these patients should not benefit from
600 800 1000 1200 s
anticholinergic drug therapy. Thus, we are
coming to the inescapable conclusion that the
site of action of these anticholinergic drugs is
unknown.
The anticholinergic drugs must work on
cholinergic mechanisms within the bladder or
lower urinary tract that are not immediately
associated with the generation of the voiding
contraction or the activity described as
overactive contractions. As they influence
sensation, it is possible that they affect
cholinergic mechanisms associated with the
generation of afferent signals in the bladder
[5-10], The nature of these additional
mechanisms and the cells expressing the
muscarinic receptors are not known.
Therefore, the search is on to identify these
novel cholinergic mechanisms in the bladder
and ascertain if they are the therapeutic
targets for the anticholinergic drugs.
Studies on the isolated whole bladder
preparation suggested that there might be
distinct cholinergic mechanisms that can
result in different forms of detrusor activity
[11,12]: localized phasic activity consisting
of propagating waves of contraction with
local stretches and global synchronous
contractions. It has been proposed that the
phasic activity plays a role in the generation
of afferent signals from the bladder [13,14],
Potentially, this mechanism could be a
candidate for the therapeutic action of the
anticholinergic drugs. Therefore, it is crucial
to examine in detail the cholinergic
mechanisms resulting in the activation of
phasic activity.
MATERIALS AND METHODS
The procedures for isolating the whole
bladder and maintaining it in vitro have been
described [11,12], Briefly, 19 female guinea-
pigs (280-400 g) were killed by cervical
dislocation in accordance with schedule 1 of
the UK Home Office regulations. The urinary
bladder and urethra were removed and placed
in Tyrodes solution (composition in mM: NaCI,
120; KCI 4.5; CaCI2 2.5; MgCI2 1; NaHC03 25;
NaH2P041; Na pyruvate 1, glucose 5) bubbled
with 5°/o C02 and 95°/o 02 (pH 7.4). The mean
(sd) bladder weight was 303 (55) mg (19
bladders). A flexible plastic cannula (2 mm
diameter) was inserted into the urethra and
secured at the bladder neck using a thread
ligature. Residual urine was removed and
replaced with Tyrodes solution. The bladder
was transferred to a heated organ bath
(30 mL at 33-36 °C) containing constantly
gassed Tyrodes solution. The cannula was
connected with the urethra uppermost
via a fluid-filled tube with a three-way
connector to a pressure transducer (model
DTX Plus, Becton Dickinson, Oxford, UK)
and a 1-mL syringe to enable variation of
the intravesical volume. The transducer
output was amplified, digitized (sampling
rate 10 Hz) and recorded using a capture
system (Acqknowledge AD, Newcastle
Photometries Systems, Newcastle, UK).
The transducer was calibrated before
each experiment. At the beginning of each
experiment, each bladder was filled with
Tyrodes to give a baseline volume of
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1000-1200 pi. These volumes were typically
the amount of urine recovered from the
guinea-pigs immediately after cervical
dislocation. The time taken from killing to the
beginning of recording was typically 30 min.
Pressure recording was begun immediately
but the bladder was left to equilibrate for at
least 20 min before any manipulations.
Initially, the responses of the isolated bladder
to cholinergic agonists, arecaidine but-2-ynyl
ester tosylate (Tocris, Avonmouth, UK) and
carbachol (Sigma, St. Louis, M0, USA), were
assessed. Then, in an attempt to identify the
muscarinic receptor subtypes involved, the
effects of selective muscarinic antagonists on
the arecaidine-induced bladder responses
were assessed. The antagonists used were the
relatively M3-selective 4-diphenylacetoxy-N-
methylpiperidine methobromide (4-DAMP:
M3 > M2i 9 :1) and darifenicin [M3 > M2,
60 :1) [15], and relatively M2-selective AFDX-
116 (M2 > M3, 4 :1). The concentrated drug
solutions were added directly to the solution
bathing the serosal/ablumenal surface of the
isolated whole bladder to achieve the required
final dilution.
The quantitative values are given as the mean
(sd). The differences between means were
determined by a paired t-test and the level for
significance set at 0.05. The number of
preparations used in the statistical analysis
for each experiment and each condition are
given in the appropriate figure legends.
RESULTS
RESPONSES OF THE ISOLATED BLADDER TO
ARECAIDINE AND CARBACHOL
Whole bladders, exposed to cholinergic
agonists, respond with complex changes
in intravesical pressure. Figure 1A shows
an example of a response induced by
the application of 300 nM arecaidine;
immediately upon application a series of
transient rises in intravesical pressure occur.
Figure IB shows an analysis of this activity.
The instantaneous frequency of the transients
(calculated as the reciprocal of the interspike
interval) is plotted against time of the
exposure. In the early stages of the response
the transients increase in amplitude and
frequency to a maximum. The maximum
frequency reached in this initial phase is
assigned the term Finit. The frequency of the
transients and their amplitude then decline.
After this phase both the amplitude and
FIG. 2. The effects ofdifferent concentrations of arecaidine on the induced transients in an isolated whole
bladder. A, a section of the original record. B, three sections of the record on an expanded time scale: 300 nM
(square), 100 nM (triangle) and 30 nM (diamond). C, an analysis of the records in B showing the instantaneous
frequency of the first 600 s of the records. The two secondarymeasurements are shown, Fmit and Fa.
Experiment done at 34 °C.
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frequency of the transients increase
eventually reaching a steady value Fss. The
amplitude of these spikes reaches a relatively
constant magnitude. In subsequent analyses
the magnitudes of Finit, Fss, and the maximum
pressure change of the transients in the initial
and steady-state phases are calculated.
Figure 2 shows the effects of different
concentrations of arecaidine; as the
concentration was increased Finit increased
but there was be little difference in Fss. The
maximum value of the amplitude of the
transients in the initial phase and in the
steady state both increased with agonist
concentration. Qualitatively similar responses
were obtained with carbachol (Fig. 3).
However, there were specific differences in
these responses. At similar concentrations,
the magnitude of Finit was greater with
carbachol and the transients in the steady
state were more variable in amplitude and
frequency. The combined data from 14
bladders is shown in Figure 4. The ability of
carbachol to generate higher frequencies in
the initial phase is clearly seen (Fig. 4A). The
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concentrations of arecaidine or carbachol on
the frequency of the transients in the steady
state is also apparent (Fig. 4B). Arecaidine was
more effective, at similar doses, in increasing
the amplitude of the transients in both the
initial and steady-state phases (Fig. 4C,D).
M3-SELECTIVE ANTAGONISTS
In each experiment, an initial control response
to agonist was elicited. During the subsequent
wash period, 4-DAMP was added to the
bathing solution. After a further 5 min a
second exposure to the same concentration of
agonist was given and the effect of 4-DAMP
determined. Upon washing off the agonist for
this response the concentration of 4-DAMP
was increased. This sequence was then
repeated for increasing concentrations of 4-
DAMP. Figure 5A shows the original records
from a bladder treated with 4-DAMP; six
bladders were studied using this protocol.
Figure 5B shows sections of the record in Aon
expanded time scales. Close examination of
these responses show that Fjnit was reduced
with increasing concentrations of 4-DAMP
while there was little effect on the amplitude.
670
© 2007 THE AUTHORS
JOURNAL COMPILATION © 2007 BJU INTERNATIONAL
KM
Hi CHANISMS IN A M OTO R/S E N S 0 R Y SYSTEM IN THE BLADDER
FIG. 3. The effects of different concentrations of carbachol on the induced transients in an isolated whole
bladder. A, a section of the original record. B, three sections of the record on an expanded time scale: 1000 nM
Itriangle),300 nM (circle) and 100 nM (square). C, an analysis of the records in B showing the instantaneous
frequency of the first 400 s of the records. The two secondarymeasurements are shown, Fm and Fss.
Experiment done at 34 °C.
Also, there was little effect on Fss. The changes
in instantaneous frequency for each 4-DAMP
concentration is shown in Figure 5C; as the
concentration of 4-DAMP increased the Finit
decreased while the Fss was little changed.
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FIG. 4. An analysis of responses from different bladders to arecaidine (circle; eight bladders) and carbachol
(triangle;six bladders). A and B show, respectively, Fmit and during exposure to different concentrations of
arecaidine or carbachol. C and D show, respectively, the variations in the amplitude of the transients during
the initial phase and late phase of the responses. *P <0.05 carbachol vs arecaidine (student t-test).
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Figure 6 shows data collected from six
experiments. The effects of 4-DAMP on Finit
and Fss are shown in A and B, respectively. At
low dose (0.3 nM) there was a significant
reduction of Flnit. As the concentration of
4-DAMP increased the reduction in Fit,it
decreased further, appearing to reach a
minimum value at =10 nM 4-DAMP of
0.07 transients/s. By contrast, the effect
of 4-DAMP on the Fss was less pronounced.
Interestingly, the lowest value of Finit at 10 nM
4-DAMP (0.07 transient/s) was approaching
the values of Fss. Thus, it is possible that there
is a component of the transients in the initial
response that reflects the mechanism in the
steady state. If this is so then the initial
component sensitive to 4-DAMP is almost
completely inhibited by 3 nM 4-DAMP.
Concentrations of 4-DAMP as low as 0.3 nM
being effective in reducing this component by
half.
Darifenicin was also effective in reducing the
phasic arecaidine-induced activity (Figs 7 and
8). As with 4-DAMP darifenicin reduced Finit
but had little effect of Fss. The amplitude of
the transients in the initial phase and in the
steady state were also reduced by darifenicin.
The reduction in Rnit with 4-DAMP and
darifenicin were very similar. Flowever, there
appeared to be a difference in the effect of 4-
DAMPand darifenicin on the amplitude of the
initial transients. This difference is shown in
Figure 9 where the data from Fig. 6A and C
and Fig. 8A and C are combined. Panel A
shows the effects of the two antagonists on
the amplitude of the transients. 4-DAMP was
more effective at these low concentrations
in reducing the amplitude of the initial
transients than darifenicin. By contrast, both
agonists were equally effective in reducing
Finit. This could suggest that the mechanisms
involved in determining the F,ni, involves M3
muscarinic receptors. The mechanisms
involved in regulating the amplitude of the
initial transients were affected more by 4-
DAMP than darifenicin. As 4-DAMP has a
partial effect on M2 receptors, which is greater
than that of darifenicin the reduction in
amplitude could also reflect an involvement
of M2 receptors. That neither 4-DAMP nor
darifenicin affected Fss significantly, although
also induced by muscarinic exposure,
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suggests less involvement of M3 receptors
in Fss.
M2-SELECTIVE ANTAGONIST
An example of an experiment showing the
effectsof AFDX-116 is shown in Figure 10and
the collected data from six bladders shown in
Figure 11. Figure 10A shows the entire
experiment while panel B shows sections of
the record on an expanded time scale. As the
concentration of AFDX-116 was increased the
amplitude of the transients was reduced. An
analysis of the instantaneous frequency
changes are shown in Fig. 10C but there
appears was little effect of AFDX-116 on Finit.
The combined data confirms that there is little
effect of AFDX-116 on the Finit or Fss. Only at
the highest concentration (1000 nM) did
AFDX-116 significantly reduce Finit or Fss. The
amplitudes of the initial and steady-state
transients were reduced by AFDX-116 at the
highest concentrations used (1000 nM).
DISCUSSION
It is widely accepted that the M3-selective
anticholinergic drugs are effective in reducing
the symptoms of OAB. Contraction of the
smooth muscle cells in the bladder involves
activation of M3 muscarinic receptors [16].
Flowever, it is unlikely that this population of
M3 receptors are involved in the therapeutic
action of anticholinergic drugs [6-10]. It is
emerging that the anticholinergic drugs
diminish the sensations of urge and so reduce
the need for frequent voiding. Thus, the
therapeutic site of action of the muscarinic
drugs must be on M3 receptors operating
within a system involved in the generation or
modulation of sensations during the filling
phase of the micturition cycle. Where these
receptors are located and what their role is in
sensory mechanisms are not known. The
search is therefore on to find these In¬
dependent mechanisms. This paper suggests
one possible mechanism.
A further complication concerns the location
and function of M2 receptors in the bladder
wall. There are data reporting that there are
more M2 receptors in the bladder than M3.
Despite this, we do not know what
physiological role these receptors serve or
where they are located [17-22], Possible
mechanisms involving the M2-dependent
regulation of detrusor contraction have been
suggested. M2 activation inhibits adenyl
FIG. 5. The effects of the Mrselective antagonist 4-DAMPon the responses of an isolated whole bladder
preparation in response to repeated exposures to 1000 nM arecaidine. A, the whole experiment; the response
in the absence of4-DAMPis described as the control. The responses in the presence of increasing
concentrations of4-DAMP are shown. B, shows these different responses on an expanded time scale. C, an
analysis of the responses showing the changes in the instantaneous frequencyof the transients with time for
the different concentrations of4-DAMP: control (square), 1 nM (diamond), 3 nM (triangle) and 10 nM (circle).
Temperature of experiments 33-34 °C.
10 nM
. , .i i 11.] .1 _1_] A
100 200 s 0 500 1000 s
A
control 1 nM 3 nM 10 nM
control
FIG. 6. Data from six bladders showing the effects ofdifferent concentrations oftheM3-selective antagonist
4-DAMP on the arecaidine-induced responses. A and B show the effects of4-DAMP on Finit and Fss,
respectively. Cand D show the effects on the amplitudes of the initial and steady transients, respectively.
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FIG. 7. The effects of the M3-selective antagonist darifenicin on the responses of an isolated whole bladder
preparation in response to repeated exposures to 1000 nM arecaidine. A, the whole experiment; the response
in the absence of darifenicin is described as the control. The responses in the presence of increasing
concentrations ofdarifenicin are also shown. B, shows two of these responses on an expanded time scale. C,
an analysisof the responses in B showing the changes in the instantaneous frequency of the transients with
time for the different concentrations ofdarifenicin: control (red circle) and 0.3 nM darifenicin (blue circle).
Temperature of experiments 33-34 °C.
A
D
control 0.1 nM 0.3nM 1 nM
FIG. 8. Data from nine bladders showing the effects of different concentrations of the M3-selective
antagonist darifenicin on arecaidine-induced responses. A and B show the effects of darifenicin on Fu< and
Fss, respectively. C and D show the effects on the amplitudes of the initial and steady transients, respectively.
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cyclase resulting in a decrease in intracellular
cAMP. Since a decrease in cAMP leads to an
increase in contractility this was proposed as
a possible function of M2 receptors in the
regulation of bladder contractility. In addition,
as M2 receptors are more prevalent within the
urothelial layer there is a further suggestion
that the urothelium might be involved in the
regulation of detrusor contractility.
It has been recognized for >120 years that the
bladder is not quiescent during the filling
phase. Small transient rises in pressure occur
that become larger and more frequent as the
bladder fills [23-26], It was proposed that this
non-micturition activity generates afferent
discharges that contribute to bladder
sensation [14,27], Phasic activity similar to
the non-micturition activity seen in vivo can
be detected in the isolated bladder [14,24],
Using this preparation it was shown that the
phasic activity or, as it is known 'autonomous
activity', can be augmented by muscarinic
agonists and this augmented activity is
increased by ATP and substance P [28]; it can
also be inhibited by calcitonin gene-related
peptide and noradrenaline [29,30], This has
lead to the idea that the non-micturition
activity can be modulated to alter the
sensitivity and output of this sensory/motor
system [14]. As the non-micturition activity is
influenced by muscarinic stimulation it
follows that reduction of this muscarinic
component by anticholinergic drugs will
reduce sensation. Thus, this mechanism could
represent the therapeutic site of action of the
antimuscarinic drugs.
The present study shows the responses of
the whole isolated bladder to muscarinic
stimulation. Exposure to an agonist results in
a complex pattern of transient rises in
intravesical pressure that change during the
period of the application. Immediately the
bladder is exposed to agonist the frequency of
the transient rises rapidly to a maximum (Flnit)
and then declines to a steady level (Fss). The
F;nit increases with increasing agonist
concentration. By contrast, the Fss is not
markedly different with different agonist
concentrations. At present, the mechanisms
that generate and regulate both frequency
and amplitude of the phasic activity are not
known. It is unlikely that they originate as a
result of activation of the M3 receptors on the
detrusor (see [14] for a discussion). However, a
detailed analysis and consideration of the




It was shown that the transient rises in
pressure induced by muscarinic agonists are
accompanied by propagating waves of
contraction over large parts of the bladder
wall and by local stretches [11,12], This led to
the idea that the transients are initiated by a
'pacemaker-like' mechanism and that the
activity is then distributed throughout the
bladder wall by specialized networks of cells,
nerves or interstitial cells (ICs) [13,14], In the
present study, that the Finit was dependent on
muscarinic agonist stimulation, suggests an
involvement of muscarinic receptors on the
cells responsible for generating the
pacemaker activity.
That the agonist-dependent changes in Finit
were sensitive to the relatively M3-selective
muscarinic antagonists 4-DAMP and
darifenicin [16], further suggests that the cells
performing the pacemaker function express
and operate with predominantly the M3
receptor subtype. The small but clear
differences in the actions of 4-DAMP and
darifenicin also support this possibility. That
the more selective agent, darifenicin, at low
concentration, affects the frequency of the
transients but not the amplitude suggests
that the pacemaker mechanisms is indeed
regulated by M3 receptors while the
mechanisms influencing the amplitude are
not exclusively so, involving both M3 and M2.
The greater decrease in the amplitude of the
initial transients with 4-DAMP can be
interpreted to suggest that this is the
consequence of inhibition of an M2
component with the less selective antagonist.
The amplitude of the transients was related to
the concentration of the muscarinic agonist
and the degree of muscle activation
resulting from the spread of activity over
the bladder surface. This suggests that the
propagation of the activity is regulated by a
muscarinic mechanism that might be more
dominated by M2 than M3 receptors. This is
supported by the finding that the relatively
M2-selective antagonist AFDX-116 [31] did
not markedly influence the Finit. Flowever,
AFDX-116 did affect the amplitude of the
transients.
The activity generated in the pacemaker
mechanism by muscarinic stimulation is
transient; the stimulus activates an initial
burst of activity that declines to a steady
state. As already stated, the Fini, depends on
the applied agonist concentration and is
inhibited by 4-DAMP and darifenicin. By
FIG. 9. Summary of the mean data from the series ofexperiments with 4-DAMPand darifenicin showing the
effects of 4-DAMP (blue diamond) and darifenicin (red diamond) on the amplitude (A) of the transients
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FIG. 10. The effects of the Mrselective antagonist AFDX-116 on the responses ofan isolated whole
bladder preparation in response to repeated exposures to 1000 nM arecaidine. A, a whole experiment; the
response in the absence ofAFDX-116 is described as the con trol. The responses in the presence of increasing
concentrations ofAFDX-116 are also shown. B, shows these different responses on an expanded time scale.
C, an analysis of the responses showing the changes in the instantaneous frequency of the transients with
time for the different concentrations ofAFDX-116: control (triangle), 100 nM (square) and 300 nM (diamond).
Temperature of the experiment 33 "C.
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MECHANISMS IN A MOTOR/SENSORY SYSTEM IN THE BLADDER
FIG. 11. Data from six bladders showing the effects ofdifferent concentrations of the Mrselective antagonist
AFDX-116 on arecaidine-induced responses. A and B show the effects ofAFDX-116 on the F,„„ and Fa
respectively. C and D show the effects on the amplitudes of the initial and steady transients, respectively.
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contrast, the Fss is less sensitive to agonist
concentration and to M3 inhibition. This
might argue that the initial transients and
steady-state transients might be dependent
upon different but interrelated mechanisms.
Indeed, it is possible that there could be two
separate mechanisms. In keeping with this
idea the nicotinic ligand lobeline was
reported to be capable of producing slow
large transient rises in pressure similar to
those seen in the steady state but did not
generate a rise in basal pressure or bursts of
high frequency activity [12]. Taken together
these data are consistent with the view that
there are two mechanisms operating to
generate and propagate phasic activity in
the guinea-pig bladder: a pacemaker, used
to determine the frequency of the phasic
activity, and a distribution mechanism used
to propagate activity in waves of
contraction throughout the bladder. This
scheme is illustrated in Figure 12. As the
initial burst of activity is activated by
muscarinic agonists and inhibited by 4-
DAMP and darifenicin, it is likely that this
pacemaker mechanism is regulated by
predominantly M3 muscarinic receptors
rather than M2 (M3 > M2). By contrast, the
large steady-state transients are less
sensitive to the M:i antagonists and might
be dependent on M2 receptors operating via
changes in intracellular cAMP (M2 > M3).
That the frequency of the large transients
generated during the steady state of an
agonist-complex response is relatively
insensitive to the M3-selective antagonists
suggests that cholinergic stimulation of these
cells might predominantly be via M2 receptors.
The M2-seleetive antagonist AFDX-116
reduced the amplitude of the transients. The
large transients in the steady state were larger
and more regular when induced by arecaidine
than with carbachol. Arecaidine is a
muscarinic agonist with a reported greater
selectivity for the M2 than the M3 receptor
[32], Thus, ICs might be activated and
regulated by M2 receptors. Activation of M2
muscarinic receptors in many cells inhibits
adenylate cyclase resulting in a decrease in
intracellular cAMP [18,19], If this is correct
then activity in the IC is regulated by cAMP: a
decrease in cAMP results in an increase in
excitability. Consistent with this idea it was
shown that procedures that elevate cAMP
(forskolin and phosphodiesterase inhibitors)
inhibit phasic activity in the isolated bladder
preparation [33]. This scheme represents a
possible role for M2 receptors in the bladder.
It must not be forgotten that there must be
a further component of bladder activity
resulting from direct activation of the M3
muscarinic receptors on the smooth muscle
probably by postganglionic parasympathetic
nerves and involved in the generation of
the voiding contraction. Activation of the
smooth muscle directly is likely to result in
simultaneous activation of all of the muscle
resulting in a contraction.
Recent studies identified possible structural
correlates of this functional framework. There
is growing evidence for the presence of a
heterogeneous network of cells, ICs,
associated with the detrusor that might
subserve the functions of pacemaker and of a
coordinating network controlling contraction
waves in the detrusor [34-40], In the guinea-
pig and mouse, the responsiveness of ICs to
nitric oxide resulting in an elevation in
intracellular cGMP has been used to identify
subtypes and their distribution [34,37,39,40].
In the guinea-pig three types of ICs have been
identified associated with the outer muscle
layer: cells running on the outer margin of the
bladder wall (muscle coat ICs), cells on the
surface of the muscle bundles (surface muscle
ICs) and cells within the muscle bundles
(intramuscular ICs) [37], Also, there is some
evidence to suggest that the intramuscular
ICs might consist of two populations of cells:
cells expressing choline acetyl transferase
(ChAT) and cells not expressing ChAT [39], In
the mouse there appear to be only two types
of IC associated with the outer muscle layers:
intramuscular and surface muscle ICs. In both
guinea-pig and mouse the surface muscleand
intramuscular ICs come into close contact
with nerve fibres, suggesting that activity in
these cells might be under neural control,
possibly cholinergic [39], In support of this
possibility, activity in an isolated bundle of
smooth muscle cells originates at specific
points on the bundle surface, presumably the
ICs [36], The concept that is evolving is that
cholinergic nerve-mediated activity in the
network of ICs is transferred to the underlying
muscle bundles resulting in coordinated
episodic waves of contractile activity. There is
a report showing that nitric oxide selectively
reduced the phasic activity in the isolated
mouse bladder [40], As the major cell type
sensitive to nitric oxide in the mouse bladder
are the ICs then this suggests that these cells
do play an integral part in the generation of
phasic activity.
The location and nature of a potential
pacemaker mechanism is not known. In the
guinea-pig, a recent study showed the
presence of a suburothelial ganglionic
network. The neurones in these ganglia are
contacted by different types of nerve fibre.
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Three types have been identified: fibres
expressing calcitonin gene-related peptide,
fibres expressing ChAT and neurofilament
protein (ChAT/NF+) and fibres expressing ChAT
but not neurofilament (ChAT/NF") [41]. The
calcitonin gene-related peptide and ChAT/NF"
fibres might be collaterals of sensory fibres,
which appear to originate in the suburothelial
layer. The ChAT/NF+ fibres might be axons from
adjacent ganglia. Furthermore, two types of
nerve fibres innervate the muscle layer ChAT/
NF+ and ChAT/NF" fibres. The ChAT/NF+ fibres
might also contact ICs in the outer muscle
layer. Thus, there is evidence for a
suburothelial ganglionic network with the
potential to receive inputs from the
urothelium and adjacent ganglia and
which has outputs to the muscle layers. It
has been speculated that such a network
might play a role in the local reflexes in the
bladder wall linking urothelial distortion to
phasic contractile activity [41]. In the context
of this discussion it is notable that the
suburothelial ganglion cells receive inputs
from two types of nerve fibre that are likely
to be cholinergic suggesting that the
ganglionic cells express cholinergic receptors.
Application of exogenous muscarinic agonists
might be expected to activate these ganglia.
If these ganglia are associated with reflex
activation of phasic activity then the direct
activation with an exogenous muscarinic
agonist will also generate phasic activity.
Therefore, there is circumstantial evidence to
suggest a role for the suburothelial ganglionic
network, the pacemaker, and the different
types of ICs, a heterogeneous network carrying
pacemaker activity to the muscle layer.
In summary, the present study using the
isolated guinea-pig bladder, shows that the
rapid component of the phasic activity
recorded is generated and its frequency
determined by activation of muscarinic
M3 receptors. This pacemaker activity is
particularly sensitive to M3-selective
antagonists at subnanomolar concentrations.
These concentrations are unlikely to affect
the voiding contraction. Thus, we have a
functional target for low doses of M3-
selective antagonists. Non-micturition
activity has been described in normal human
subjects and in patients with OAB syndrome.
Thus, we can make the tentative suggestion
that the anticholinergic drugs exert their
therapeutic action by inhibiting the
pacemaker activity in the bladder wall
involved in the generation of this motor/
sensory system.
FIG. 12. A schematic diagram suggesting a possible arrangementofmechanisms to account for the complex
actions ofcarbachoi and arecaidine and the muscarinic antagonists on the isolated whole bladder
preparation. A, a block diagrammatic representation of the basic phenomena. Activation of the bladder via
postganglionic parasympathetic nerves during voiding are shown. The different components of the phasic
activity are shown: the initial fast component and the steady-state component. B, is a cartoon suggesting
how these phenomena might be related to cellularmechanisms and anatomical features within the bladder.
The possibility is suggested that there is: (i) A pacemaker element, driven by a mechanism dominated by M3
receptors, (ii) A distribution network, involving M2 components. This network contacts and communicates
with the muscle resulting in phasic contractile activity. In the absence ofmuscarinic inputs phasic activity
can be activated by the nicotinic ligand lobeline suggesting a further specialized region within the network.
(Hi) Contractions of the detrusor, controlled byM3 receptors possibly activated directly by efferent
parasympathetic cholinergic nerves.
Bladder activity
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OBJECTIVE
To quantify changes in autonomous activity
in response to alterations in intravesical
volume, to explore the possible underlying
regulatory mechanisms.
MATERIALS AND METHODS
Experiments were conducted using whole
isolated bladders from six female guinea pigs
(280-400 g). A cannula was inserted into the
urethra to monitor intravesical pressure and
the bladder was suspended in a heated
chamber containing carboxygenated
physiological solution at 33-36 °C. All drugs
were added to the solution on the ablumenal
bladder surface.
RESULTS
An increase in intravesical volume followed
by a rapid reduction lead to a complex series
of activity comprising of several distinct
phases. After a volume increase there was an
initial 'burst' of frequency which gradually
declined to a 'steady state'. After a volume
reduction there was a period of quiescence
with spontaneous activity gradually
returning to levels seen before the increase,
termed the 'inhibitory phase'. The frequency
of transient contractions, both immediately
after a volume increase and at steady state,
increased both with increasing intravesical
volume and dose of arecaidine. The length of
the inhibitory phase increased both with the
duration and magnitude of volume increase.
However, the inhibitory phase was not
entirely dependent n the magnitude of
volume change, as the inhibitory phase was
shorter when the volume was not returned
to baseline levels. Increasing doses of
arecaidine shortened the inhibitory phase.
CONCLUSIONS
These observations suggest that the
regulation of volume-induced spontaneous
activity relies on complex excitatory and
inhibitory inputs. The rapid burst of activity
resulting from a rise in volume suggests the
presence of a rapidly adapting mechanism.
Rapid reduction in intravesical volume leads
to a quiescent period, i.e. the inhibitory
phase. This is related to both the duration of
intravesical volume increase and its
magnitude. However, similar volume
changes are more effective when the volume
is reduced back to baseline, as opposed to
the bladder being incompletely emptied.
Furthermore, the frequency of transient
contractions remained constant once a
steady state was reached, with no evidence
of inhibition before volume reduction. This
suggests that mechanisms involved in the
generation of the inhibitory phase initiated
during bladder filling require >30 s to have a
significant effect, but depend on a reduction
in volume to be triggered, with the response
dependent on the volume reduced. The
mechanisms involved in generating and
modulating the inhibitory phase seem to be
regulated by a strong cholinergic input but
the exact nature of these mechanisms is
unknown. The potential importance of these
results in terms of the general physiology






The isolated bladder is capable of generating
spontaneous co-ordinated activity involving
localized contractions and propagating waves
over the bladder surface. This activity, termed
'autonomous activity', results in an increase in
intravesical pressure consisting of regular,
rhythmical transient contractions [1,2]. This
activity can be augmented by adding the
muscarinic agonists arecaidine or carbachol
to give larger increases in intravesical
pressure, associated with increases in the
amplitude of localized contractions and
frequency of the propagating waves [2],
Autonomous activity has been studied most
extensively in the guinea pig, but has also
been reported in other animals [3-5]. Similar
activity analogous to autonomous activity,
unrelated to the act of micturition, has also
been shown to be present during the filling
phase of many species, including man
[3,6-10], In the guinea pig, autonomous
activity augmented by muscarinic stimulation
can be manipulated in several ways. The
frequency of transient contractions can be
increased by adding a,(J-methylene ATP (a
nonhydrolysable analogue of ATP), substance
P and sodium nitroprusside (a nitric oxide
donor) [11,12], whereas there is a reduction in
frequency with noradrenaline [13]. These
combined findings suggest that the
mechanisms regulating phasic activity receive
both excitatory and inhibitory inputs [12,13].
The physiological role of autonomous activity
is not understood. Autonomous activity and
augmented activity are associated with
localized microcontractions (micromotions)
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of the bladder wall, accompanied by local
stretches [1-4]. Such activity occurs in both
the normal and pathological bladder, where
local contractions generate small pressure
changes accompanied by local stretches
[1-3]. This phasic motor activity is associated
with phasic discharges in afferent nerves
[14-16], suggesting that it forms the motor
component of a motor/sensory system in the
bladder wall.
This idea that such a motor/sensory system
existed in the bladder was first proposed in
the early part of the 20th century [14]. It has
also been known for some time that this
motor/sensory system has the capacity to be
modulated by different inputs. Data taken
from cat experiments show that the
amplitude and frequency of this activity can
be influenced by sympathetic nerve inputs
[6,8],
In response to increasing intravesical volume
the frequency and amplitude of transient
contractions has been found to increase [17].
As phasic activity is considered to be part of
an integrated motor/sensory system, given its
responses it is suggested that the system
receives inputs directly related to intravesical
volume. It was previously proposed that
several complex arrangements exist within
the bladder that could account for the
physiological responses seen within phasic
and volume-related activity. The excitatory
effect of substance P and the inhibitory effect
of calcitonin gene-related peptide (CGRP) on
phasic activity suggest the presence of a
sensory-axon collateral reflex within the
bladder wall, supporting a role for the release
of sensory neurotransmitters within the wall
of the bladder [18]. It was documented
previously that afferent nerves can send
collateral fibres to structures within the tissue
where they originate [19-21]. However, with
prolonged exposure to capsaicin, leading to
the elimination of substance P/CGRP sensory
nerves [20], volume-induced changes are not
affected. This suggests that the local sensory-
collateral reflex is not involved in the volume
response. Also, as all potential neural sensory
influences would be removed via the action of
capsaicin, non-neural mechanisms must
therefore be involved in the regulation of
volume-induced activity.
In addition to the effects of increasing
intravesical volume, a rapid decrease results
in a period of quiescence, where there is a
prolonged period of inhibition of phasic
activity, followed by a gradual return [17]. The
mechanisms involved in this process are
unknown, although given the lack of effects
of tetrodotoxin or capsaicin they are likely to
be strongly related to non-neuronal activity
(as described previously). However, the
actions of ODQ, an inhibitor of guanyl cyclase,
suggest a potential role for interstitial cells in
either its generation or co-ordination [17].
Other potential non-neuronal sources of
inhibition have been proposed, one of which
isa urothelium-derived 'inhibitoryfactor' able
to inhibit contraction of detrusor smooth
muscle [8], although its effects upon phasic
activity have not been assessed.
Changes in phasic activity in response to
changes in intravesical volume are complex. It
is proposed that phasic activity is related
to sensation and therefore might be a
mechanism through which bladder volume
can be assessed. Inhibition after a volume
decrease might occur to suppress sensation
during or immediately after voiding that
could otherwise be uncomfortable. The
mechanisms behind these volume-related
responses are unknown, although they seem
to be related to local mechanisms inherent to
the bladder wall. The aim of the present
experiments was to further characterize the
intrinsic properties of these responses in an
attempt to further illustrate potential
mechanisms through which they might act,
and assess their role in the integrative
physiology of the isolated bladder.
MATERIALS AND METHODS
The procedures for isolating the whole
bladder and maintaining it in vitro were
described previously [1,2]. Briefly, 13 female
guinea pigs (weight 280-400 g) were killed by
cervical dislocation in accordance with
schedule 1 of the UK Home Office regulations.
The urinary bladder and urethra were
removed and placed in Tyrode's solution
(composition, mM: NaCI, 120; KCI 4.5; CaCI2
2.5; MgCI2 1; NaHC03 25; NaH2P0, 1; Na
pyruvate 1, glucose 5) bubbled with 5°/o C02
and 95% 02 (pH 7.4). The mean (sd) bladder
weight was 303 (55) mg (11 guinea pigs). A
flexible plastic cannula (2 mm diameter) was
inserted into the urethra and secured at the
bladder neck using a thread ligature. Residual
urine was removed and replaced with Tyrode's
solution. The bladder was transferred to a
heated organ bath (30 mL, 33-36 °C)
containing constantly gassed Tyrode's
solution. The cannula was connected with the
urethra uppermost via a fluid-filled tube and
three-way connector to a pressure transducer
(DTX Plus, Becton Dickinson, Franklin Lakes,
NJ, USA) and a 2.5-mL syringe to enable
the intravesical volume to be varied. The
transducer output was amplified, digitized
(sampling rate 10 Hz) and recorded using
an computer-based capture system. The
transducer was calibrated before each
experiment. At the outset each bladder was
filled with Tyrode's solution to give a baseline
volume of 600-800 jiL. These volumes were
typically the amount of urine recovered from
guinea pigs immediately after cervical
dislocation. Volumes were changed typically
over 10 s for each specific increase/decrease.
The time taken from killing the guinea pig to
beginning recording was typically 30 min.
Pressure recording was begun immediately
but the bladder was left to equilibrate for
>20 min before any manipulations. The drug
used was the muscarinic agonist arecaidine
but-2-ynyl ester tosylate (Tocris, UK).
Concentrated drug solutions were added
directly to the bath to achieve the required
final dilution. All drugs were added to the
solution bathing the serosal surface of the
isolated whole bladder.
Quantitative values are given as the mean
(sd), with the significance of differences
between means determined using a paired f-
test, the level for significance being set at
0.05. The number of preparations used in the
statistical analysis for each experiment and
each condition are given in the appropriate
figure legends.
RESULTS
For each of the experiments a standard
control response was obtained [17], and the
method underpinning the analysis of the
experimental traces is shown in Fig. 1.
The effects of the magnitude of intravesical
volume change, duration of volume increase
and increasing doses of arecaidine were all
assessed individually. To assess the effects
of the magnitude of volume change,
experiments were conducted in the presence
of 100 nM arecaidine. Volumes were increased
for 500 s before a decrease. Typical examples
of the responses from the same organ
preparation are shown in Fig. 2. The frequency
of transient contractions, both immediately
after a volume increase (IF,nit) and at steady
state (F„), were higher after larger volume
increases. Furthermore, IFinlt represents a
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FIG. 1. Top panel; typical example of a 'volume response' obtained from an isolated guinea pig bladder,
augmented by 100 nM arecaidine. t, represents the time at which intravesical volume was increased and t2
the point where volume was reduced back to baseline volume, (t, - tj is termed the 'duration of volume
increase'. The interval increasing, or decreasing, volume is typically <10s. (a) period immediately after a
volume increase, where there is an initial increase in frequency and underlying pressure, followed by a
gradual decrease. Qualitatively this area immediately after the volume increase is termed the 'initial phase',
(b) period after a volume increase where the frequency, amplitude and underlying pressure of transient
contractions remain relatively constant, termed 'steady state', (c) time immediately after a volume decrease,
where there is a quiescentperiod followed by a gradual return in activity, termed the 'inhibitory phase'. A clear
demarcation of the endof the inhibitoryphase is difficult; therefore, the point atwhich the frequency returns
to 66.6% of the frequency before the volume increase was typically used in calculations; labelled the Y. (d)
refers to thepoints used to calculate the increase in underlying pressure. Bottom panel; illustrates the change
in instantaneous frequency of the transients during the volume response shown above. The red dashed line
represents a line of best fit drawn during the period ofincreased volume, (y,) represents a vertical axis drawn
at the point of volume increase. Intersection of the line ofbest fit and (y,) represents the frequency at the
pointofvolume increase (IFiniJ, extrapolation of this intersection to the ordinate axis giving the value oflFtni„
shown as (x,). In this case IFinit equals 0.78 transients/s. (d) represents the F55. (a-cj are used in the calculation
of r for the inhibitory phase, the point when frequency returns to 66.6% of its baseline 'before volume
increase'; (a) represents the baseline frequency before the volume increase - note the frequency after a
volume decrease is returning to this level; (b) represents the lowest frequency after a volume decrease; (c)
represents an arbitrary line drawn 66.6% of the distance between (a) and (b). (TJ represents the time at
volume decrease (TJ is extrapolated from the intersection between the instantaneous frequencyplot and (c);





























'burst' of activity that slowly reduced to form
a 'steady state'. Also, the length of the
inhibitory phase was not solely dependent on
the increase in intravesical volume.
Figure 2a,b show that the length of the
inhibitory phase was related to the magnitude
of volume increase if the volume was then
reduced back to baseline values. However,
Fig. 2c highlights that despite a similar
volume change, compared to that in Fig. 2b,
the inhibitory phase was reduced if the
volume was not fully returned to baseline.
This suggests that both volume increase and
decrease are important factors in generating
the inhibitory phase. Further comparison of
the traces also shows that the shift in
underlying pressure (P^f,) also increased at
higher volumes. Figure 3 shows an analysis of
these results obtained from five separate
guinea pigs.
The effects of a variable duration of filling
were assessed by increasing the volume for
10, 30, 100 and 500 s, respectively. All
responses were assessed in the presence
of 100 nM arecaidine and by increasing/
decreasing the volume by 2000 pi. A typical
example of the differing duration of increase,
applied to the same isolated bladder, is shown
in Fig. 4. As the volumes both at baseline and
after an increase remain constant there were
no differences in the frequency of either the
pre-filling or initial phase between volume
responses. What is apparent is that the
inhibitory phase increased with the duration
of volume increase. Figure 5 shows an
analysisof the inhibitory phase reported from
five separate bladders, again showing that the
inhibitory phase was related to the duration
of the volume increase. There was a
statistically significant difference between all
data points apart from the durations 10 and
30 s.
The effects of the two arecaidine
concentrations (100 and 300 nM) on volume-
induced responses were compared, with
typical examples from the same bladder
shown in Fig. 6. All volume responses were
assessed with a volume change of 2000 pL
and duration of fill of 500 s. It was described
previously that increasing the dose of
arecaidine results in an overall increase in the
frequency and amplitude of transient
contractions [2], However, these experiments
also showed that increasing doses of
arecaidine also increased IFinit in addition to
F„. The effects were similar on the increase in
Pshift, with this being larger at higher doses.
Conversely, the inhibitory phase was
significantly shorter in the presence of the
higher dose of arecaidine. Figure 7 shows
mean data collected from five different
bladders on the effects of 100 and 300 nM
arecaidine on the inhibitory phase, change in
underlying pressure at steady state (Pshif,), IFinit
and Fss (Fig. 7a-d), respectively.
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FIG. 2. Three volume responses, relating to differing volume changes, from the same isolated guinea pig
bladder preparation. The amount by which intravesical volume was increased and then decreased is
illustrated beneath each trace. Each response was assessed in the presence of 100 nM arecaidine and the
volume increased for 500s: (a) a 2.0-mL increase followed by a 2.0-mL decrease; (b) a 1.5-mL increase and
1.5mL decrease;and(c) a 2.0-mL volume increase with a decrease of 1.5mL Ordinate axes, pressure (cmH20)
and abscissa time (s). The pre-filling phases are similar for all three, but in comparing (a) and (b) there is an
increase in frequency initially and at steady state. Also, note a reduction in the inhibitory phase from (a)
through to (c).
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Volume responses with a varying
duration of intravesical volume
increase, assessed in the presence
of 100 nM arecaidine with volume
changes of2.0mL. The duration of
each volume increase is shown
beneath each trace. Ordinate,
































FIG. 3. Data accumulated from five bladders
illustrating the effects of different volume changes
on the volume response: (a) the effects of three
combinations of volume changes on x of the
inhibitory phase. Ordinate, x (s) and abscissa,
volume increase/decrease (mL); (b) represents PsMt-
Ordinate, pressure (cmH20) and abscissa, volume
increase (mL);(c) the effects oftwo volume increases
on IFin„ (maroon), and at Fss (yellow). The blue column
represents the baseline transient frequency before
the volume increase. Ordinates, frequency
(transients/s) and abscissae, volume increase (mL).
Data points separated by a line in (b) represent
results from the same bladder. Data in (a) + (c) are
shown as the mean (so). A significant difference















It was shown previously that changes in
intravesical volume lead to changes both in
the frequency and amplitude of spontaneous
phasic activity [1,2], and that spontaneous
transient contractions were associated with a
burst of afferent discharge. As phasic activity
is considered to be part of an integrated
motor/sensory system, the responses in
activity to volume suggest that the CNS
receives inputs directly related to intravesical
■volume. In addition, it was also shown that
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FIG. 6. Typical traces ofvolume responses assessed in the presence of 100 and 300 nM arecaidine, (a) and lb),
respectively. The amounts by which the intravesical volumes were changed are shown beneath each trace, in
addition to the duration of volume increase. In these cases volume changes were 2.0 mL, lasting for 500 s.
Ordinates represent pressure (cmH20) and the abscissa, time (s). Note the increased frequency in all three
phases (before filling, initial, steady state) in the presence of300 nM arecaidine (b), compared to 100 nM (a).
Also, note the reduction in the inhibitory phase in the presence of300 nM arecaidine (b).
FIG. 5. Data acquired from five bladders showing the
effects ofdifferentduration ofvolume increase on x
of the inhibitory phase. Ordinate, x of the inhibitory
phase (s) and abscissae, duration ofvolume increase
(s). Data points are shown as the mean (so). Apart
from at 10-30s, there was a significant difference
between all other values IP <0.05, Student's'.-test).
200
0L, ' ' ' ' '
0 100 200 300 400 500
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phasic activity can receive further excitatory
and inhibitory inputs [11,12], and as such
afferent discharge related to volume could be
influenced by these other stimuli. Therefore,
sensory perception of intravesical volume has
the capacity to be modulated by mechanisms
acting in the periphery [17]. However, there
are several major unanswered questions
relating to the generation and modulation of
the phasic activity, and to the specific cellular
mechanisms associated with the volume-
induced changes in activity.
The urothelium is known to release ATP in
response to mechanical distortion [8], It was
suggested that the role of urothelial-released
ATP is to modulate the firing of afferent nerve
fibres, in turn influencing bladder sensation
[22-24]. However, a further suggestion is that
ATP can indirectly act on the bladder via
alterations in phasic activity [10], inducing
sensory neurotransmitter release via
antidromic activation of collateral afferent
nerve fibres [17]. However, the effect on
volume-induced inhibition has not been
assessed. Further potential sources of
non-neuronal mechanisms might include
interstitial cells and a nonspecific substance
termed 'inhibitory factor'. Interstitial cells
could have a role in modulating volume-
induced activity by inhibiting phasic activity
after a volume reduction, as ODQ, an inhibitor
of guanyl cyclase, reduced the duration of this
inhibition [17], whilst 'inhibitory factor' is
speculated to be released from the urothelium
in response to stretch that results in an
inhibition of detrusor contraction [25],
However, the results on phasic activity again
have not been assessed.
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A pacemaker mechanism appears to be a key
component generating phasic activity [26].
Therefore, inputs from various sources must
integrate here to exert their effect. The
location and nature of this potential
pacemaker mechanism are unknown. In the
guinea pig, a recent study showed the
presence of a suburothelial ganglionic
network, the neurones of which are contacted
by different types of nerve fibre. Three types
were identified: fibres expressing CGRP, fibres
expressing choline acetyltransferase (ChAT)
and neurofilament protein (ChAT/NF^), and
fibres expressing ChAT but not neurofilament
(ChAT/NF") [27], The CGRP and ChAT/NF"
fibres might be collaterals of sensory fibres
that appear to originate in the suburothelial
layer. The ChAT/NF* fibres might represent
axons from adjacent ganglia. Furthermore,
two types of nerve fibres are known to
innervate the muscle layer, i.e. ChAT/NF* and
ChAT/NF- fibres. The ChAT/NF* fibres might
also contact interstitial cells in the outer
muscle layer. Thus, there is evidence for a
suburothelial ganglionic network with the
potential to receive inputs from the
urothelium and adjacent ganglia, which has
an output to the muscle layers. It was
speculated that such a network is involved
in the local bladder wall reflexes linking
urothelial distortion to phasic contractile
activity [27], The suburothelial ganglion cells
receive inputs from two types of nerve fibre
that are likely to be cholinergic, suggesting
that the ganglionic cells express cholinergic
receptors. Therefore, the mediation of
ganglionic activity is likely to have a strong
cholinergic influence, with application of
exogenous muscarinic agonists activating
these ganglia. Thus, there is circumstantial
evidence to support a structural framework
that has the potential to mediate the
responses in phasic activity previously
described, in addition to allowing speculation
as to their involvement in volume-induced
changes.
The present results illustrate the responses of
the isolated guinea pig bladder to changes in
intravesical volume, duration of volume
increase and the effects of the two doses of
arecaidine (100 and 300 nM) on volume-
induced 'augmented' activity ('volume
response'). After an increase in intravesical
volume there is a complex series of events,
similar to those described after adding
arecaidine [26]; again an 'initial phase'
consisting of a burst of high-frequency, low-
amplitude transients followed by a 'steady
state' consisting of regular transient
contractions of a lower frequency but greater
amplitude. After a reduction in intravesical
volume there is a period of quiescence, with
the transient contractions gradually returning
to their baseline frequency and amplitude.
The 'initial phase' after a volume increase
comprises a succession of rapid, small-
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FIG. 7. Data collected from five different isolated
bladder preparations on the effects on the volume
response in the presence of 100 and 300 nM
arecaidine. Datapoints connected by a line represent
results collected from the same bladder preparation;
(a) the effects of the two arecaidine doses on the
inhibitory phase; ordinate axis, z for the inhibitory
phase (s);(b) represents the effects on Pshlfl; ordinate
axis, pressure (cmH20); (c) the effects on frequency
after a volume increase (IF,n,J, (maroon) and Fss
(yellow). The blue column represents the baseline
frequency before any volume increase. Data
are shown as the mean (so). Ordinate axis,
instan taneous frequencyoftransien ts (transien ts/s).
In all three panels the abscissae relate to the two
doses of arecaidine in which the volume response
was assessed. There was a significant difference
between the effects of the two concentrations,
















superimposed on an initial sudden increase in
underlying basal pressure, followed by a
gradual decline. The overall magnitude of this
'initial' response depends on the increase in
intravesical volume, as illustrated by both IFinit
and Pst,itt, being significantly higher after a 2-
mlthan a 1.5-mL increase. However, as Pshit
declines to'steady state' levels, frequency also
gradually reduces, with the amplitude of
transients increasing. As the detrusor is
composed of slowly adapting smooth muscle
the decrease in Pshift after a volume increase
could be accounted for by relaxation of the
detrusor as it accommodates the increased
volume. However, as the urine within the
bladder will act as any other fluid, being
relatively incompressible, the volume within
the bladder would remain relatively constant
despite the pressure change. As the frequency
of phasic activity is related to intravesical
volume the decrease in frequency after a
volume increase suggests the governing
mechanisms become 'overloaded', requiring a
period of adaptation before the true volume-
related frequency is achieved (steady state).
Although these volumes have been increased
at unphysiological rates the findings suggest
the mechanisms involved in the regulation of
volume-related frequency have a component
that is rapidly adapting, allowing a degree of
desensitization to occur in response to high
rates of filling.
The magnitude of the 'initial phase' seems to
be directly related to the magnitude of the
increase in intravesical volume, as shown by
the differences between increases of 2 and
1.5 mL. Also, when the raw data were
analysed from previous records illustrating
the effects of smaller sequential increases in
volume on the initial phase, the initial phase
was smaller [17], However, the final 'steady
state' between the present data and that of
Lagou eta/. [17] at comparable volumes,
remains similar, suggesting that the 'steady
state' is unaffected by the rate of volume
increase. Furthermore, under physiological
conditions there is no 'initial phase', although
a gradual increase in frequency, amplitude
and underlying pressure is apparent [28],
similar to that seen in the steady state at
increasing volumes during the present
experiments. Also, on detailed inspection of
these records an inhibitory phase is also
evident, illustrating that quiescence after a
volume reduction is a true physiological
response, as opposed to a factor related to
increased filling rates [28].
After a volume reduction there is a period of
quiescence, termed the 'inhibitory phase'. As
noted previously, this was apparent both
in vitro [17] and in vivo [28]. The present
experiments further illustrate the 'inhibitory
phase' to be influenced by several factors,
consisting of volume increase, duration of
increase, muscarinic agonist concentration
and degree of bladder emptying. The length of
the inhibitory phase increased with volume,
but this was not entirely dependent on the
absolute change in volume. It was shown that
the length of the inhibitory phase also
depends on the volume decrease, with longer
inhibitory phases when the volume returned
to baseline. This is highlighted when the mean
results of a volume increase and decrease of
1.5 mL (157 s) are compared with those after
a volume increase of 2.0 mL and decrease of
1.5 mL (118 s). From this simple observation it
could be argued that a two-stage process is
evident in the regulation of the inhibitory
phase. A volume increase might act as a
volume-dependent stimulus for the synthesis
of agents, or initiation of mechanisms,
involved in the inhibitory phase that are
released/triggered again in a volume-
dependent manner as the bladder empties. In
turn, this suggests that the stimulus of
volume decrease is of similar importance to
that of volume increase in determining the
length of the inhibitory phase. It can be
further argued that an increase in the
inhibitory phase after a return to baseline
volume would suggest that maximum
mechanical distortion, as opposed to pure
stretch, is required for the full effects of the
inhibitory response to be seen. Whether this is
predominantly related to specific structures is
open to speculation, but it might indicate a
role for the urothelium, as this might be
indicative of the urothelium unfolding as the
bladder fills and re-folding as it empties. ATP
and nitric oxide released from the urothelium
on unfolding/re-folding could easily have an
effect on suburothelial purinergic receptors
[22-24] or interstitial cells [17]. Certainly,
suburothelial interstitial cells seem to be
implicated in some way to the inhibitory
phase, as ODQ, an inhibitor of guanyl cyclase
and therefore cell signalling via cGMP, i.e.
interstitial cells, significantly reduces its
length.
The duration of volume increase also has a
role in the length of the inhibitory phase, with
a longer duration of filling being associated
with longer inhibitory phases. There was an
insignificant difference in the length of the
inhibitory phase after a duration of filling of
<30 s, with a small difference between the
duration of fill of 100 and 500 s. However,
there was a substantial difference after a 30-
and 100-s volume increase, suggesting that
the rate of increase in the mechanisms
involved in the regulation of the inhibitory
phase increases substantially between these
300
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time points. This relationship between the
inhibitory phase and duration of filling
further supports the idea of agents/
mechanisms involved in the inhibitory phase
being synthesized/initiated in response to
a volume increase. It also supports the
inhibitory phase to be a true physiological
response as opposed to flaccidity related to
stretch-induced damage of the underlying
detrusor muscle.
The response of phasic activity in the isolated
bladder to alterations in intravesical volume is
complex. However, the effects illustrated after
adding 100 and 300 nM arecaidine suggest
a strong cholinergic component, or
components, involved in the modulation of
all three stages; initial, steady state and
inhibitory phase, with cholinergic inputs
exerting an excitatory effect by acting directly
on the pacemaker mechanisms.This increased
pacemaker stimulus results in an increase
in IFini, and Fss. However, it also leads to a
reduction in the inhibitory phase. This
suggests that the mechanisms involved in
generating the inhibitory phase involve a
balance between both inhibitory and
excitatory stimuli, with an excitatory
component being cholinergically mediated.
The mechanisms involved in providing the
inhibitory stimulus for the inhibitory phase
are not entirely known. It was suggested
previously that interstitial cells might play
some part in modulating the inhibitory phase
[17], although undoubtedly additional factors
also need to be considered. The observations
described previously add weight to the
argument that distortion of the urothelium
might release factors involved in inhibition,
with maximal distortion and a duration of
volume increase of >30 s being required for
maximum inhibition. One of these factors
includes ATP, another being that of'inhibitory
factor' previously described [25], 'Inhibitory
factor' is derived from the superficial layer
of the bladder and has been shown to be
released after mechanical distortion, leading
to a decrease in the strength of detrusor
contraction. It was also shown to be a readily
diffusible substance, as it can also reduce
contractions in nearby undistorted bladders.
Certainly, in the present observations, there
was a reduction in amplitude during the
inhibitory phase, associated with a reduction
in frequency. However, during the inhibitory
phase, electrical-field stimulation results in
detrusor contraction [17], suggesting that the
inhibitory phase is not related to flaccidity of
1 1 60
the detrusor muscle. Furthermore, possibly
the inhibitory, and other factors, involved in
the inhibitory phase exert their effects on the
control of the detrusor, as opposed to the
detrusor itself.
From these observations it was speculated
that the regulation of volume-induced
spontaneous activity and modulation of the
inhibitory phase relies on a complex series of
excitatory and inhibitory inputs. A rapid
increase in intravesical volume leads to a
burst of increased frequency that gradually
declines, suggesting the presence of a rapidly
desensitizing mechanism involved in
modulating volume-related activity that
becomes pronounced at high rates of filling. A
rapid reduction in intravesical volume leads to
a quiescent period, the inhibitory phase. This
is related to both the duration of intravesical
volume increase and its magnitude. However,
similar volume changes are more effective
when volume is reduced back to baseline, as
opposed to the bladder being incompletely
emptied. Furthermore, the frequency of
transient contractions remains constant once
a steady state has been reached, with no
evidence of inhibition before volume
reduction. These functional observations
suggest that mechanisms involved in
generating the inhibitory phase initiate
during bladder filling, requiring >30 s to exert
a significant effect. However, they depend on
a reduction in volume to be triggered, with
the response dependent on the volume
reduced. The mechanisms involved in
generating and modulating the inhibitory
phase seem to be regulated by a strong
cholinergic input, but the exact nature of
these mechanisms is unknown. Certainly
structures have been identified, in the form
of interstitial cells and ganglia, capable of
generating and modulating such activity.
Furthermore, their close proximity to the
urothelium which is capable of releasing ATP,
nitric oxide and acetylcholine in response to
stretch, suggests a potential role for the
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